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Summary  
Communication between cancer cells and the microenvironment is a complex yet crucial 
issue in disease progression. Recent studies highlight an important role for small extracellular 
vesicles (exosomes) secreted by cancer cells, as modulators of cancer-associated stroma, 
angiogenesis and metastatic priming. The intrinsic factors regulating exosome biogenesis 
and secretion in cancer cells are, therefore, highly relevant in studies of cross-
communication in the cancer milieu. 
We generated prostate cancer cells bearing stable knockdown of putative exosome-
regulating factors (CD9, Rab5a, Rab11b, Rab35, VAMP7 and VPS25); and examined the 
impact on cell health, vesicle secretion and on communication with fibroblastic stromal cells. 
We highlight that Rab11b or Rab35 regulate phenotypically distinct exosome subpopulations 
each accounting for only around 20% of the total. Depleting Rab11b or Rab35 leaves a vesicle 
population insufficient for driving fibroblast to myofibroblast differentiation, leading to 
diminished angiogenesis and attenuated invasive behaviours in 3D in vitro models. 
Correcting for differences in vesicle quantity revealed that perturbed differentiation due to 
loss of Rab11b-dependent vesicles, could be restored by normalising quantity. This, however, 
was not the case for Rab35-dependent vesicles.  Co-implantation of tumour cells with 
stromal fibroblasts in xenografts similarly showed that Rab11b knockdown had little effect 
on growth rates in vivo. In contrast, significant attenuation was evident when using Rab35-
knockdown cells. 
The study concludes that a Rab35 regulated exosome sub-population is particularly 
important for communication between cancer and stromal cells; and is required for 
generating a microenvironment conducive for disease promotion.    
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1.1 Prostate Cancer 
1.1.1 Aetiology and Risk Factor 
Prostate cancer is the most common cancer to affect men in the UK, where more than 46,700 
cases are diagnosed each year (CRUK, 2015). The risk factors for developing prostate cancer 
are complex and remain incompletely understood (Karan et al., 2008). The risk of developing 
prostate cancer increases exponentially over the age of 50 years (Farmer, 2008). Similarly, a 
positive family history of prostate cancer can result in an increased risk of prostate cancer 
diagnosis (Madersbacher et al., 2011), accounting for 5 - 10% of all prostate cancer cases. 
Other cohort-based and meta-analysis based studies have revealed patients who have 2 or 
more relatives with prostate cancer, have a greater than 3-fold risk of developing prostate 
cancer, compared to men with no family history (Carter et al., 1992, Kicinski et al., 2011). The 
basis for this risk remains unclear, but possible reasons have included recessive or X-linked 
inheritance. 
Furthermore, there is a link between ethnicity and prostate cancer incidence. In a 
population-based study of men with newly diagnosed prostate cancer, it was shown that 
African-Americans and Hispanics were more likely to present with clinically aggressive 
advanced-stage prostate cancer, than non-Hispanic Caucasian men (Hoffman et al., 2001). 
They reported a 3-fold relative risk for prostate cancer in African-Americans, compared with 
Caucasian men. A comprehensive cohort study on ethnicity and prostate cancer in the UK, 
found similar findings with the highest incidence rate for prostate cancer in Caribbean men, 
followed by Caucasian and Asian men (Ben-Shlomo et al., 2008). In contrast, the lowest risk 
was found among native Asian men (Chinegwundoh et al., 2006). Although the lack of 
systemic prostate cancer screening in Asian countries may explain part of that difference 
(Bunker et al., 2002), this alone cannot fully explain the lower incidence in Asian migrants in 
the UK and US (Odedina et al., 2009). These differences may arise due to a combination of 
inherited genes and environmental factors. As one environmental factor example, soy food 
consumption is typically common in Asian populations and is associated with a 25 - 30% 
reduced risk of prostate cancer (Kurahashi et al., 2007). Taken together, along with major 
risk factors such as age and family history, a combination of ethnicity and environmental 
factors, such as diet, may contribute to prostate cancer development. 
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1.1.2 Diagnosis and Treatment 
Diagnosis 
Currently, prostate cancer frequently has no clinical symptoms that distinguishes itself from 
similar problems to the prostate, such as benign prostate hyperplasia (BPH) and prostatitis. 
It remains difficult to rely on symptoms to discriminate between these diseases (Young et 
al., 2015). Patients that are suspected of prostate cancer will undergo diagnosis procedures, 
which may include digital rectal examination (DRE) and examining levels of prostate specific 
antigen (PSA).  
One of the current methods for prostate cancer detection is analysing abnormally high levels 
of PSA in serum. PSA is a protein secreted by prostate epithelial cells (Webber et al., 1995), 
which increases with age (Catalona et al., 1991). Typically, men under the age of 60 have a 
PSA level of 3ng/ml, which increases to 4ng/ml by the age of 60 and further increases to 
>5ng/ml in men over the age of 70 (Punglia et al., 2003). Elevated PSA levels are also seen in 
BPH or prostatitis (Cannon and Getzenberg, 2008), hence PSA has poor specificity for 
prostate cancer. Though, elevated PSA levels (>10ng/ml), are likely to be caused by prostate 
cancer and occasionally BPH (Punglia et al., 2003). The variability of PSA testing within an 
individual can often complicate detection. PSA testing can be misleading, as a study revealed 
60% of men with abnormally high levels of PSA do not have prostate cancer, compared to 
15% of men who has prostate cancer have normal PSA levels (Thompson et al., 2004). 
Despite these issues, the PSA test is a commonly used approach for aiding diagnosis, but 
there remains controversy for solely relying on PSA, as other prostate related problems, such 
as BPH, prostatitis or infections of the prostate (Selley et al., 1997, Cannon and Getzenberg, 
2008, Serretta et al., 2008) may be present and cannot be discriminated. 
DRE is often used in combination together with PSA testing to screen for prostate cancer, 
involving the back surface of the prostate being felt for any hard, lumpy or abnormal areas 
which may indicate prostate cancer. It appears that DRE has a high specificity for prostate 
cancer, as false negative results are rare (Hoogendam et al., 1999); and including DRE with 
PSA testing give a significantly higher predictive accuracy, compared to DRE alone for 
prostate cancer diagnosis (Bretton et al., 1994, Chu et al., 2011). DRE has a limited positive-
predictive value in men with a low PSA value and should not necessarily be recommended 
as a sole screening tool; as it remains insensitive and may miss the early disease stage. 
Furthermore, patients often undergo trans-rectal ultrasound (TRUS) and then a needle 
biopsy for a further definitive diagnosis (Lopes et al., 2015). This procedure involves inserting 
a needle with an ultrasound probe through the rectum, that guides the needle to the 
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prostate for tissue sample collection (Harvey et al., 2012). Samples can be histologically 
examined and if positive, the cancer is staged using the Gleason Scoring System. This 
separates the cancer diagnosis into five different histological grades (Grade 1 tissues are well 
differentiated and carry the best prognosis; Grade 5 tissues are poorly differentiated and 
have a poor prognosis). Tissue samples obtained from two different sites with the graded 
tissue score are added together to give a Gleason score between 2 - 10. A higher score 
indicates an aggressive cancerous tissue, that has poor prognosis compared to a lower 
Gleason score (Humphrey, 2004, Chen and Zhou, 2016). There still remains difficulty in 
precisely locating the tumour, as needle biopsy may be extracted from a non-cancerous 
region of a cancer-positive prostate resulting in false negatives (Quon et al., 2015). 
Nonetheless, false negatives should not completely rule out prostate cancer. Using TRUS as 
a primary screening test is not recommended as it has low sensitivity. Prostatic biopsy is 
considered when results from PSA or DRE indicates possible prostate cancer. Overall, a 
combination of PSA testing, DRE and TRUS would give a clearer indication of prostate cancer, 
compared to performing these tests alone. 
Treatment 
Men with localised disease can have very different prognosis and face a wide variety of 
treatment options to minimise intervention-related complications. Prostate cancer 
treatment is based on risk assessments that often combine patient age, clinical tumour stage, 
serum PSA, Gleason score and number of positive prostate biopsies. Many low-score 
(Gleason score of 6 or less) localised (small and organ confined) prostate cancers are typically 
treated with radical prostatectomy (removal of prostate), external-beam radiotherapy, or 
brachytherapy (Kupelian et al., 2004), whereas metastatic prostate cancer require different 
treatments. Radical prostatectomy is normally performed in men with good health and 
localised prostate cancer (Pierorazio et al., 2010), as surgical risks such as blood loss or 
infections can arise post-operation that may be detrimental to men with poor health (Gao et 
al., 2014). After surgery, impotency is one problem that can occur and the patient’s quality 
of life should be considered. Radical prostatectomy may, therefore, only cater to a subset of 
prostate cancer patients. Low PSA levels can be measured to ensure surgical removal was 
successful. However, if PSA levels start to rise again, other forms of treatment may be 
required, such as radiotherapy or hormone therapy. 
Radiotherapy is the best alternative for men who do not meet the surgical criteria. Radiation 
is administered to treat localised prostate cancer, but may be suitable for advanced prostate 
cancer. External beam radiotherapy is used to treat patients, which involves exposure of high 
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energy X-rays to target the prostate (Zelefsky et al., 2002), to damage tumour cells and 
attenuate tumour growth. There are different types of external beam radiotherapy, such as 
3D Conformal Radiotherapy (3D CRT), that utilises imaging software to shape the radiation 
beam closely around the prostate (Fiveash et al., 2000). This minimises damage to the 
surrounding tissues. An improved approach to 3D CRT, is to use Intensity Modulated 
Radiotherapy (IMRT), where the radiation beam matches the shape, size and position of the 
prostate in greater detail (Teh et al., 2001). But importantly, it gives precise controlled doses 
of radiation beams to cancer cells, whilst minimising damage to outer regions of the prostate 
compared to 3D CRT. Similarly, brachytherapy (Nickers et al., 1997), involves implanting a 
small radioactive source at the tumour or metastatic sites. These radioactive sources include 
small metal implants (radioactive gold or iodine) or radioactive seeds, administered at high 
doses to kills tumour cells (Langley and Laing, 2004). The side effects that arise with 
radiotherapy treatment, include bowel, erection and urinary problems (Zelefsky et al., 2002, 
Gill et al., 2011). In patients with advanced prostate cancer, radiation is applied for palliative 
purposes to either shrink or slow tumour growth, or to control symptoms such as severe 
bone pain. 
Testosterone is an androgen hormone with multiple functions, playing a role for the 
development and function of the male reproductive system. Testosterone is converted into 
dihydrotestosterone (DHT) in the testis, binding with the androgen receptor (AR) that is 
expressed in most prostate cancer cells (Wu et al., 2013). In aggressive prostate cancer, 
testosterone activates androgen-responsive genes, playing roles in cell proliferation to 
accelerate tumour growth (Xiao et al., 2003). Therefore, androgen deprivation by medical or 
surgical castration (orchiectomy), to remove the testicles could supress testosterone. 
Orchiectomy was a common method used for reducing testosterone levels (by 60%), whilst 
the remaining 40% is considered to be produced by the adrenal glands (Labrie et al., 1997). 
This procedure is irreversible and often associated with significant psychological impact. 
Alternatively, androgen deprivation therapy (ADT) using anti-androgen agents was 
developed to maintain low testosterone levels. Diethylstilbestrol (DES) was initially used to 
treat prostate cancer (Malkowicz, 2001). This mechanism inhibits luteinising hormone 
releasing-hormone (LHRH) release from the hypothalamus with a subsequent suppression of 
luteinising hormone (LH) and thus, testosterone suppression. Side effects included 
significant cardiovascular and thromboembolic toxicity (Malkowicz, 2001). Otherwise, 
introducing LHRH agonists, such as leuprolide and goserelin, provided an effective treatment 
for advanced prostate cancer. After an initial surge of LH/follicle stimulating hormone (FSH), 
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a constant exposure to LHRH agonists results in receptor downregulation in the pituitary 
gland (Kovacs and Schally, 2001). This cascade decreases testosterone production, as 
inhibition of LH and FSH is observed. Treatment demonstrated a 90% decline in testosterone, 
whilst 10% remains. This is due to the peripheral conversion of circulating adrenal steroids 
into testosterone. ADT in combination with surgery was shown to prolong survival, 
compared to patients with surgery and no hormone therapy, over 5 years of assessment in 
randomised trials (Schmitt et al., 2001, Demir et al., 2014). Adverse side effects can arise 
from ADT, such as metabolic and cardiovascular events (Saylor and Smith, 2009), cognitive 
function (Mohile et al., 2010) and urinary function (Axcrona et al., 2012). ADT is effective in 
tumour regression, yet some prostate cancers are androgen independent. Such cancers 
cannot be treated with ADT and are difficult to treat (Isaacs and Coffey, 1981, Hotte and 
Saad, 2010). 
Androgens have been pivotal in the pathogenesis of prostate cancer and ADT treatment gives 
a good response to prostate cancer, which leads to remission for 18 – 24 months. After this 
time, patients receiving ADT often experience a rise in PSA levels, signifying resistance to ADT 
(Eisenberger et al., 1998), leading to recurrence and alternative forms of treatments. This led 
the generation of several cytotoxic chemotherapeutic drugs to be used in advanced prostate 
cancer (Scher et al., 2008). 5-fluorouracil and cyclophosphamide was initially utilised to 
palliate some advanced prostate cancer patients in earlier clinical trials. Though, 
mitoxantrone was the first chemotherapeutic drug approved by the FDA to show a significant 
palliative response in combination with prednisone (Tannock et al., 1996). Docetaxel was the 
first drug that showed an overall survival benefit in prostate cancer patients, leading to 
reduced tumour size and slowing tumour progression (Serpa Neto et al., 2011, Miyake et al., 
2012). It was clear that docetaxel was the standard of care in advanced prostate cancer 
patients in combination with prednisone, as multiple small phase 2 trials could not improve 
the current standard of care. Other treatments include using cabazitaxel in combination with 
prednisone to show an overall survival benefit to metastatic patients compared to 
chemotherapy alone (de Bono et al., 2010). Administering these chemotherapeutic drug 
treatments are not the primary form of treatment for patients with early stage prostate 
cancer. It is offered to patients with advanced or metastatic prostate cancer, who are not 
responding to ADT (Stein et al., 2012, Recine and Sternberg, 2015). More often, a 
combinational treatment of ADT, radiotherapy and chemotherapy is given that can prolong 
the remission duration for many months, but many side effects are present from this. 
Toxicity with the docetaxel or cabazitaxel treatment always resulted in side effects that were 
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exclusively haematologic, such as neutropenia, anaemia or thrombocytopenia (Tannock et 
al., 1996, de Bono et al., 2010). Therefore, recommended patients considered for 
chemotherapy must be otherwise in good health. Despite the medical advances in diagnosis 
and treatment, patients with metastatic prostate cancer remain incurable. Therefore, it 
remains pivotal to understand the molecular mechanisms involved in tumour growth and 
metastasis that may allow us to identify new targets to halt or slow down disease 
progression.  
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1.2 Cancer-Associated Stroma 
1.2.1 The Reactive Stroma 
The prostate gland is composed of two distinctive compartments: epithelial (including 
secretory exocrine glands) and the surrounding connective tissue stroma. The stroma of the 
prostate is heterogeneous and is composed of smooth muscle cells, fibroblasts, endothelial 
cells, mesenchymal stem cells (MSCs) and various immune cells. The smooth muscle cells are 
the major stromal cell type in the normal prostate (Grossfeld et al., 1998). The mutual 
interaction between epithelia and stroma via androgen receptors, is vital for prostate 
development and differentiation (Hayward et al., 1997). After peak reproductive age, the 
histological architecture of the prostate begins to undergo age-related changes. Although 
key mechanisms are not fully understood, these changes might be attributed to altered 
androgen action and a persistent effect on the prostate gland. 
The normal stromal compartment has an intrinsic flexibility to respond quickly to developing 
situations, such as wound healing and disrupted homeostasis. Stromal compartments within 
the microenvironment adjacent the epithelium act co-ordinately when the epithelium 
sustains damage. The genotypic or phenotypic alterations that occur during this damage 
response have been referred to as the “reactive stroma”. This altered stroma is like that 
found in a generic wound healing scenario and includes matrix remodelling and altered 
expression of repair-associated growth factors and cytokines (Gabbiani, 2003, Desmoulière 
et al., 2005). As an example, the interstitial smooth muscle cells are displaced by α-smooth 
muscle actin and vimentin positive myofibroblasts (Tuxhorn et al., 2002b), as shown in Figure 
1.1. These changes within the tissue architecture indicates an expanding interstitium, 
accompanied largest by alpha-smooth muscle actin (α-SMA) positive cells. This leads to 
tissue remodelling and gradual collapse and it is the tissue with greatest stromal changes 
that we believe to be proactively involved in this progressive aggressive disease state. 
These similar observations are often described in prostatic intraepithelial neoplasia (PIN), 
where the histological changes are reminiscent of cancer, evidence by loss of cellular 
polarity, increased proliferative potential and genetic instability (Ayala and Ro, 2007, 
Bettendorf et al., 2008). With increasing levels of PIN, nuclear aberration and basal cell 
disruption are observed. This aligns with an increased frequency and incidence that is found 
in men with prostate cancer than without, consequently, PIN is often considered a precursor 
for prostate cancer (Sakr, 1999). Though, these changes in the reactive stroma are suggested 
to be key in the initiation of other prostatic diseases, such as BPH. In prostate cancer, these 
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interactions are proposed to play a role in the development prostate cancer and metastasis 
(Tuxhorn et al., 2002a, Cano et al., 2007). These types of reactions are well-documented for 
breast and colorectal cancer (Orimo et al., 2005, Bendardaf et al., 2007). Therefore, these 
stromal changes are not secondary to tumour development, but remain an important early 
event during carcinogenesis and go hand in hand with the development of the disease. 
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Figure 1.1: Myofibroblasts replace smooth muscle cells in diseased prostate stroma. 
Normal and cancerous prostate samples were obtained from radical prostatectomy 
specimens and analysed by immunohistochemistry with α-SMA (green), vimentin (red) 
and DAPI (blue). Co-localisation was only observed in the blood vessel walls. Enhanced 
expression of both α-SMA and vimentin double positive cells with the interstitium, 
indicative of a myofibroblastic phenotype in the prostate cancer. Source: (Tuxhorn et al., 
2002b). 
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1.2.2 Tumour-Associated Myofibroblasts 
The origins of myofibroblasts with cancerous prostate tissues have been suggested to derive 
from either fibroblasts (Desmoulière et al., 1993), smooth muscle cells (Xie et al., 2011), 
pericytes (Hosaka et al., 2016), epithelial cells (Radisky et al., 2007), endothelial cells 
(Zeisberg et al., 2007), adipose tissue-derived cells (Desai et al., 2014) and MSCs (Mishra et 
al., 2008), or perhaps all cells above. During tissue repair, fibroblasts undergo a phenotype 
change from their normal quiescent state, to a proliferative and contractile phenotype 
termed myofibroblasts. In normal conditions, fibroblasts exhibit homeostatic function, in 
maintaining an appropriate matrix and tissue structure. First, fibroblasts can differentiate 
into proto-myofibroblasts, which are characterised by the formation of β- and γ- cytoplasmic 
actins (Vyalov et al., 1993). The stimuli to trigger this phenotypic transition remains poorly 
understood, however, mechanical tension has been shown to generate proto-myofibroblasts 
from fibroblasts (Tomasek et al., 2002), characterised by the formation of stress fibres. These 
proto-myofibroblasts can generate mechanical tension in the extracellular matrix (ECM), 
which activates transforming growth factor-β1 (TGF-β1) (Wipff et al., 2007). TGF-β1 can 
cause differentiation of proto-myofibroblasts into myofibroblasts, characterised by the 
expression of α-SMA (Darby et al., 1990), ultimately providing contractile capacity akin to a 
muscle cell. 
These differentiated myofibroblasts are morphologically and functionally distinct from their 
resting and quiescent counterparts (Hinz et al., 2001). These features are shown by a higher 
organisation of α-SMA stress fibres, connected to the extracellular fibronectin fibrils via focal 
adhesion complexes (Clark, 1990, Hinz et al., 2001), as shown in Figure 1.2. This connection 
allows the myofibroblasts to possess a mechanotransduction system, where these actin 
fibres can generate contractile force to be transmitted to the surrounding ECM 
(Chrzanowska-Wodnicka and Burridge, 1996). Once induced, myofibroblasts deposit 
increasing amounts of stiff fibrillar ECM composed of collagen and fibronectin splice variants. 
This enables the contraction of ECM, activating TGF-β, triggering downstream Smad2/3 
phosphorylation, as shown in Figure 1.3. This allows the secretion of other soluble factors 
released by myofibroblasts allowing further differentiation and growth, thus allowing this 
positive feedback and remodelling mechanism to occur. Once the original structure of the 
ECM is repaired at the injury site, the myofibroblasts may undergo apoptosis (Darby et al., 
2014); when the wound is eventually fully restored. Though in cancer, restoration does not 
occur and a persistent ‘tissue-repair’ state exists in a chronic fashion exacerbating the 
disease (Schafer and Werner, 2008, Ohlund et al., 2014). 
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Figure 1.2: Fibroblast differentiation into myofibroblasts during wound healing. The 
interstitial fibroblasts are characterised by the production of fibronectin and the 
absences of filamentous actin, α-SMA and ED-A fibronectin. Under mechanical stress, 
fibroblast can differentiate into proto-myofibroblast, which form actin-containing stress 
fibres that connects to focal adhesion complexes. Under the control of TGF-β1 and other 
regulating factors, proto-myofibroblasts can increase the expression of α-SMA and ED-A 
fibronectin, along with mechanical stress, to differentiate into myofibroblasts and a 
contractile phenotype. Once wound healing is completed, myofibroblasts may undergo 
apoptosis, but this remodulation is slow or does not happen in cancer. Source: (Falke et 
al., 2015). 
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Figure 1.3: TGF-β/Smad and other signalling pathways involved in myofibroblast 
activation. Once TGF-β1 is released from the latency associated peptide (LAP)-latent 
TGF-β binding protein (LTBP) complex, the active homodimer form of TGF-β1 binds to 
TGF-β receptor 2 (TGFR2), which recruits and activates TGFR1. The activate TGFR1 
phosphorylates Smad2 and Smad3, which complex with Smad4 and translocate with the 
nucleus. In addition, other pathways such as EGF/EGFR and CD44/HA interaction can 
contribute to Smad phosphorylation. This promotes the transcription of α-SMA, collagen 
type I, fibronectin which induces fibroblast activation and matrix deposition. Source: 
(Meng et al., 2016) 
Chapter 1. Introduction 
 
14 
 
1.2.3 Tumour-Associated Myofibroblasts Promote Cancer Progression 
During tumourigenesis, differentiation of fibroblasts to myofibroblasts has been studied 
since the 1970s (Ryan et al., 1973, Ryan et al., 1974). Such activated “fibroblasts” often 
termed tumour-associated myofibroblasts, have been assessed for their role in stromal-
epithelial interactions regarding tumour progression. In one elegant example, fibroblastic 
stromal cells isolated from BPH or prostate cancer are added to immune-deficient mice co-
implanted with epithelial cells as xenografts (Olumi et al., 1999). It was demonstrated that 
tumour-associated myofibroblasts could make a non-tumourigenic prostate epithelial cell 
line tumourigenic, whereas normal tissue fibroblasts were not able to elicit tumourigenesis, 
as shown in Figure 1.4. We can observe that the prostate cancer tissue with myofibroblasts 
exhibits greater number of blood vessels, appearing to play a role in promoting angiogenesis, 
compared to the tissue containing normal fibroblasts. Similarly, myofibroblasts isolated from 
patients with aggressive breast cancer enhanced the growth rate of breast carcinomas in 
vivo, then that of normal mammary fibroblasts taken from the same patients (Orimo et al., 
2005). Tumour-associated myofibroblasts enhanced the aggressive phenotype of breast 
cancer cells (Yu et al., 2014). There is a consensus that tumour development is not solely 
determined by malignant cancer cells; and that tumour-associated myofibroblast have a 
major influence on dictating tumour progression and outcome.   
As tumour-associated myofibroblasts play significant roles in the tumour stroma and during 
tumour progression, they are viewed as good predictors for cancer prognosis in various 
cancers. In one study, isolated stroma from prostate cancer patients after radical 
prostatectomy, showed significant differences between the myofibroblast phenotype and 
progression free-survival. Patients with identical Gleason score, but changes in increased 
stroma intensity by immunohistochemical (IHC) staining, could identify patients with greater 
risk of prostate cancer relapse (Tomas et al., 2010). It was also shown in metastatic breast 
cancer samples to be abundant in α-SMA positive myofibroblasts, compared to non-invasive 
breast cancer patient samples (Yamashita et al., 2012). In multiple studies, the identification 
of stromal markers, often myofibroblasts, associate robustly with disease relapse across 
various cancer types (Moorman et al., 2012, Huang et al., 2014, Calon et al., 2015, Luksic et 
al., 2015), highlighting the role of tumour stroma in treatment response. Also, the tumour-
associated myofibroblasts can promote tumour-supporting functions, by stimulating cancer 
cell proliferation and progression through the secretion of various cytokines, chemokines or 
ECM. For example, hepatocyte growth factor (HGF) or vascular endothelial growth factor 
(VEGF) can enhance tumour progression, by promoting tumour invasion and angiogenesis. 
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Figure 1.4: Tumour-associated myofibroblast promotes tumour growth. Image of 
prostate cancer-derived myofibroblast grown with prostate epithelial cells (Left Side), 
compared to normal fibroblasts with prostate epithelial cells (Right Side). Tissue 
recombinants were harvested after 85 days of growth in nude mice. The tissue containing 
tumour-associated myofibroblasts weighed 1250mg, with dramatically stimulated 
growth and altered histology of the epithelial population and clear macroscopic 
involvement of angiogenic support. In contrast, the normal fibroblasts weighed 10mg 
under identical conditions halting endothelial vascularisation. Scale bar: 1cm. Source: 
(Olumi et al., 1999). 
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Angiogenesis 
Angiogenesis, or the formation of new blood vessels from the pre-existing vasculature, is a 
vital component in numerous physiological and pathological responses. In normal 
physiological responses, a variety of angiogenic signals induces endothelial cells to detach 
their junctional adhesion from their neighbouring cells, sprout near gradients of pro-
angiogenic factors, proliferate to form provisional tubes, recruit perivascular cells to provide 
stability and maturation, re-organise with vascular smooth muscle cells and pericytes to form 
a functional blood vessel network (Carmeliet and Jain, 2000). Monolayer of endothelial cells 
often form capillaries, creating a semi-permeable barrier between the surrounding tissue 
and blood, allowing nutrient and waste product exchange to and from surrounding cells 
(McDonald and Baluk, 2002, Nagy et al., 2010). 
In cancer, multiple sources of pro-angiogenic factors contribute to vascular remodelling, that 
aids tumour growth and progression (Adams and Alitalo, 2007). Once a tumour lesion grows 
beyond the capacity for nutrient, waste and O2 to diffuse passively, it experiences hypoxia or 
nutrient deprivation. Thus, angiogenesis is initiated and tumour cells exploit this process for 
tumour growth. The secretion of growth factors activates normal surrounding quiescent 
cells, to initiate a cascade of events that become quickly dysregulated. This involves an 
‘angiogenic’ switch, that is regulated between anti- and pro-angiogenic cytokines and 
examples of pro-angiogenic growth factors include: fibroblast growth factor (FGF), platelet 
derived growth factor (PDGF), HGF and VEGF (Ferrara, 1993, Boccaccio et al., 1998, Dunn et 
al., 2000). VEGF stimulates the migration, sprouting and proliferation of endothelial cells. 
However, this may initially provide the tumour with more nutrients and oxygen, the ultimate 
response is poor, as the continuously remodelled tumour vasculature is leaky, causing 
irregular blood flow (Hoeben et al., 2004). Tumour tissues often exhibit abnormally high 
blood vessel densities, in comparison to normal tissues (Olumi et al., 1999). These differences 
in blood vessels were documented to increase during early tumour formation, indicating 
their role in tumour growth (Kamoun et al., 2010). 
Tumour-associated myofibroblasts have been documented to secrete these pro-angiogenic 
growth factors, such as HGF and VEGF, that can promote angiogenesis at primary tumour 
sites (Xin et al., 2001, Zhang et al., 2003). In a tumour:fibroblast xenograft model, tumour-
associated myofibroblasts extracted from invasive breast carcinomas, promoted tumour 
growth of breast carcinoma cells significantly more than those with normal mammary 
fibroblasts (Orimo et al., 2005). They promoted tumour growth by secreting stromal cell-
derived factor 1 (SDF-1), promoting angiogenesis by mobilising endothelial cells into 
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carcinomas; and gives rise to highly vascularised tumours. In an oesophageal carcinoma 
model, the presence of tumour-associated myofibroblasts was essential for efficient human 
microvascular endothelial cell network formation; selective VEGF inhibition blocked the 
formation of a vascular network in this model (Noma et al., 2008). Furthermore, co-culturing 
diseased stromal cells from prostate cancer with endothelial cells, promoted vessel-like 
structure formation in vitro (Webber et al., 2015). The diseased stromal cells were IHC 
stained to be α-SMA positive, indicating a myofibroblastic-like phenotype. These studies give 
evidence that myofibroblasts are important components of the tumour microenvironment 
that may enhance endothelial vessel formation. 
Tumour Invasion and Metastasis 
Tumour cells can migrate and invade, escaping from the primary tumour site to a new 
secondary distant site to form a new secondary tumour. It has been reported that 
myofibroblasts are present at the invasive leading edge of primary tumours, such as 
colorectal cancer in vivo (Illemann et al., 2004); and proposed to play a role in supporting 
tumour invasion. In one study, tumour-associated myofibroblasts are commonly found in the 
stroma of oral squamous cell carcinomas and are often concentrated at the leading edge of 
the tumour (Lewis et al., 2004). Furthermore, cell conditioned media (CM) obtained from 
tumour-associated myofibroblasts derived from colorectal cancer, were found to promote 
invasion of colorectal cells in a collagen gel matrix (Cat et al., 2006). In contrast, cell CM from 
normal fibroblasts derived from healthy patients, failed to support tumour cell invasion, 
compared to tumour-associated myofibroblasts. In contrast to fibroblasts, myofibroblasts 
secrete elevated levels of HGF and VEGF resulting in a significant increase in the invasive 
capacity of tumour cells through collagen/matrigel matrices (Lewis et al., 2004, Cat et al., 
2006). Blocking the HGF and VEGF levels, decreased the invasive capacity of tumour cell 
invasion (De Wever et al., 2004). Other growth factors, such as epidermal growth factor 
(EGF), FGF, HGF, insulin-like growth factor (IGF), PDGF and VEGF, are secreted at elevated 
levels in tumour-associated myofibroblasts, compared to normal fibroblasts (Dunn et al., 
2000, Orimo et al., 2005, Weigel et al., 2014, Webber et al., 2015).  
Other soluble factors such as matrix metalloproteinases (MMPs) may be involved in 
enhancing tumour cell’s invasive capacity. MMPs are matrix degrading enzymes that 
breakdown the components of the basement membrane and ECM, such as collagen, elastin, 
fibronectin and laminin (Sang, 1998, Lu et al., 2011). Expression of MMP-1 is detected in 
areas of ECM remodelling and has been described in a wide variety of advanced cancer 
(Bendardaf et al., 2007, Pulukuri and Rao, 2008). Similarly, cell CM from tumour-associated 
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myofibroblasts derived from aggressive breast cancer cells contained elevated levels of 
MMP-1, compared to normal mammary fibroblasts (Boire et al., 2005). Furthermore, 
elevated levels of MMP-13 have been associated with decreased overall survival and lymph 
node metastasis in breast cancer (Shah et al., 2012), bone metastasis in renal cell carcinoma 
(Kominsky et al., 2008); and invasive capacity in lung cancer (Hsu et al., 2006) and colorectal 
cancer (Leeman et al., 2002). Also, administration of a selective MMP-13 inhibitor in mice 
significantly inhibited primary tumour growth and breast cancer-associated bone 
remodelling in xenografts (Shah et al., 2012). Inhibition of MMP-1 activity demonstrated a 
reduction in the motility of both breast and prostate cancer cells in a Boyden transwell 
invasion chamber (Boire et al., 2005, Giannoni et al., 2010). In the same prostate cancer 
model, spontaneous metastasis was not observed when administering prostate cancer cells 
alone or with fibroblasts from healthy stroma into mice (Giannoni et al., 2010). Yet, the ability 
for prostate cancer cells to metastasise to the lung was obvious, when co-cultured with 
tumour-associated myofibroblasts in vivo. 
In prostate and other carcinomas, the interstitial stroma contains an abnormally high 
amount of tumour-associated myofibroblasts, capable of supporting tumour growth, partly 
through encouraging angiogenesis, invasion and metastasis. An assortment of factors has 
been proposed to be involved in triggering fibroblast differentiation. Though, it has been 
shown that tumour-derived, nanometre sized extracellular vesicles (EVs) can trigger 
fibroblast differentiation. More specifically, tumour-derived exosomes can generate this 
response to produce distinct tumour-associated myofibroblasts, supporting angiogenesis 
and tumour growth. 
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1.3 Exosome Biology 
1.3.1 Different Types of Extracellular Vesicles (EVs) 
Cells can secrete different types of membrane-bound vesicles, collectively termed as EVs; 
and these have been given many names throughout the literature: membrane vesicles, 
membrane particles, nanoparticles, ectosomes, microvesicles (MVs) and exosomes. We may 
categorise secreted EVs in terms of their intracellular origin or based on their size (Théry et 
al., 2009). More commonly characterised vesicles such as exosomes, are formed in 
endosomal compartments and released upon fusion with the plasma membrane. Other 
vesicles, however, may be released directly from the plasma membrane by budding and 
shedding. These include microvesicles or membrane particles (Heijnen et al., 1999). Dying 
cells can release vesicles, referred to as apoptotic bodies, which are distinct from exosomes 
(Théry et al., 2001). 
Currently there is no consensus in the field as to a proper nomenclature and the precise 
definition of each type of EVs, because different research groups utilise different methods to 
isolate, purify and characterise EVs. More recently, one of the position statements published 
by the International Society of Extracellular Vesicles (ISEV) created minimal experimental 
requirements for defining EV characterisation and function (Lotvall et al., 2014). To define 
EVs, researchers firstly must report several proteins or lipids expected to be present in the 
EVs of interest, including quantitation of contaminants not necessarily expected present on 
EVs. Furthermore, characterisation of single vesicles within a mixture should be performed, 
such as low magnification images showing a broad description of the state and morphology 
of the entire isolated EV population and high magnification to define structural depth of 
individual vesicles; as well as size distribution measurements providing diameters of many 
EVs to give an indication of heterogeneity of the EV preparation studied. Some of these 
requirements may allow us to distinguish vesicles secreted by the plasma membrane from 
those derived from endocytic compartments, such as exosomes. 
1.3.2 Exosome Characterisation 
One of the first studies to observe the presence of EVs was by electron microscopy (EM), 
demonstrating these EVs were involved in calcifying matrix within newly formed bone 
(Anderson and Reynolds, 1973). Following studies described exosomes during the 
maturation of red blood cells, as reticulocyte purge cellular mass and the transferrin receptor 
(Harding et al., 1983, Pan et al., 1985). In the first instance, utilising either gold particles or 
anti-transferrin antibodies, an EM approach was used to monitor the process of the 
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endocytosed receptor during trafficking in the cell and following release. The transferrin 
receptor was detected in early endosomes, before being trafficked to multi-vesicular 
endosomes (MVEs). Many of the gold particles were located on smaller nanometre sized 
‘bodies’ (around 50nm in diameter), which were released upon MVE fusion with the plasma 
membrane. Following on, one study demonstrated that secreted vesicles could be isolated 
and analysed by ultracentrifugation at 100,000 x g, normally present on the plasma 
membrane (Johnstone et al., 1987). The term ‘exosome’ was first reported used to categorise 
secreted EVs of heterogeneous sizes, including one population with diameters between 500 
and 1000 nm; and a smaller population of around 40nm (Trams et al., 1981).  
Later, this nomenclature was adopted for vesicles, as their secretion and presence inside 
multivesicular endocytic compartments was reported in reticulocytes (Harding et al., 1983, 
Pan et al., 1985). Exosome are formed by budding of the limiting membrane of ‘sorting’ 
vacuolar endosomes towards the lumen of these compartments, thus forming intraluminal 
vesicles (ILVs), the endosomes are referred as MVEs. The fusion of MVEs with the plasma 
membrane enables the release of ILVs into the extracellular space and these secreted ILVs 
are referred to as exosomes. Due to their endosomal origin, exosomes possess several 
hallmarks of ILVs of the MVEs, such as their size, which ranges from 30 to 150 nm in diameter, 
reflecting exosome heterogeneity (Colombo et al., 2013).  
Molecular Composition of Exosomes 
Since their initial description of exosomes, many efforts have been made to further 
characterise the protein composition of exosomes. Many studies of EVs biochemical 
composition involved analysis of bulk populations obtained by ultracentrifugation, that often 
provides a heterogeneous EV population. The development of proteomic analysis soon 
allowed identification of non-determined proteins in isolated EVs. Mass spectrometry was 
used for peptide mapping on exosomes derived from dendritic cell (DC) mouse cultures 
(Théry et al., 1999) and similarly, on exosomes isolated from various cell types (Théry et al., 
2001, Lamparski et al., 2002). By characterising exosomes from numerous studies, these 
results were assembled in a database called ExoCarta (Mathivanan and Simpson, 2009), 
which was refined into a more comprehensive database called Vesiclepedia (Kalra et al., 
2012) and EVpedia (Kim et al., 2015), that incorporates data from other EV types and 
additional data on lipids and nucleic acid. 
Initial proteomic studies showed exosomes contain a specific subset of cellular proteins, 
some found in all cell types, whereas others are specific to the cell type. These include 
Chapter 1. Introduction 
 
21 
 
proteins from the plasma membrane, endosomes or cytosol, although proteins from the 
endoplasmic reticulum, mitochondria or nucleus are often absent. For example, the 
apoptosis-linked gene 2-interacting protein (ALIX) and tumour susceptibility gene 101 
(TSG101) are known components of the endosomal complex required for transport 
machinery (ESCRT) (Morita et al., 2007). The function of the ESCRT complex is involved in 
forming MVEs, loading and sorting of cargo proteins into ILVs, working at the MVE membrane 
and recognising ubiquitinylated proteins that are incorporated into the vesicles. Tetraspanins 
such as cluster of differentiation (CD)9, CD63, CD81 or CD82, are often enriched on the 
exosome’s surface. CD9 was first identified in DC-derived exosomes (Théry et al., 1999); and 
several studies describe CD63 and CD81 as frequently identified proteins and are considered 
classical “markers”. CD9 is often found enriched in exosomes derived from prostate cancer 
cell lines (DU145) (Liu et al., 2014, Webber et al., 2014). Also, exosomes express major 
histocompatibility molecules class I (MHC-I) and II (MHC-II), playing roles in immune-
regulation by presenting antigenic peptides (Lamparski et al., 2002). Other common 
exosomal-associated proteins include heat shock protein 70 (HSP-70) and 90 (HSP-90), which 
assists in protein folding and trafficking, acting as chaperones (Clayton and Tabi, 2005, Mayer 
and Bukau, 2005), accelerating peptide loading onto MHC-I and -II and playing roles in the 
cellular response to environmental stresses (Cho et al., 2005). Also, a subset of the 
endosomal/lysosomal proteins are found in exosomes, such as the lysosomal associated 
membrane protein 1 (LAMP1) and 2 (LAMP2). Some examples show exosomes from tumour 
cells contain LAMP1 (Wolfers et al., 2001) and LAMP2 is detected from DC-derived exosomes 
(Escola et al., 1998). Moreover, the presence of proteins, such as calnexin or GP96, derived 
from the endoplasmic reticulum are mostly absent in exosomes (Wolfers et al., 2001, Cho et 
al., 2005). This highlights some proteins present on the exosome’s surface or inside the 
lumen that differs between cell types, representing a specific subcellular compartment and 
not an array of random cell fragments. 
Fewer studies have analysed the lipid composition of exosomes, but it differs from the 
plasma membrane. The exosomal membrane does not have an asymmetrical distribution of 
the lipid phosphatidylethanolamine (PE), compared to asymmetrical distribution in the inner 
leaflet of the plasma membrane. This may be due to a lack of flippase in exosomes, which 
actively maintains phospholipid asymmetry in the plasma membrane and possible MVEs 
(Laulagnier et al., 2004). It was reported exosomes are enriched in ceramide, which was 
linked to vesicle biogenesis and release from oligodendrocytes (Trajkovic et al., 2008). Cargo 
was shown to be segregated into distinct subdomains on the endosomal membrane and that 
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the transfer of exosome-associated domains into the lumen did not depend on the ESCRT 
machinery, but required ceramide; therefore, an ESCRT-independent mechanism. Also, 
nucleic acids are often confined within exosomes and reports highlighted that messenger 
ribonucleic acid (mRNA) or micro ribonucleic acid (miRNA) can be present in exosomes from 
biological fluids (Valadi et al., 2007, Kosaka et al., 2010). This suggests the expression 
patterns of these nucleic acids may act as markers for the diagnosis and prognosis of 
different pathologies. Other reports have revealed possible functions for secreted EVs 
carrying nucleic acid in tumour cell migration and growth (Skog et al., 2008, Zhang et al., 
2010). These studies highlight the complexity behind the molecular composition of 
exosomes, as there remains no universal marker as shown in Figure 1.5. The use of compiling 
multiple studies into a main database, such as Vesiclepedia, will contribute to the 
harmonisation of the nomenclature of different EVs.
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Figure 1.5: Molecular composition often found on exosomes. Schematic representation 
of the composition and membrane orientation of exosomes, encompassing families of 
proteins, lipids and nucleic acid. Commonly found are tetraspanins include CD9, CD63 
and CD81; and many others such as MHC-I, heat shock proteins (HSP70 and HSP90), 
LAMP proteins (LAMP1 and LAMP2), ESCRT components (ALIX and TSG101), Rab proteins 
(Rab5a, Rab11b, Rab27a, Rab35), growth factors, cytokines, mRNA/miRNA and lipids. 
Adapted from source: (Colombo et al., 2014). 
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1.3.3 Methods for Exosome Isolation and Purification 
Exosome Isolation and Purification 
The general protocol used in earlier studies to isolate and purify exosomes (Johnstone et al., 
1987, Raposo et al., 1996) is based on ultracentrifugation. It involves numerous successive 
steps (Théry et al., 2006), where a centrifugation spin at 400 x g is aimed at removing cell 
pellets. The remaining supernatant is centrifuged again at 400 x g and subsequently at 2000 
x g, to remove dead cells and larger cellular debris. A subsequent ultracentrifugation step at 
10,000 x g is used to pellet other types of EVs, such as microvesicles, which are larger in size 
and sediment easier. Alternatively, some variations are implemented in practice, for example 
serial filtration through 0.22µm filters will eliminate contaminating vesicles or debris, prior 
to exosome pelleting. The final ultracentrifugation step at 100,000 – 200,000 x g is used to 
pellet the exosomes as shown in Figure 1.6. It is important to take into consideration that 
this only enables an enrichment of exosomes and not a proper purification, since other EVs 
of similar size, as well as protein aggregates, are likely to sediment at the same speed. 
Ultracentrifugation remains commonly used to isolate or enrich a certain EV type and 
variations of this protocol can considerable vary from one laboratory to another. Different 
protocols have been developed to purify the exosomes, which will be discussed in the 
following paragraphs. 
Other protocols have been developed using antibody-coated magnetic beads (Clayton et al., 
2001) or latex beads (Lamparski et al., 2002, Caby et al., 2005). These rely on the expression 
of specific surface proteins, which are used to capture exosomes on beads, which can be 
analysed by flow cytometry. However, this protocol is limited, requiring their further use in 
additional experiments, as it remains difficult in extracting exosomes from beads requiring 
extra steps for functional studies and remains predominantly used to identify molecular 
signature markers. 
Another method to purify exosomes from other contaminants can be performed by using a 
continuous sucrose density gradient (Raposo et al., 1996, Escola et al., 1998). Exosomes have 
a biochemical property allowing floatation at a density of 1.1 – 1.2g/ml, compared to vesicles 
from the golgi apparatus floating at 1.05 – 1.1g/ml (Théry et al., 2006) and the density of 
protein aggregates at 1.22g/ml (Quillin and Matthews, 2000). The differing density of the 
potential contaminants (protein aggregates) of exosomes make the sucrose gradient an 
approach to purify exosomes from crude vesicle concentrates. The exosomes will be 
obtained in different fractions of the sucrose gradient and the remaining fractions can either 
be pooled together for analysis or examined independently. An alternative to sucrose density 
Chapter 1. Introduction 
 
25 
 
gradients is to involve ultracentrifugation of the cell CM in sucrose deuterium oxide (D2O) 
cushions. This protocol was commonly used to isolate clinical grade exosomes (Lamparski et 
al., 2002); and is more reproducible as a daily preparative method, compared to gradients.
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Figure 1.6: Flowchart for isolating and purifying exosomes based on ultracentrifugation 
and 30% sucrose/D2O cushion method. Flow chart showing the steps involved for 
removal of viable cells, dead cells, cellular debris and larger EVs, to obtain a crude 
exosome pellet. Alternatively, the filtered supernatant is ultracentrifuged with a sucrose 
cushion to present exosomes from pelleting. The cushion is washed thereafter to obtain 
a purified exosome pellet. Adapted from source: (Lamparski et al., 2002, Théry et al., 
2006). 
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More recently, commercially available methods to promote quick and simple exosome 
purification protocols, such as Total Exosome Isolation Reagent (TEI), ExoQuick™ or 
ExoSpin™, have been released (Sunkara et al., 2016). These easy-to-use precipitation 
solutions have many disadvantages present with these kits. They do not specifically enrich 
exosomes, but also co-precipitate non-exosomal impurities, showing background 
contamination in cryo-EM images (Van Deun et al., 2014). There have been suggestions that 
using density gradient-based isolation method, such as iodixanol (OptiPrep™) can be applied 
to obtain a purer exosome preparation compared to sucrose-based gradients. A study has 
encouraged the use of an iodixanol-based gradient, which improves the separation of 
exosomes from viruses and small apoptotic bodies (Cantin et al., 2008). Though, using the 
OptiPrep™ gradient is a complex and time-consuming process.  
As there are multiple protocols used to isolate exosomes, each technique must be validated 
for any given cell type or biological fluids as a source of exosomes, to confirm the identify for 
the given purified exosome. This often requires a combination of multiple assays, which are 
described in further detail below. 
Exosome Detection 
As exosomes are small nanometre sized EVs, cryo-EM allows the direct visualisation of the 
morphology and size of exosomes. Pelleted vesicles, resuspended in a small volume of buffer 
are normally adsorbed onto glow-discharged holey carbon grids. Exosome samples are 
vitrified in liquid ethane, to prevent the formation of crystal structures and preserve the 
native vesicle structure (Conde-Vancells et al., 2008). Furthermore, the presence of selected 
proteins on the surface of exosomes can be detected by immuno-EM (Théry et al., 2006). 
Using specific antibodies, gold particles can identify a few proteins in the same sample 
simultaneously, whilst determining the purity of the exosome preparation to assess if the 
debris/contaminants are present (Bobrie et al., 2012). Though, it would remain difficult to 
separate these exosomes for functional based experiments. 
Classical biochemistry methods, such as Western blotting, can provide information on the 
enrichment of proteins present on exosomes. The protein content can be compared 
between cell lysates and the exosomal pellet. A different pattern often reveals a good purity, 
since it rules out the presence of cell compartments not usually represented in exosomes, 
such as the endoplasmic reticulum. Western blotting is routinely used to investigate the 
presence of specific exosomal-associated proteins and compared to cell lysates (Raposo et 
al., 1996, Théry et al., 1999). As some examples, exosomes are enriched in ALIX or TSG101 
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(dependent on the cell type), but does not contain proteins from cell compartments, such as 
calnexin or GP96 (endoplasmic reticulum marker). 
Similarly, another technique that allows the quantitative analysis of protein content is flow 
cytometry. There are limitations, as a typical flow cytometer detection limit is 500nm and as 
exosomes are between 30 – 150nm, they would appear as background noise. Beads have 
been coated with antibodies against proteins, typically found on the exosome’s surface that 
will increase the chances of investigating exosomes exclusively. Alternatively, a microplate 
immuno-phenotyping assay can also provide a quantitative analysis, as exosomes are bound 
onto enzyme-linked immunosorbent assay (ELISA) strip plates. Primary antibodies can be 
used to target proteins of interest typically found on the surface of exosomes; and time-
resolved fluorescent can be determined by using a microplate reader. Though, a bulk assay 
like an ELISA plate would have difficulty in distinguishing sub-population of vesicles, which 
flow cytometry might be able to accomplish. 
Another technique used to give an indication of how heterogeneous the exosome sample is 
using Nanoparticle Tracking Analysis (NTA) (Nanosight™). NTA is used to measure size 
distribution and concentration of nanoparticles (Dragovic et al., 2011). Quantification of 
nanoparticles by NTA are predominantly based on two principles: the movement of particles 
in suspension under Brownian motion and their movement, which will scatter light that can 
be individually tracked by the NTA software. This software will calculate the exosome’s 
diameter by using the Stokes Einstein equation. One main advantage of using NTA compared 
to other technologies, such as resistive pulse sensing or dynamic light scattering (DLS), is the 
speed and simplicity of analysing many particles simultaneously; and the suitability of the 
method for particles of heterogeneous sizes. Though, multiple parameters, such as the 
sample dilution, camera shutter speed and gain, length and number of videos, and detection 
threshold, must be set by the user to acquire reproducible results. One downfall for NTA, is 
it does not discriminate the morphology of different EVs (cannot distinguish an exosome and 
microvesicle of similar sizes) and the results are less accurate when samples are 
polydispersed; however, this approach is better than using DLS.  
There is no consensus on a ‘gold standard’ method to isolate and/or purify; and subsequently 
characterise exosomes. There are multiple techniques that can provide different 
information, in terms of morphology, size and molecular composition about the isolated 
exosome preparation. It is, therefore, important to use these techniques in an informed 
fashion and stipulate clearly the method used to characterise the isolated EVs in question. 
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1.3.4 The Functions of Exosomes in Cancer 
Since the 1980s, numerous diverse functions have been attributed to exosomes. Exosomes 
are known to exhibit functions like their parent cell. For example, initial studies described 
the release of the transferrin receptor during reticulocyte maturation. It was suggested that 
these membranous structures (exosomes) were used by cells to remove obsolete molecules 
(Harding et al., 1983, Pan et al., 1985), a process key for differentiation into erythrocytes. 
However, this role as cellular waste may not have done the EV field much favour as for a long 
time, the fate of EVs was amounted with waste and nothing more. Though, seminal work 
from the Institut Curie groups, identified cell-activating roles for exosomes. Exosomes from 
antigen presenting cells such as B cells, are enriched in MHC-II and have shown to be 
functional in antigen presentation, leading to T cell stimulation (Raposo et al., 1996). It was 
shown that exosomes secreted from DCs bear antigen and MHC-peptide complexes, 
participating in immune responses (Théry et al., 1999). Other studies have also highlighted 
that exosomes secreted by intestinal epithelial cells are involved in humoral responses and 
transfer antigenic information from the apical domain to the immune cells in the gut (Van 
Niel et al., 2003). Additional reports support the concept that exosomes from one cell may 
fulfil a function on the recipient cell. The findings that exosomes carry protein, lipid and 
nucleic acids such as mRNA and miRNA, that are functional in recipient cells (Valadi et al., 
2007), strengthens this notion. In cancer, these discoveries suggest exosomes may play roles 
in cell-to-cell communication and contribute through varied mechanisms for the pathological 
processes of cancer. 
Exosomes and the Immune Response 
Many studies have investigated the function of exosomes derived from tumour cells. It has 
been reported exosomes can carry tumour antigens to induce an efficient anti-tumour 
response. Melanoma-derived exosomes has been reported to be presented to antigen 
presenting DCs for cross presentation to cytotoxic T lymphocytes (CD8+ T Cells) via MHC-I 
molecules (André et al., 2002). These activated T cells can trigger an anti-tumour response 
that suppresses tumour growth in vivo (Wolfers et al., 2001). Although the potential here for 
immune responses against murine viruses contaminating the EV preparations is high and 
may explain the specific potent immune response generated by exosomes in mice. Additional 
studies demonstrated HSP70-enriched exosomes from pancreas and colorectal cancer can 
stimulate natural killer (NK) cell activity, resulting in NK-mediated apoptosis of tumour cells 
(Gastpar et al., 2005, Lv et al., 2012). The data suggests that tumour-derived exosomes can 
inhibit tumour progression by promoting these immunological responses. 
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On the other hand, tumour exosomes have been described to exert immunosuppressive 
functions, such as tumour cells escaping from CD8+ T-cells. Some studies have reported that 
melanoma and prostate cancer cell-derived exosomes express CD95L (Fas-Ligand), inducing 
apoptosis of Fas positive CD8+ T cells in a dose-dependent manner (Andreola et al., 2002, 
Abusamra et al., 2005). This apoptotic effect was abrogated by blocking FasL on the tumour 
exosomes. Also, in another study, tumour-derived exosomes can inhibit myeloid 
differentiation into DCs and trigger differentiation of myeloid cells into immunosuppressive 
cells (Yu et al., 2007, Xiang et al., 2009). It was demonstrated the cytotoxic function of NK 
cells was impaired following tumour exosome treatment (Clayton et al., 2007). But, 
CD4+CD25+ Treg cells remained interleukin (IL)-2 responsive through induction of Foxp3 
expression and their inhibitory function was enhanced by tumour exosomes, showing this 
appears to be contributed by TGF-β-associated exosomes. In one study, a CD8+ T cell line pre-
incubated with tumour exosomes bearing NKG2D ligands had significantly decreased the 
CD8+ T cell capacity to kill target cells (Clayton and Tabi, 2005). NKG2D is an activating 
receptor for NK or CD8+ T cells, whose aberrant loss in cancer appears key for immune 
evasion. The follow-up study demonstrated that TGF-β positive exosomes appear to have a 
role in downregulating NKG2D expression by NK and CD8+ T cells, impairing effector immune 
function (Clayton et al., 2008). Furthermore, it was reported that cancer exosomes 
expressing CD39 and CD73 can suppress T cells through adenosine production (Clayton et al., 
2011). These exosomes are capable of dephosphorylating exogenous adenosine 
triphosphate (ATP) and 5’AMP to form adenosine, which are due to the functional CD39 and 
CD73 by exosomes. The mechanisms behind these actions remain poorly understood, 
however, these are some examples how cancer-derived exosomes may direct escape from 
immune surveillance. 
From numerous studies, tumour exosomes may play different contrasting roles in cancer. 
Exosomes may exert an anti-tumour response, as well as triggering an immunosuppressive 
function. These differences in the role of tumour exosomes may possess different 
phenotypes from different cancer types and thus, the differences in function is observed. 
Exosomes and Drug Resistance 
Cancer exosomes may have other functions that involve the support for drug resistance. One 
study demonstrated that ovarian cancer cells resistant to the chemotherapeutic drug, 
cisplatin, were secreting elevated levels of exosomes, compared to cells sensitive to 
chemotherapy (Safaei et al., 2005). It is proposed that once the chemotherapeutic drugs 
reach cancer cells, the secreted exosomes can expel these drugs away from the cancer cells. 
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Similarly, manipulated breast cancer cell lines that became insensitive to chemotherapeutic 
drugs, such as adriamycin or docetaxel, were found to transfer mRNA/miRNA traits that were 
linked to drug resistant traits via exosomes (Levchenko et al., 2005, Chen et al., 2014). It was 
shown that ribonucleic acid (RNA) is retained within the exosome (Valadi et al., 2007), which 
can give sufficient protection from RNAse degradation, which may transferred to recipient 
cells. These observations suggest that cells may also acquire drug resistance traits from 
exosomal RNA. From multiple studies, cancer cells may acquire drug resistant traits from 
surviving cells treated with chemotherapy. These surviving cells may carry genes resistant to 
drug treatment, allowing a small proportion of cancer cells to survive, which may ultimately 
lead to a positive feedback mechanism to occur that may allow cancer to relapse. 
Exosomes and the Stromal Response (Angiogenesis) 
Studies have demonstrated tumour exosomes can directly support angiogenesis by 
interacting with endothelial cells. Murine multiple myeloma-derived exosomes carried 
multiple angiogenesis-related proteins, such as angiogenin, FGF and VEGF, enhancing 
angiogenesis and directly promoting endothelial cell growth by modulating pathways such 
as PI3K/Akt and p120/signal transducer and activator of transcription (STAT) 3 pathway 
(Wang et al., 2016a). Tspan8 was often overexpressed in pancreatic and prostate cancer 
(Uhlen et al., 2010), correlating with increasing levels of angiogenesis in vivo. These Tspan8-
positive exosomes promoted endothelial cell branching and elevated pro-angiogenic growth 
factor levels in vitro, thus promoting angiogenesis (Gesierich et al., 2006). Elevated 
transcription levels of urokinase-type plasminogen activator (uPA), VEGFR and von 
Willebrand Factor (vWF) was found in endothelial cells, when treated with Tspan8 positive 
exosomes from rat adenocarcinoma cells. These observations overlapped with enhanced 
endothelial cell migration, branching and proliferation (Nazarenko et al., 2010). It was 
reported that the mRNA content of glioblastoma EV demonstrates an enrichment of 
transcripts related to pro-angiogenic function; and provided evidence that EV delivers mRNA 
that is subsequently translated into proteins in recipient cells (Skog et al., 2008). Similar 
observations have shown an enhanced proliferative impact on endothelial cells and 
enhanced tubule formation shown in 3D in vitro culture (Hong et al., 2009). In one study, 
exosomes from colorectal cancer were found to promote endothelial proliferation and 
tubule formation in vitro (Huang and Feng, 2016); and the transfer of exosomal miRNA (such 
as miRNA-92a) may play a role in this process (Umezu et al., 2013). Such alterations in miRNA 
can enhance endothelial cell migration and tube formation. Similarly, this was shown in 
squamous carcinoma and colorectal cancer cells secreting exosomes enriched in proteins 
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and cell cycle-related mRNAs, that can facilitate angiogenesis and metastasis (Thompson et 
al., 2013). Tumour exosomes, therefore, may play roles in supporting angiogenesis in vitro 
and in vivo, possibly due to the transfer of genetic information to recipient endothelial cells. 
Stromal Myofibroblasts 
Stromal myofibroblasts have been known to support tumour growth and progression 
(Tuxhorn et al., 2002a, Kalluri and Zeisberg, 2006), but the first report of an exosomal role 
was documented in a prostate cancer model (Webber et al., 2015). Specifically, TGF-β1 
positive cancer exosomes from mesothelioma and prostate (DU145 or PC3) cells have been 
shown to trigger fibroblast differentiation to myofibroblasts, as characterised by α-SMA 
onset into stress fibres (Webber et al., 2010). Exosomes from breast (MCF-7), prostate 
(LNCAP) or colorectal (CaCO2) cancer cell lines with low/undetectable levels of TGF-β1 failed 
to trigger fibroblast differentiation into α-SMA positive myofibroblasts (Webber et al., 2010). 
Blocking TGF-β1 signalling revealed fibroblast differentiation into myofibroblasts to be 
reliant on TGF-β1 associated exosomes, that triggered the SMAD-dependent pathway. 
Similarly, it was shown that TGF-β1 positive exosomes can modulate MSCs, skewing towards 
an α-SMA positive myofibroblastic cell, but recombinant human TGF-β1 (rhTGF-β1) could not 
generate the same phenotype (Chowdhury et al., 2015). So, vesicles containing TGF-β1 is a 
potent stimulus driving myofibroblast onset irrespective of the precursor type. 
Phenotypic analysis discovered major differences in myofibroblasts generated from soluble 
rhTGF-β1 or TGF-β1 positive exosomes. These differences are highlighted by a significant 
elevation in secreted pro-angiogenic growth factors, such as FGF-2, HGF, uPA and VEGF, in 
exosomal-induced myofibroblasts and these effects were inhibited by blocking TGF-β1 
signalling (Webber et al., 2015). The myofibroblast type was sufficient to support migration 
of endothelial cells and formation of vessel-like structures. Myofibroblasts generated from 
rhTGF-β1-treated conditions failed to recapitulate this pro-angiogenic function (Webber et 
al., 2015). Similarly, exosome-differentiated MSCs supported the proliferation, motility and 
organisation of endothelial cells and heightened invasive behaviour (Chowdhury et al., 
2015). Exosomes as a stimulus, therefore, provided a myofibroblast type that cannot be 
generated by soluble TGF-β1 stimulation. The exosome generated stroma exhibits a 
phenotype of functional properties akin to in vivo educated prostate cancer stroma; and 
supports tumour growth in xenograft (Webber et al., 2015).  
The need for cancer exosomes to drive stromal differentiation to a disease-associated 
phenotype has been shown in different ways. Targeting Rab27a, a guanosine 
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triphosphatases (GTPase) protein involved with trafficking MVEs to the plasma membrane 
would potentially inhibit exosome secretion from tumour cells. Silencing Rab27a depleted 
80% of exosomes from prostate cancer cells, likely to 15 – 20% of TGF-β1 positive exosome 
(Webber et al., 2015). In functional terms, CM from wild type prostate cancer cell drove 
stromal fibroblast differentiation to an α-SMA-positive myofibroblast phenotype, supporting 
vessel-like structure formation. However, CM from DU145 Rab27aKD cells failed to trigger 
differentiation and an angiogenic effect, with reduced secretion of pro-angiogenic growth 
factors. Also, these effects were shown in vivo in terms of promoting tumour growth, where 
Rab27a-dependent exosomes and stromal cells communicate, creating a tumour 
microenvironment for disease progression. Furthermore, xenografts containing DU145 
Rab27aKD cells failed to grow big tumours, even in the presence of fibroblasts, suggesting 
that stromal-assisted growth is lost. It remains unclear, however, what other intrinsic factors 
regulating exosome biogenesis and secretion in cancer cells that can modulate the cross-
communication within the tumour microenvironment.
Chapter 1. Introduction 
 
34 
 
1.4 Molecular Mechanisms of Biogenesis and Secretion of Exosomes 
1.4.1 The Endocytic Pathway 
Different Mechanisms for Endocytosis 
Endocytosis is a process where the cells uptake macromolecules or particles that cannot 
penetrate through the plasma membrane by diffusion, or transport through membrane 
pores. It involves the creation of a newly formed endosome by invagination and subsequent 
inward pinching of the plasma membrane. This process plays a role in a variety of cellular 
response, including remodelling of the plasma membrane, nutrient uptake, antigen uptake 
and presentation; regulation of the cell surface signalling receptors. There are numerous 
mechanisms for endocytosis (Doherty and McMahon, 2009), which can be categorised into 
either phagocytosis or pinocytosis. Phagocytosis engulfs large particles (including bacteria 
and pathogens) to eliminate them, which occurs in specialised cells, such as macrophages. 
Binding of the particle to cell surface receptors triggers the plasma membrane to remodel 
(involving actin polymerisation) and leads to pseudopodia formation surrounding the 
particle. This internalisation in a structure is called a phagosome, which is destined for 
lysosomal degradation through the action of hydrolytic enzymes.  
Pinocytosis can occur in all cell types via several mechanisms: clathrin-dependent 
endocytosis, caveolae-dependent endocytosis and macropinocytosis and other related 
mechanisms, as shown in Figure 1.7. Macropinocytosis occurs in a comparable way to 
phagocytosis, to the extent of actin remodelling at the plasma membrane, which engulfs 
extracellular fluid and molecules within to form a large endosome. Caveolae contains a 
cholesterol-binding protein (caveolin) that forms flask-shape invaginations (50nm) at the 
plasma membrane. Clathrin-dependent endocytosis (receptor-mediated endocytosis) is one 
of the most characterised mechanisms (Benmerah and Lamaze, 2007). It involves the 
polymerisation of clathrin lattices through the action of different adaptor complexes to form 
clathrin-coated pits, to cluster cargo together via cell surface receptors. The release of 
clathrin-coated vesicles from the plasma membrane is mediated by dynamin and requires 
GTP hydrolysis by this protein. The formation of newly-formed endosomes from these 
various mechanisms, leading next to fusion with an intracellular compartment, is known as 
an early endosome.
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Intracellular Compartments of the Endocytic Pathway 
The endocytic pathway consists of multiple complex membrane compartments, which leads 
to the recycling of endocytosed material to the plasma membrane, trafficked for their 
degradation in the lysosomes or delivery to the trans-Golgi network (Gruenberg, 2001, 
Stenmark, 2009). These membrane compartments are enriched in specific proteins, such as 
Rab GTPases (Stenmark, 2009); and they can be identified by endocytic tracers or by ligands 
of cell surface receptors. Early endosomes serve as a focal point for the endocytic pathway 
and sorting events are initiated at this compartment to determine the subsequent fate of 
internalised proteins or lipids. Early endosomes are tubulo-vesicular structures located at the 
cell’s periphery and are identified by proteins, such as early endosome antigen 1 (EEA1), 
Rab4 or Rab5; and the presence of the transferrin receptor, following internalisation after 5 
- 10 minutes (Rybin et al., 1996, Rubino et al., 2000). The mildly acidic conditions within the 
early endosomes induces ligand uncoupling that will unload cargo destined for either 
degradation or recycling. The cargo destined for recycling will accumulate in tubular 
membrane compartments, termed recycling endosomes, which are less acidic than early 
endosomes (Stenmark, 2009). These are located near the Golgi apparatus within the 
perinuclear region, identified by Rab4 and Rab11 proteins; and the transferrin receptor is 
reached after 15 minutes of internalisation. 
MVEs or late endosomes are formed during the maturation of the early endosome 
(Stoorvogel et al., 1991). These are characterised by the presence of ILVs and these ILVs 
accumulate other cell-surface receptors and molecules destined for lysosomal degradation. 
As one example, the EGF receptor once internalised, reaches the late endosome 
compartment after 30 minutes. These late endosome compartments are identified by 
proteins, such as LAMP1, LAMP2, CD63 or Rab7 (Kobayashi et al., 2000, Savina et al., 2005). 
Their main function was to fuse with lysosomes to ensure degradation of their content. 
Lysosomes have a low pH with a feature of an electron dense morphology, which possess 
markers, such as LAMP1, LAMP2, CD63 and Rab9 (Eskelinen, 2006, Raposo et al., 2007). 
Many studies have demonstrated that endosomal compartments with MVE hallmarks can be 
fated for fusion with the plasma membrane, leading to exocytosis of ILVs as exosomes, rather 
than fated for lysosomal fusion. This has raised questions whether different subpopulations 
of MVEs can occur simultaneously in cells with some destined for degradation or for 
exocytosis. 
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Figure 1.7: Different mechanisms of endocytic pathways. In the classical clathrin-
dependent endocytosis, receptors and their bound ligands are organised into specialised 
domains of the plasma membrane through interactions with adaptor protein complexes 
during endocytosis. These areas invaginate, leading to scission and are coated with 
clathrin to form a clathrin-coated pit. Similarly, caveolin-dependent endocytosis and 
another mechanism that does not require clathrin/caveolin/dynamin can also 
internalised cargo. These vesicles uncoat and fuse with early endosomes that is direct to 
late endosomes or lysosomes. Source: (Gould and Lippincott-Schwartz, 2009). 
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MVE Heterogeneity in Cells 
The existence of different subpopulations of MVEs in cells were initially observed in the 
distribution of cholesterol in different endosomal compartments (Möbius et al., 2003); 
staining cholesterol with perfringolysin O (cholesterol-binding toxin) in an EM technique. 
MVEs stained positively and negatively for cholesterol in EBV-transformed B cell lines. MVEs 
which stained positively demonstrated that there were the main lipid compartments which 
contained most ILVs. This finding agrees with other studies characterising the lipid 
composition of exosomes, which shows a clear enrichment of exosomes in cholesterol 
(Laulagnier et al., 2004, Trajkovic et al., 2008), as compared to other cellular membranes. A 
fusion profile showing the release of cholesterol-enriched EVs was seen within these cells. 
Another study also provides evidence of two distinct populations of MVEs (White et al., 
2006), after internalisation of EGFR to a subpopulation of MVEs that were positive for CD63. 
Detailed immuno-EM analysis showed another subpopulation of MVEs that were CD63 and 
lysobisphosphatidic acid (LBPA) positive, but did not contain any EGFR. It is possible that 
MVEs containing LBPA were destined for lysosomal degradation, rather that fusion with the 
plasma membrane. Furthermore, another study revealed the presence of different MVEs by 
making comparisons between immature DCs and DCs undergoing cognate interactions with 
T cells (cells loaded with an antigen and incubated with antigen-specific T cells) (Buschow et 
al., 2009). In immature cells, MHC-II molecules are predominantly sorted into MVEs fated for 
degradation. Though, in the presence of antigen-specific T cells, DCs secrete exosomes that 
are enriched in MHC-II and CD9, from newly formed MVEs. This study points to a difference 
in MHC-II sorting, indicating two distinct MVE pathways: one for lysosomal targeting and the 
other for exosome secretion. The gives some evidence that different subpopulations of 
exosomes can exist, although there might be other types of EVs that exists from different 
MVE, suggesting that different MVE can co-exist in the same cell. 
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1.4.2 Biogenesis of Exosomes 
ESCRT-Dependent Mechanisms 
As previously described, exosomes are formed within MVEs during early endosome 
maturation. Research into the molecular mechanisms that proceeds with ILV formation was 
first observed in yeast Saccharomyces cerevisiae, a model organism for studies involving 
endocytic trafficking and a pathway of lysosomal degradation (Raymond et al., 1992). 
Mutations in the vacuolar sorting (VPS) protein showed impaired MVE formation and an 
accumulation of cargo that was directed for vacuolar degradation (Rieder et al., 1996). 
Additional studies showed their orthologues in mammalian cells could form ESCRT 
complexes, which were described as 4 different components: ESCRT-0 (Katzmann et al., 
2002), ESCRT-I (Katzmann et al., 2002), ESCRT-II (Babst et al., 2002b) and ESCRT-III (Babst et 
al., 2002a), as shown in Figure 1.8. These complexes interact with one another and are 
recruited by the endosomal limiting membrane where they carry out their function. The 
recruitment of these complexes to the endosome membrane is transient, since the function 
of VPS4 (ATPase) is to release these complexes once their function is complete (Babst et al., 
1998). 
ESCRT-0 
The ESCRT-0 complex is a heterodimer formed by HRS (HGS, hepatocyte growth factor 
regulated kinase substrate) and STAM (signal transducing adaptor molecule). This complex 
is key for selecting ubiquitinylated cargo at the endosomal membrane. Phosphattidylinositol-
3-phosphate (PI(3)P) is abundant in endosome membranes which is bound onto by HRS, 
initiating recruiting of this complex to the endosomal membrane. HRS and STAM contribute 
to cargo selection by interacting with monoubiquitinated proteins, through their ubiquitin 
binding domains (UBD) (Urbe et al., 2003). These subunits are proposed to recruit clathrin to 
form a double-layered coat on the endosomal membrane (Sachse et al., 2002), to accumulate 
cargo into microdomains that will subsequently bud to form ILVs. HRS recruits ESCRT-I by 
interaction with the ESCRT-I subunit, TSG101 (Katzmann et al., 2002, Bache et al., 2003). 
ESCRT-I 
The ESCRT-I complex consists of TSG101, VPS28, one isoform of VPS37 and one of the MVB12 
subunits. ESCRT-I can bind ubiquitin through the UBD of TSG101, which increases the 
efficiency of ubiquitinated cargo sorting (Teo et al., 2004). Furthermore, this complex of 
ESCRT-0 and ubiquitin has been shown to interact with ALIX and ESCRT-II. TSG101 is key in 
the ESCRT-dependent pathway and depletion leads to a loss of function of the entire complex 
(Hanson and Cashikar, 2012). 
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ESCRT-II 
The ESCRT-II complex consists of VPS22, VPS36 and together two subunits of VPS25. In yeast, 
VPS36 contains a GLUE domain which interacts with PI(3)P, ubiquitin and ESCRT-I; and the 
two VPS25 subunits are able to bind to the ESCRT-III subunit, VPS20 (Teis et al., 2010). This 
ESCRT-II complex enables the recruitment of ESCRT-III to endosomal membrane (Babst et al., 
2002a). It remains unknown whether inhibition of two ESCRT-II subunits (VPS25) in 
mammalian cells will stop the recruitment of ESCRT-III. 
ESCRT-III 
In mammalian cells, the ESCRT-III complex consists of 4 core subunits: charged multivesicular 
body proteins (CHMPs) 6, CHMP4, CHMP3 and CHMP2; and other associated proteins 
CHMP1, CHMP5 and IST1. In yeast, the ESCRT-III complex also consist of 4 core subunits: 
VPS20, VPS32, VPS24 and VPS2; and other associated proteins DID2, VPS60 and IST1 
(Increased Sodium Tolerance Protein 1). In yeast, the ESCRT-II protein, VPS25, binds to VPS20 
(Teis et al., 2010), initiating ESRCT-III recruitment to the endosome and complex formation. 
VPS20 recruits VPS32 (CHMP4 in mammalian cells), which polymerises and forms filaments 
that clusters cargo together (Teis et al., 2008). VPS32 recruits VPS24 and in turn recruits 
VPS2, which engages with the ATPase VPS4 that uncouples the ESCRT-III complex. 
Furthermore, VPS32 recruits the accessory protein ALIX, which stabilises VPS32 filaments 
and recruits DOA4 (deubiquitinating enzyme) required for cargo deubiquitination (Hurley 
and Odorizzi, 2012). ESCRT-III associated proteins CHMP1, CHMP5 and IST1 have been 
described as modulators of VPS4 ATPase activity (Nickerson et al., 2010), which can influence 
the size and rate of ILV formation. 
Accessory Proteins 
VPS4 is a vital aspect of the ESCRT pathway, since it uncouples the ESCRT-III subunit from the 
endosomal limiting membrane, recycling these components for additional formation of new 
MVEs. In mammalian cells, a dominant negative form of the VPS4 protein demonstrates an 
impaired capacity to hydrolyse ATP, therefore, inhibiting ILV formation and promoting 
accumulation of ESCRT protein on abnormal endosomes (Sachse et al., 2004). The accessory 
protein ALIX has been shown to interact with ESCRT-I and ESCRT-III; and proposed to be a 
key mediator in viral budding (Fisher et al., 2007) and cytokinesis (Carlton et al., 2008). ALIX 
also appear to play a role in MVE formation. During MVE formation, it has been proposed 
ALIX binds to CHMP4 and TSG101, as well as other proteins in the formation of multiple 
ESCRT complexes, but their exact function in the ESCRT pathway for ILV formation is 
unknown. 
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Figure 1.8: The ESCRT-dependent machinery in endosomal sorting and MVE biogenesis. 
Receptors in the limiting membrane of MVE are ubiquitinated in response to ligand 
binding. ESCRT-0 recognises the ubiquitin moieties which internalises cargo into specific 
domains of the limiting membrane. ESCRT-0 recruits ESCRT-I, in conjunction with the 
transfer of ubiquitinated cargo. Together with ESCRT-II, ESCRT-I mediates invagination of 
the MVE’s limiting membrane. ESCRT-III is recruited by binding onto ESCRT-II and cargo 
is deubiquitinated. Spiral-shaped ESCRT-III filaments assembles around the neck of the 
forming vesicle to promote abscission, forming an ILVs. VPS4, recruited by ESCRT-III, 
mediates the disassembly of ESCRT-III oligomers, so that the subunits are recycled. 
Source: (Rusten et al., 2012). 
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ESCRTs and Exosomes 
The role for ESCRT proteins in exosome biogenesis has been based on accumulating evidence 
from several cell lines. A study observed on mouse DCs demonstrated that silencing the HRS 
gene (ESCRT-0 component) attenuates exosome release (Tamai et al., 2010). The authors 
observed a significant attenuation in exosome release from DCs deficient (siRNA-treated 
DCs) in HRS, which were stimulated for exosome secretion with a calcium ionophore. This 
attenuation resulted in defective antigen presentation to cytotoxic T cells and was not due 
to a compromised lysosomal degradation pathway. Additionally, an RNA interference screen 
was performed to target 23 individual ESCRT components in HeLa cells (Colombo et al., 
2013). Silencing ESCRT-0 (HRS and STAM1) or the ESCRT-I gene (TSG101) reduced the 
secretion of exosomes (characterised by CD63 and MHC-II expression).  
ALIX has been involved in exosome biogenesis in multiple studies. One study observed that 
during reticulocyte maturation, the chaperone protein HSP70 binds to the newly 
endocytosed transferrin receptor via the cytoplasmic domain of the adaptor protein 2 (AP2), 
which undergoes degradation by the proteasome (Géminard et al., 2004). Binding of ALIX on 
the transferrin receptor within the same cytoplasmic domain in the absence of AP2, suggests 
to link the receptor to the ESCRT machinery for cargo sorting into the ILVs. Supporting this 
notion, it was reported that exosomes contain syndecans, that can bind to heparan sulphate 
from the extracellular matrix, but also to syntenin (small scaffolding protein) via their 
cytoplasmic domain and ALIX, which in turns interacts with syntenin (Baietti et al., 2012). 
Syntenin overexpression increased exosome secretion (elevated CD63 and HSP70), which 
was dependent on ALIX. Silencing either syndecan, syntenin or ALIX attenuated exosome 
secretion. Supporting these findings, two regulators of this syntenin-ALIX complex, GTPase 
ADP ribosylation factor 6 (ARF6) and its effector phospholipase D2 (PLD2), demonstrated a 
role for affecting exosome biogenesis and budding into MVEs (Ghossoub et al., 2014). Data 
suggest that ALIX might be responsible for loading and packaging of miRNA into ILVs (Iavello 
et al., 2016); and recruiting ESCRT-III components to ESCRT-I domains on the endosome 
membrane. Interestingly, these data support a role for ESCRT-related proteins (HRS or ALIX) 
in exosome biogenesis, but the relationship between ESCRT-dependent exosome formation 
and their cargo load remains poorly understood. 
ESCRT-Independent Mechanisms 
The presence of different MVE subpopulations in a single cell has suggested that different 
mechanisms may operate in cells to generate these distinct endosomal compartments, thus 
challenging the concept that the ESCRT machinery always mediates MVE biogenesis. To 
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address whether ESCRT are necessary for ILV biogenesis, a study silenced four ESCRT proteins 
(HRS, TSG101, VPS22 and VPS24) implicated in all ESCRT complexes, to abolish ESCRT-related 
function (Stuffers et al., 2009). Inhibition of all four ESCRT proteins revealed changes in the 
endosomal compartments, with the presence of enlarged MVEs and with few internal 
vesicles next to the limiting membrane. Though, ILVs were still formed in these altered 
structures, indicating that independent ESCRT pathways can ensure MVE formation. 
In one study, it was demonstrated in an oligodendroglial cell line that budding of ILVs into 
MVEs was independent of ESCRT function and required the sphingolipid ceramide (Trajkovic 
et al., 2008). Inhibition of neutral sphingomyelinases (nSMase; enzyme hydrolysing 
sphingomyelin to ceramide) with GW4869 decreased proteolipid protein (PLP)-associated 
exosome release. This suggested that PLP sorting into ILVs required ceramide and 
independent of ESCRT. Treatment of embryonic kidney  (Chairoungdua et al., 2010, Kosaka 
et al., 2010) with GW4869 also reduced secretion of exosomal associated protein markers 
(CD63, CD81 or TSG101). Though, treatment of cells with GW4869 induces cell death, which 
provides an inaccurate analysis of exosome secretion. In contrast, in human melanoma cells, 
the depletion of nSMase impairs neither MVE biogenesis or exosome secretion (van Niel et 
al., 2011). It was proposed that inhibition of ESCRT function (HRS, TSG101 or VPS4) did not 
alter the sorting of premelanosomal (PMEL) protein (a component of melanosomes) on ILVs. 
MVEs were still capable of forming cells where the ESCRT machinery had been disrupted, 
albeit their morphology was different from that of the control (Theos et al., 2006). Another 
study has proposed that the tetraspanin, CD63, has a role in sorting PMEL to ILVs (van Niel 
et al., 2011). In melanoma cells (MNT-1), CD63 is detected with PMEL in MVEs and 
abundantly on ILVs than on the limiting membrane. Silencing CD63 inhibits ILV formation in 
MVEs and causes PMEL to accumulate at the limiting membrane, demonstrating that CD63 
participates in protein sorting to the ILVs. Other tetraspanins, such as CD9, might have an 
effect, but remains poorly understood in the context of exosome secretion. These results 
and other studies suggests that MVEs and subsequent sorting mechanisms for the sorting 
cargo can be performed via ESRCT-dependent and independent mechanisms, that gives rise 
to a heterogeneous population of MVEs. 
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1.4.3 Exosome Secretion 
The process of exosome secretion involves the trafficking of MVEs or late endosomes to the 
vicinity of the plasma membrane for docking and fusion; and consequently, ILV release into 
the extracellular space. This complex process involves multiple molecules that are 
responsible for different steps: cytoskeleton proteins (actin or tubulin), molecular motor 
proteins (kinesin) mediates transport to the plasma membrane, the Rab protein family will 
be heavily involved in endosomal membrane trafficking; and the SNARE protein family will 
be involved in the final phases of fusion. The precise molecular machinery behind exosome 
secretion is not fully understood, however, multiple studies have identified potential 
proteins involved and this will be discussed in greater detail below. 
Several studies have analysed whether exosome secretion is constitutive or regulated in 
various cell types. Exosome secretion can be induced by a rise in intracellular calcium levels 
in the haematopoietic cell line (K562) (Savina et al., 2003) or in mast cells (Valadi et al., 2007). 
Degranulation of mast cells has been related to increased exosome secretion (Laulagnier et 
al., 2004). Alternatively, exosome secretion is normally analysed at the steady state (absence 
of stimulus), which remains difficult to exclude the possibility that some unsuspected signal 
or stimulus may trigger or modify this secretion. In one study, exosome secretion might be 
increased by cognate interactions with antigen-specific CD4+ T lymphocytes (Buschow et al., 
2009). Exosome secretion by rat cortical neurons can be stimulated by depolarisation of the 
cells (Faure et al., 2006). Furthermore, γ-irradiation induced deoxyribonucleic acid (DNA) 
damage can promote exosome secretion through activation of the p53-regulated protein, 
TSPAN6 (Yu et al., 2006). 
Rab Protein Family 
The Rab protein family are small monomeric GTPases which are regulators of trafficking 
different endosomal compartments within the cell; Rabs can be involved in either vesicle 
budding, tethering to the membrane of an acceptor compartment or motility through the 
cytoskeleton, which will ultimately fuse with the target compartment (Pfeffer, 2001, 
Stenmark, 2009). There are over 70 Rab GTPases, each of which are associated with a specific 
endosomal compartment. The regulatory function of these Rab proteins is based on their 
capacity to switch between an inactive GDP-bound form to an active GTP-bound form, 
considered to be the active conformation (Pereira-Leal and Seabra, 2001). This cycle is 
regulated by guanine nucleotide exchange factors (GEFs), which facilitate GDP release and 
subsequent GTP binding. Alternatively, GTP hydrolysis can be catalysed by the Rab GTPases 
themselves or by GTPase activating proteins (GAPs). 
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The first study that provided evidence for Rab proteins involvement in exosome secretion 
came from studying the erythroleukaemia cell line, K562, which releases exosomes 
containing the transferrin receptor (Savina et al., 2002). Overexpression of the dominant 
negative form of Rab11 (unable to hydrolyse GTP), resulted in attenuated secretion of 
HSP70-associated exosomes, suggesting a role for Rab11. This follow up study suggested that 
Rab11 was involved in tethering MVEs to the plasma membrane, with the final fusion step 
requiring calcium ions (Savina et al., 2005). 
Later, a screening approach was performed in HeLa-CIITA cells to target multiple Rab 
GTPases in their role in exosome secretion (Ostrowski et al., 2010). A total of 59 Rab proteins 
were targeted by an RNAi approach and proposed that Rab2b, Rab5a, Rab9a appeared to 
modulate exosome secretion, with Rab27a and Rab27b, however, having the greatest role. 
It was shown that silencing these Rab proteins decreased the secretion of exosomes bearing 
CD63, CD81 and MHC-II. Additional analysis unravelled that silencing Rab27a, increased MVE 
size and altered its docking to the plasma membrane. However, silencing Rab27b altered 
docking of smaller MVEs to accumulate in the perinuclear region of the plasma membrane. 
Alternatively, another screen was performed that targeted Rab-activating proteins (Rab-
GAPs) in oligodendroglial cell lines (Hsu et al., 2010), revealing that TBC1D10A-C act as 
regulators of exosome secretion. Rab35 was identified as a target of TBC1D10A-C and Rab35 
inhibition (either by siRNA or by using a dominant negative mutant) indicated a significant 
decrease in secretion of PLP-exosomes. Rab35-dependent exosome secretion was also 
confirmed in another study by using primary oligodendrocytes (Fruhbeis et al., 2013). 
Interestingly, different observations were reported in various cell types. In Drosophila S2 
cells, inhibition of Rab11 by dsRNA attenuate the secretion of small EVs containing wingless 
or Evi (Beckett et al., 2013), whereas Rab27 or Rab35 did not. In another study, inhibition of 
Rab11 or Rab35 in retinal epithelial cells attenuated the secretion of flotillin associated EVs, 
whereas Rab27a/b did not play a role (Abrami et al., 2013). In multiple tumour cell lines of 
various origins (prostate, breast or melanoma), silencing Rab27a decreased the secretion of 
exosomes pelletable by ultracentrifugation (Bobrie et al., 2012, Peinado et al., 2012, Webber 
et al., 2015). According to the literature (Stenmark, 2009), Rab11 and Rab35 are proposed to 
associate with the recycling endosomes and Rab27a to the late endosome, as shown in 
Figure 1.9. The conflicting observations in various studies suggests that heterogeneous MVEs 
can generate different subpopulations of secreted exosomes, that may vary from cell type 
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and become enriched with specific proteins (CD63, ALIX, TSG101) or other cell-specific 
proteins (PLP, transferrin receptor or Wnt-associated). Additional investigation will be 
required to elucidate the roles of Rab11b or Rab35 in the context of prostate cancer cells.
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Figure 1.9: The multiple molecular machineries of exosome secretion. Multiple 
molecular machineries of exosome secretion have been described. For MVE-dependent 
secretion, the Rab protein family (Rab11, Rab27 and Rab35) has been documented to 
promote secretion of exosomes and may act on specific MVEs along the endocytic 
pathway. Other related plasma membrane EVs, ARF6 and some ESCRT components has 
been proposed to regulated outward budding. Adapted from Source: (Colombo et al., 
2014). 
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SNARE Protein 
During intracellular vesicle trafficking, the final step fusion of the vesicle with the acceptor 
membrane depends on a family of proteins called SNARE (soluble N-ethylmaleimide-
sensitive fusion attachment protein (SNAP) receptors) (Jahn and Scheller, 2006). SNARE 
proteins were originally categorised as vesicular SNAREs (v-SNARE: vesicular-associated 
membrane proteins), if they were located on the vesicle’s membrane; and target SNAREs (t-
SNARE), if located on the membrane of acceptor compartments (Rao et al., 2004, Chaineau 
et al., 2009). It has been proposed SNARE proteins form complexes with SNAPs between two 
membranes and mediate membrane fusion between the two organelles. In multiple studies, 
calcium regulated fusion of secretory lysosomes with the plasma membrane has been shown 
to involve SNAP-23 at the plasma membrane and lysosomal vesicle-associated membrane 
protein (VAMP)7 in epithelial cells (Rao et al., 2004) or VAMP8 in mastocytes (Puri and Roche, 
2008), but the SNARE complex involved with MVE fusion with the plasma membrane to 
modulate exosome secretion has not been thoroughly investigated. One study proposed the 
role for VAMP7 to promote the secretion of MVEs to release acetylcholinesterase containing 
exosomes in the human leukaemic cell line, K562 (Fader et al., 2009). Other studies 
performed in Drosophila identified YKT6, a SNARE protein involved in endoplasmic reticulum 
to golgi apparatus transport, as required for MVEs to fuse with the plasma membrane to 
release Wnt positive exosomes (Meiringer et al., 2008) or Evi positive exosomes (Koles et al., 
2012). More recently, inhibition of YKT6 from the lung cancer cell line, A549, significantly 
attenuated exosome secretion, characterised by a loss of TSG101 associated exosomes (Ruiz-
Martinez et al., 2016), but additional investigations will be required in other cell lines to 
confirm these findings. 
  
Chapter 1. Introduction 
 
48 
 
 
 
  
Figure 1.10: Model of fusion machinery on an endosomal membrane. The two 
membrane are within the vicinity of each other, but the SNAREs are not yet in contact. 
Once membranes are primed for fusion, the SNARE complexes begin to start zipping, 
drawing the membranes closer to each other. The lateral tension in the transbilayer 
contact area induces membrane breakdown, yielding a fusion pore and the release of 
exosome. Adapted from Source: (Lorentz et al., 2012). 
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1.5 Hypothesis and Thesis Aims 
I hypothesise that cancer cells secrete distinct sub-populations of exosomes and that these 
may impart distinct molecular phenotypes and functions. 
The main objective of my Thesis is to gain an insight on the components putatively implicated 
in exosome biogenesis and secretion. I have focussed on proteins involved in four protein 
families: tetraspanin, ESCRT, Rab and SNARE. Given their involvement in ILV formation in 
yeast and mammalian models, it is proposed that the ESCRT family are involved in exosome 
biogenesis and secretion. Though, studies have challenged the concept that ILV formation 
solely by ESCRT complexes is not entirely true, with the notion that ESCRT-independent 
mechanisms must exist. It has been proposed that Rab and SNARE proteins have roles in 
endosomal trafficking of ILVs between different subcellular compartments and subsequent 
fusion with the plasma membrane to secrete exosomes. This proposes the idea that vesicle 
heterogeneity is present, where exosome subpopulations may co-exist and be regulated by 
specific proteins. Here, I will investigate the roles of these proteins: CD9, Rab5a, Rab11b, 
Rab35, VAMP7 and VPS25 in one cell type and understand the impact they have upon 
exosome secretion. 
Many studies have highlighted the role for exosomes secreted by cancer cells, as modulators 
of cancer associated stroma, angiogenesis and metastatic priming; promoting a disease 
associated phenotype. It remains unclear whether the factors responsible for generating this 
disease associated phenotype or whether this is due soluble factors or specific vesicle 
subpopulations driving this phenotype. I will assess the outcome of knockdown on secreted 
vesicles and their role in stromal-cell activation capacity. 
Lastly, the exosome generated myofibroblasts may also be considered as a direct stimulus 
for tumour growth, supporting tumour cell expansion, migration and invasion. I will be 
establishing 3D-spheroid culture incorporating tumour cells and fibroblasts, to mimic an in 
vivo 3D microenvironment. It remains poorly understood if the outcome of knockdowns on 
secreted vesicles will affect the 3D tumour spheroid growth and their ability to invade. Much 
of the in vitro experiments we investigate, will be assessed to see if it is translated into the 
in vivo setting. 
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2.1 Culture of Human Cell Lines 
2.1.1 Monolayer Culture 
DU145 is a prostate cancer cell line derived from a metastatic brain tumour and purchased 
from American Tissue Culture Collection (ATCC, USA). The cells were cultured in Roswell Park 
Memorial Institute (RPMI)-1640 (Lonza, Slough, UK) media, supplemented with 100 U/ml 
penicillin (Lonza), 100 µg/ml streptomycin (Lonza) and 10% foetal calf serum (FBS; 
ThermoFisher Scientific, Loughborough, UK). FBS was depleted of bovine exosomes by 
overnight centrifugation at 100,000 x g for 24 hours, followed by filtration though 0.22 µm 
and then 0.1 µm vacuum filters (Millipore, Watford, UK). Adult lung fibroblasts (Coriell 
Institute for Medical Research, USA) were cultured in DMEM/F12 (Lonza) containing 100 
U/ml penicillin (Lonza), 100 µg/ml streptomycin (Lonza) and 10% exosome-depleted FBS 
(ThermoFisher Scientific). Human umbilical vein endothelial cells (HUVEC) were purchased 
from Lonza, and maintained using the endothelial cell growth medium (EGM)-2 BulletKit™ 
(Lonza). Cell lines were all maintained at 37oC in an atmosphere of 5% CO2 in a humidified 
CO2 incubator. Mycoplasma test was carried out using a MycoAlert™ Mycoplasma Detection 
Kit (Lonza) every 2 months. All tissue culture work was carried out in a class II biosafety 
cabinet. 
2.1.2 Bioreactor Flasks for Prostate Cancer Cell Line (DU145) 
DU145 cells were seeded into bioreactor flasks (Wheaton, New Jersey, USA); and maintained 
at a high-density culture for exosome production. The bioreactor flask has two 
compartments; a cell and a medium compartment, which is separated by a 10kDa semi-
permeable membrane (Figure 2.1). This membrane allows the continuous diffusion of 
nutrients into the cell compartment with the removal of any waste products in the medium 
compartment. The medium compartment contains 500ml of culture media and the cell 
compartment contains 15ml of culture media which maintains cells. The cells are attached 
to a woven, polyethylene terephthalate (PET) matrix providing a large surface area for 
attachment; allowing secreted exosomes to be present in the cell CM. A low volume present 
in the cell compartment from these bioreactor flasks allows exosomes to 8 – 10 more 
concentrated per ml, compared to monolayer T-75cm2 flasks, thus reducing cost, labour and 
time (Mitchell et al., 2008).  
Cells were seeded into the cell compartment of the bioreactor flasks at an initial density of 
1.5 – 3.0 x 107 cells in 15ml of required supplemental culture media and 10% exosome-
depleted FBS. The medium compartment was filled with 500ml RPMI-1640 with required 
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supplements and 10% FBS. DU145 cell CM from these bioreactor flasks were collected and 
replaced with fresh media on a weekly basis. The CM containing exosomes from the cell 
compartment were centrifuged at 400 x g for 7 minutes at 4oC, an additional 400 x g for 7 
minutes at 4oC, followed by a 2000 x g for 15 minutes at 4oC to remove dead cells and cellular 
debris. The CM was collected and filtered using a 0.22µm Millex GP syringe filter (Merck 
Millipore, Massachusetts, USA), to remove any remaining debris and larger vesicles. The CM 
was stored at -80oC, until required for exosome purification.  
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Figure 2.1: Integra Bioreactor Flask. The bioreactor flask contains two compartments: 
the cell compartment containing the exosomes (maximum 20ml) and the medium 
compartment (500 – 1000ml) separated by a 10kDa semi-permeable membrane. The 
membrane allows continuous diffusion of nutrients and waste products between both 
compartments. Efficient gas exchange is ensured by a silicone membrane which forms 
the compartment base. This provides an optimal oxygen supply and control of carbon 
dioxide by providing a short diffusion pathway with the cell compartment. Source: 
(Scientific Laboratory Supplies, 2017). 
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2.2 Isolation and Characterisation of Exosomes 
2.2.1 Sucrose Cushion Method 
For all experiments, unless stated otherwise, exosomes were isolated from cell CM using the 
sucrose cushion method, as this is less labourious for exosome isolation, compared to the 
sucrose gradient method. Pre-cleared DU145 cell CM samples were obtained from -80oC and 
defrosted at 37oC. 
The CM was underlain with 4ml of 30% sucrose/D2O (density of 1.2 g/ml) and 
ultracentrifuged at 100,000 x g (SW-32 rotor, Beckman Coulter, High Wycombe, UK) for 2 
hours at 4oC. Approximately 2 - 3ml of the central base of the sucrose cushion solution was 
collected and diluted in excess phosphate buffered saline (PBS). The exosomes were pelleted 
by ultracentrifugation again at 100,000 x g for 2 hours at 4oC (fixed angle 70Ti rotor, Beckman 
Coulter). Exosome pellets were resuspended in PBS and stored at -80oC, until required for 
further experimental use. 
The protein concentration for exosome samples were evaluated using the MicroBCA Protein 
Assay (ThermoFisher Scientific). A standard curve was performed by serial dilution from 
2000µg/ml BSA to 0µg/ml. Exosomes were diluted 1:8 with PBS and absorbance values were 
calculated from the standard curve, to determine the protein content from exosome 
preparations. Unless stated otherwise, exosomes isolated from the sucrose cushion protocol 
will be described as purified DU145 exosomes. These exosomes are used in fibroblast 
differentiation experiments at a dose of 200µg/ml, which is equivalent to a dose of 1.5ng/ml 
rhTGF-β1, as described previously (Clayton et al., 2007, Webber et al., 2010). 
2.2.2 Cryo-Electron Microscopy 
For cryo-EM, this was performed in collaboration with Prof. Juan Falcon-Perez (CIC bioGUNE, 
Derio, Spain). Exosome or vesicle concentrates were directly adsorbed onto glow-discharged 
holey carbon grids (QUANTIFOIL, Großlöbichau, Germany). Grids were blotted at 95% 
humidity and rapidly plunged into liquid ethane with the aid of VITROBOT (Maastricht 
Instruments BV, Maastricht, The Netherlands). Vitrified samples were imaged at liquid 
nitrogen temperature using a JEM-2200FS/CR Transmission Electron Microscope (JEOL, 
Tokyo, Japan), equipped with a field emission gun and operated at an acceleration voltage 
of 200 kV. 
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2.2.3 Microplate Immuno-Phenotyping Assay 
Exosomes or vesicle concentrates were diluted in PBS and bound onto high protein binding 
ELISA strip 96-well plates (Greiner Bio-One, Frickenhausen, Germany), at a dose of 1µg/well 
and incubated overnight at 4oC. The wells were washed 3 times using a Tris-based wash 
buffer (Kaivogen, Turku, Finland), to remove unbound particles. Blocking solution (1% 
BSA/PBS; weight/volume: w/v) was added for 2 hours, before being washed 3 times. Primary 
antibodies were added at 1µg/ml (Table 2.1), for 2 hours at room temperature (RT). After 
washing wells 3 times, primary antibodies were detected by goat anti-mouse biotinylated 
antibody (Perkin Elmer, Massachusetts, USA) (diluted in 0.1% BSA/PBS w/v), at a 200ng/ml 
working concentration for 1 hour at RT. The wells were washed 3 times, before adding a 
europium-streptavidin conjugate (Perkin Elmer) in assay buffer (Kaivogen), for 45 minutes at 
RT. The wells were washed 6 times, before adding enhancement intensifier (Kaivogen), for 5 
minutes at RT and signal assessed by time-resolved fluorescence (TRF) on a PHERAstar FS 
Microplate Reader (BMG Labtech, Aylesbury, UK). 
2.2.4 Development of Permeabilised Exosomes for Microplate Immuno-Phenotyping 
Assay 
Exosomes were diluted in PBS and bound onto high protein binding ELISA strip plate (Greiner 
Bio-One) at a dose of 1µg/well and incubated overnight at 4oC. The wells were washed 3 
times using a wash buffer (Kaivogen), to remove unbound particles. Blocking solution (1% 
BSA/PBS, w/v) was added for 2 hours, before washed 3 times. Radioimmunoprecipitation 
assay (RIPA) lysis buffer (Santa Cruz, Texas, USA) was added for 1 hour at RT, before being 
washed 3 times. Primary antibodies (ALIX and TSG101) were added at 1µg/ml (Table 2.1), for 
2 hour at RT. After washing wells 3 times, the primary antibodies were detected by goat anti-
mouse biotinylated antibody (Perkin Elmer) (diluted in 0.1% BSA/PBS, w/v), at a 200ng/ml 
working concentration for 1 hour at RT. The wells were washed 3 times, before adding a 
europium-streptavidin conjugate (Perkin Elmer) in assay buffer (Kaivogen) for 45 minutes at 
RT. The wells were washed 6 times, before adding enhancement intensifier (Kaivogen) for 5 
minutes at RT and signal assessed by TRF on a PHERAstar FS Microplate Reader (BMG 
Labtech). 
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2.2.5 Western Blotting 
Cell lysates were extracted from whole cells (1 x 106) and prepared by resuspending in RIPA 
lysis buffer (Santa Cruz, Texas, USA) containing: 1X protease inhibitor cocktail, 200mM 
phenylmethane sulfonyl fluoride (PMSF), 100mM sodium orthovanadate and 1X lysis buffer 
(All from Santa Cruz). Insoluble material was removed by centrifuging samples at 10,000 x g 
for 10 minutes at 4oC, split into aliquots and stored at -80oC for future use. Protein 
concentration was determined by Bradford Protein Assay (BioRad, Hemel Hempstead, UK). 
20µg of cell lysate or exosomes (isolated from the sucrose cushion method) or vesicle 
concentrates (isolated from ultracentrifugation) were boiled in lithium dodecyl sulphate 
(LDS) sample buffer (Invitrogen, USA), either reducing with 20mM dithiothreitol (DTT; Santa 
Cruz) or under non-reducing conditions. Boiled samples and molecular weight markers 
(Magic Mark™ XP and SeeBlue® Plus 2 Precision Stain; Life Technologies, USA) were loaded, 
and subjected to electrophoresis for 45 minutes on NuPAGE™ precast 4-12% Bis-Tris gradient 
gels (Life Technologies). The gels were run using 1x NuPAGE™ MOPS sodium dodecyl 
sulphate (SDS) running buffer (Life Technologies) and an Invitrogen™ PowerEase® 500 
(ThermoFisher Scientific) power supply. Proteins were transferred onto methanol activated 
polyvinylidene fluoride (PVDF) membranes (GE Life Sciences, UK), using 25mM Tris, 192mM 
glycine (both Sigma-Aldrich, St Louis, USA) and a BioRad Mini Trans-Blot Electrophoretic 
Transfer Cell (BioRad). Furthermore, the tank was placed in ice to optimise recommended 
cooling conditions and the blots were run for 90 minutes at a constant 80V. The membranes 
were blocked overnight at 4oC in PBS containing 0.5% (w/v) Tween®20 (Sigma-Aldrich) and 
5% (w/v) non-fat powdered milk (Marvel, London, UK). The membrane was incubated with 
primary antibodies (Table 2.1), at 1µg/ml for 2 hour at RT. Membranes were washed 3 x 5 
minutes with 0.5% Tween®20 (Sigma-Aldrich) in PBS and incubated with a goat anti-mouse-
HRP conjugate (Santa Cruz) for 1 hour at RT. After a further 3 x 5 minutes wash, the bands 
were detected using C-Digit blot scanner (Li-Cor, Lincoln, USA) and an enhanced 
chemiluminescent substrate (Li-Cor). 
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Primary Antibody 
Specificity: 
Isotype Size (kDa) Catalogue 
Number 
Company 
ALIX IgG1 95 Sc-166952 Santa Cruz 
Calnexin IgG1 90 Sc-23954 Santa Cruz 
CD9 IgG2B 27 MAB1880 R&D Systems 
CD63 IgG1 25 MCA2142 AbD Serotec 
CD81 IgG1 26 MCA1847EL BioRad 
GAPDH IgG 40 #Y3322 BioChain 
HSP70 IgG1 70 Sc-66048 Santa Cruz 
HSP90 IgG1 90 Sc-69703 Santa Cruz 
LAMP1 IgG1 120 Sc-20011 Santa Cruz 
LAMP2 IgG1 120 Sc-18822 Santa Cruz 
MHC-I IgG2A 45 16-9983-85 eBioscience 
Rab5a IgG2B 25 Sc-130010 Santa Cruz 
Rab11b IgG 26 PA5-31348 ThermoFisher 
Scientific 
Rab35 IgG 25 PA5-31674 ThermoFisher 
Scientific 
TSG101 IgG2A 43 Sc-7964 Santa Cruz 
VAMP7 IgG2A 25 MAB6117 R&D Systems 
VPS25 IgG1 21 Sc-271648 Santa Cruz 
Table 2.1: Table of primary antibodies used for Western Blot and plate-based assays. 
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2.2.6 Nanoparticle Tracking Analysis 
NTA is a method that visualises and analyses nanometre particles (10 – 1000 nm) in liquids. 
Based on a laser-illuminated microscopical technique, NTA utilises the properties of light 
scattering and Brownian motion to analyse nanoparticles in real-time. Brownian motion is 
defined as the random motion of nanoparticles suspended in liquid; their rate of movement 
is related to the temperature and viscosity of the liquid. NTA uses high-intensity laser beams 
sent through the sample chamber, the particles in suspension in the path of this beam can 
scatter light and can be detected by a highly sensitive camera over multiple frames (Figure 
2.2). The NTA software can track each particle on a frame-by-frame basis and the velocity of 
particle movement is used to calculate particle size by applying the Stokes-Einstein equation: 
 
Each particle is visualised and analysed separately; and the resulting estimate of particle size 
distribution and particle size does not suffer in terms of intensity distribution, which is often 
observed in another method, such as DLS. The use of high intensity laser beams combined 
with a low-background optical configuration, allows particles of nanometre dimensions to 
be visualised, though this is dependent on the particle refractive index (Ri; dictates the 
interactions between light and nanoparticles). Particles with very high Ri (colloidal gold) can 
often determine size down to 15nm diameter for lower Ri particles, such as those of 
biological origin (exosomes), the smallest detectable size can only be around 30nm. 
Here, exosomes can be modelled as nanoparticles by determining the light scattering 
intensities of nanoparticles, temperature and liquid viscosity. Each exosome preparation was 
analysed, where size distribution profiles and particle counts were determined using NTA 
(Malvern Instruments, Malvern, UK). The analysis was performed on a NanoSight™ NS300, 
but configured with a temperature controlled 488nm laser module and a high-sensitivity 
sCMOS Camera System (OrcaFlash 2.8, Hamamatsu C11440, Hamamatsu City, Japan) and a 
syringe-pump system (Malvern Instruments). 
Dt = TKB / 3πd 
Dt: Diffusion constant (product of diffusion coefficient D and time t) 
T: Sample temperature 
KB: Boltzmann’s constant 
: Solvent viscosity 
d: Diameter of spherical particle 
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100nm standard latex beads (Malvern Instruments) were tested to confirm the NTA 
measurements were accurate. Samples were administered and recorded under controlled 
flow using the NanoSight™ syringe pump (set to 50) and script control system for each 
sample. Six replicate videos of 30 seconds were taken and temperatures were set at 25oC. 
Videos were batch analysed using NTA 3.1 software (version 3.1 build 3.1.54), with the 
camera’s sensitivity and detection threshold set at 14-16 and 1-3, respectively, to reveal 
small particles taken in light scatter mode. On some occasions, videos were also taken 
following application of long fluorescence filter, so that only particles emitting light at 
>500nm were visible.  Samples were diluted in nanoparticle-free water (Fresenius Kabi, 
Runcorn, UK), so that the particle concentration (particles / ml) was within the linear range 
of the instrument. The area under the histogram for each triplicate measurement was 
averaged to be used as a particle concentration measurement and corrected for cell number. 
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Figure 2.2: Nanoparticle Tracking Analysis (NTA): A laser beam is passed through the 
sample chamber and the particles in suspension in the path of the beam scatter light that 
can visualised by a x20 magnification microscope, which is mounted a video camera. The 
camera captures a video file of the particles moving under Brownian motion. The NTA 
software tracks particles individually and can calculate their hydrodynamic diameters 
using the Stokes Einstein equation. The NanoSight™ provides high resolution particle 
size, concentration and provides real time monitoring in the heterogeneous particle 
population observed by visual. Source: (Malvern Instruments, 2017). 
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2.3 Generation of Lentiviral Transduced DU145 Cell Lines 
2.3.1 shRNA Lentiviral Particle Transduction 
Gene silencing and knockdown using RNAi interference (RNAi) technology is a commonly 
used tool to stably silence gene expression. The introduction of small interfering (siRNAs) 
into cultured cells provides a quick and efficient method of knocking down gene expression 
and is a ubiquitous tool in molecular biology. However, siRNA has been shown to be effective 
only in the short term for gene inhibition and in certain transformed mammalian cell lines, 
while short hairpin RNA (shRNA; sequence of RNA that forms a tight hairpin turn), offers a 
possibility to stably and potently silence gene expression. 
Using shRNA can offer stable and long term gene silencing that is often achieved by using 
clonal selection methodologies, such as the pLKO.1 plasmid containing the puromycin 
resistance gene, followed by selection. The MISSION® shRNA lentiviral transduction particles 
(Sigma-Aldrich) can often permit efficient transduction and integration of the specific shRNA 
construct into the host cells. The host genome can transcribe the target shRNA in the 
nucleus, export it from the nucleus to be processed by Dicer (endoribonuclease), that is 
primed into the RNA-inducing silencing complex (RISC). This complex cleaves their 
designated target mRNA and represses mRNA translation, resulting in target gene silencing 
(Figure 2.3). 
Wild type DU145 cells were seeded into 96-well flat bottomed plates at 5,000 cells/well, 
exosome-depleted media. At day 1, the DU145 cells were stably transduced with MISSION® 
shRNA lentiviral transduction particles (Table 2.2) (Multiplicity of Infection (MOI): 20) in the 
presence of hexadimethrine bromide (8µg/ml) (Sigma-Aldrich). At day 2, puromycin 
(1.25µg/ml) (Sigma-Aldrich) was added and media was changed daily, where each 
knockdown was confirmed at both the mRNA and protein level.  The cells were cultured in 
the presence of puromycin until passage 6, when deemed free of lentiviral particles for 
experimental use. For my Thesis, the non-mammalian (NM) DU145 control (CTR) (transduced 
with a non-mammalian control shRNA) and knockdown of CD9 (CD9KD), Rab5a (Rab5aKD), 
Rab11b (Rab11bKD), Rab35 (Rab35KD), VAMP7 (VAMP7KD) and VPS25 (VPS25KD) cells, were 
generated and selected for additional experiments. 
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Figure 2.3: shRNA-mediated gene silencing via lentiviral transduction particles. The 
shRNA are incorporated into the lentiviral particle systems, which permit the 
transduction of the viral genome into the cytoplasm, where they are reverse transcribed. 
The DNA intermediate is imported into the nucleus, where it is stably integrated in the 
host genome. Following transcription, the shRNA sequence is exported to the cytoplasm 
where Dicer, processes the shRNA into the siRNA duplexes. This endogenously derived 
siRNA binds to the target mRNA and is incorporated into the RISC complex for target-
specific mRNA degradation; thus preventing protein translation. Source: (Sigma, 2016). 
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Target TRC Number Sequence Clone ID 
C
D
9
 
TRCN0000296953 (#953) CCGGTTCTACACAGGAGTCTATATTCTCGAGAATATAGACTCCTGTGTAGAATTTTTG NM_001769.2-277s21c1 
TRCN0000296958 (#958) CCGGCCTGCAATGAAAGGTACTATACTCGAGTATAGTACCTTTCATTGCAGGTTTTTG NM_001769.2-1072s21c1 
TRCN0000291711 (#711) CCGGGCTGTTCGGATTTAACTTCATCTCGAGATGAAGTTAAATCCGAACAGCTTTTTG NM_001769.2-150s21c1 
TRCN0000057469 (#469) CCGGCATTGGACTATGGCTCCGATTCTCGAGAATCGGAGCCATAGTCCAATGTTTTTG NM_001769.2-201s1c1 
TRCN0000057470 (#470) CCGGGCTGTTCGGATTTAACTTCATCTCGAGATGAAGTTAAATCCGAACAGCTTTTTG NM_001769.2-150s1c1 
R
ab
5
a
 TRCN0000380597 (#597) GTACCGGGAGAGTCCGCTGTTGGCAAATCTCGAGATTTGCCAACAGCGGACTCTCTTTTTTG NM_004162.4-615s21c1 
TRCN0000380466 (#466) GTACCGGCAAGGCCGACCTAGCAAATAACTCGAGTTATTTGCTAGGTCGGCCTTGTTTTTTG NM_004162.4-934s21c1 
TRCN0000273641 (#641) CCGGGCAGCCTTCCTTTCCAAAGTTCTCGAGAACTTTGGAAAGGAAGGCTGCTTTTTG NM_004162.4-2298s21c1 
TRCN0000011215 (#215) CCGGGCAGCCTTCCTTTCCAAAGTTCTCGAGAACTTTGGAAAGGAAGGCTGCTTTTT NM_004162.3-2139s1c1 
TRCN0000007974 (#974) CCGGCCAGGAATCAGTGTTGTAGTACTCGAGTACTACAACACTGATTCCTGGTTTTT NM_004162.3-999s1c1 
R
ab
1
1
b
 TRCN0000381919 (#919) GTACCGGTTTGCTGCACCCATGAAACTCCTCGAGGAGTTTCATGGGTGCAGCAAATTTTTTG NM_004218.3-951s21c1 
TRCN0000381558 (#558) GTACCGGAGACAGCAACATCGTCATCATCTCGAGATGATGACGATGTTGCTGTCTTTTTTTG NM_004218.3-435s21c1 
TRCN0000380618 (#618) GTACCGGCATTCAAGAACATCCTCACAGCTCGAGCTGTGAGGATGTTCTTGAATGTTTTTTG NM_004218.3-587s21c1 
TRCN0000029185 (#185) CCGGCCTATTCAAAGTGGTGCTCATCTCGAGATGAGCACCACTTTGAATAGGTTTTT NM_004218.1-36s1c1 
TRCN0000029188 (#188) CCGGCAAGCACCTGACCTATGAGAACTCGAGTTCTCATAGGTCAGGTGCTTGTTTTT NM_004218.1-288s1c1 
R
ab
3
5
 TRCN0000380335 (#335) GTACCGGTGATGATGTGTGCCGAATATTCTCGAGAATATTCGGCACACATCATCATTTTTTG NM_006861.4-475s21c1 
TRCN0000380080 (#080) GTACCGGTTCACGAAATCAACCAGAACTCTCGAGAGTTCTGGTTGATTTCGTGAATTTTTTG NM_006861.4-453s21c1 
TRCN0000380003 (#003) GTACCGGGGAGAATGTCAACGTGGAAGACTCGAGTCTTCCACGTTGACATTCTCCTTTTTTG NM_006861.4-601s21c1 
TRCN0000047796 (#796) CCGGAGAGCAGTTTACTGTTGCGTTCTCGAGAACGCAACAGTAAACTGCTCTTTTTTG NM_006861.4-207s1c1 
TRCN0000047794 (#794) CCGGCCTCCGAGCAAAGAAAGACAACTCGAGTTGTCTTTCTTTGCTCGGAGGTTTTTG NM_006861.4-649s1c1 
V
A
M
P
7
 TRCN0000379810 (#810) GTACCGGATGAGAGAACAAGGAGTTAAACTCGAGTTTAACTCCTTGTTCTCTCATTTTTTTG NM_005638.4-867s21c1 
TRCN0000298636 (#636) CCGGGCGAGTTCTCAAGTGTCTTAGCTCGAGCTAAGACACTTGAGAACTCGCTTTTTG NM_005638.4-485s21c1 
TRCN0000298637 (#637) CCGGTCTTATGAGCTATCTACTAAACTCGAGTTTAGTAGATAGCTCATAAGATTTTTG NM_005638.4-1157s21c1 
TRCN0000293928 (#928) CCGGGGAAAGAAGAAGTTACCATTACTCGAGTAATGGTAACTTCTTCTTTCCTTTTTG NM_005638.4-837s21c1 
TRCN0000059888 (#888) CCGGGCGAGGAGAAAGATTGGAATTCTCGAGAATTCCAATCTTTCTCCTCGCTTTTTG NM_005638.3-561s1c1 
V
P
S2
5
 TRCN0000381980 (#980) GTACCGGAGTCCAGCTTCCTGATCATGTCTCGAGACATGATCAGGAAGCTGGACTTTTTTTG NM_032353.2-321s21c1 
TRCN0000322763 (#763) CCGGCCCTTTACTTCTTACCTCCCACTCGAGTGGGAGGTAAGAAGTAAAGGGTTTTTG NM_032353.2-585s21c1 
TRCN0000322707 (#707) CCGGAGTCGATCCAGATTGTATTAGCTCGAGCTAATACAATCTGGATCGACTTTTTTG NM_032353.2-255s21c1 
TRCN0000144757 (#757) CCGGGAGTCGATCCAGATTGTATTACTCGAGTAATACAATCTGGATCGACTCTTTTTTG NM_032353.2-254s1c1 
TRCN0000143764 (#764) CCGGCCTGTCTCCCTTTACTTCTTACTCGAGTAAGAAGTAAAGGGAGACAGGTTTTTTG NM_032353.2-578s1c1 
Table 2.2: Table of MISSION® lentiviral particles (Sigma-Aldrich) used to transduce DU145 cells. 
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2.3.2 Reverse Transcription and Quantitative Polymerase Chain Reaction  
RNA Extraction 
RNA was extracted from confluent lentiviral transduced DU145 cell lines or 3D spheroids, 
using 1ml TRI Reagent® per well (Sigma-Aldrich). Afterwards, 200µl of chloroform was added 
(Sigma-Aldrich) to each sample and mixed by inverting the sample numerous times in 
eppendorf tubes (Greiner Bio-One). The samples were centrifuged at 16,000 x g for 20 
minutes at 4oC, to allow the separation of both aqueous and phenol phases. The colourless 
aqueous layer was removed and mixed with ice-cold isopropanol at -20oC for 24 hours, to 
allow precipitation of RNA. Samples were centrifuged at 16,000 x g for 20 minutes at 4oC, to 
wash away the isopropanol and the RNA pellets were washed in ice-cold 70% ethanol 
(volume/volume: v/v). This washing step was repeated twice and afterwards, the RNA pellets 
were air dried at RT and dissolved in 11µl molecular biology grade water. 
1µl of RNA sample was administered onto the NanoDrop™ 2000 Spectrometer 
(ThermoFisher Scientific) which obtains a ratio of absorbance measured at 260nm and 
280nm. RNA and DNA both will absorb at 260nm, they will contribute to the total absorbance 
of the sample. A ratio >1.7 is generally accepted as ‘pure’ RNA and used for analysis. If the 
ratio is considerably lower, it may indicate the presence of protein, phenol or other 
contaminants that absorb strongly near 280nm. For nucleic acid quantification, the 
extinction coefficient for RNA is 40 and the modified Beer-Lambert equation used is: 
Reverse Transcription 
Reverse transcription was performed using the random primer method in a final volume of 
20μl per reaction, containing 1μg of RNA of the sample, 2μl of 10X reverse transcription 
buffer, 0.8μl of 25X deoxynucleotide triphosphates (dNTPs) (mixed nucleotides of dATP, 
dCTP, dGTP and dTTP) mix, 2μl of 10X reverse transcription random primers, 1μl of 
Multiscribe™ reverse transcriptase and 1μl of RNase Inhibitor (all from ThermoFisher 
Scientific). A negative control was included, which substituted RNA sample for molecular 
biology grade H2O. The samples were loaded onto the S1000 Thermal Cycler (BioRad) to 
begin reverse transcription, which involved incubation at 25oC for 10 minutes to allow the 
primers to anneal to the RNA. The primers were then extended in the presence of dNTPs 
using reverse transcriptase at 37oC for 2 hours, generating cDNA. The cDNA was then heated 
at 85oC for 5 seconds to deactivate the RT. The cDNA samples were stored at -20oC. 
C (Nucleic acid concentration µg/ml) = A (Absorbance) * ɛ (Extinction Coefficient) 
      b (Path length in cm) 
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Quantitative Polymerase Chain Reaction (qPCR) 
qPCR was carried out with 20µl per reaction, containing 1µl of sample cDNA, 10µl of 
TaqMan® Universal Master Mix (20X) (ThermoFisher Scientific), 8µl of H2O and 1µl of a 
TaqMan® gene expression assay primer and probe mix (all from ThermoFisher Scientific) 
(Table 2.3). A negative control was prepared using H2O substitute for the cDNA. The PCR 
amplification was performed in a StepOnePlus™ Real-Time PCR System Thermocycler 
(ThermoFisher Scientific). Samples were amplified by heating them to 50oC for 2 minutes, 
then at 95oC for 15 seconds and 60oC for 1 minute, for a total of 40 cycles. The comparative 
CT method was used for relative quantification of target gene expression. The CT (threshold 
cycle where amplification is in the linear range of the amplification curve) for the standard 
reference gene (glyceraldehyde 3-phosphate dehydrogenase: GAPDH) were subtracted from 
the target gene CT to obtain the ΔCT for each sample. Target gene expression was calculated 
in each experimental sample relative to control samples by: 
 
 
The ‘ΔCT 1’ is the mean ΔCT value calculated for the experimental samples, whereas the ‘ΔCT 
2’ is the mean ΔCT value calculated for the control samples (GAPDH). The data was analysed 
using the StepOnePlus™ Software (Version 2.0, ThermoFisher Scientific). 
 
Primer and 
Probe Mix 
Assay ID Amplicon 
Length 
Catalogue 
Number 
CD9 Hs00233521_m1 72 #4331182 
GAPDH Hs02758991_g1 93 #4331182 
MMP-1 Hs00899658_m1 64 #4331182 
MMP-13 Hs00233992_m1 91 #4331182 
Rab5a Hs00991290_m1 157 #4331182 
Rab11b Hs00188448_m1 72 #4331182 
Rab35 Hs00900055_m1 66 #4331182 
TIMP-3 Hs00165949_m1 59 #4331182 
VAMP7 Hs00194568_m1 80 #4331182 
VPS25 Hs00260613_m1 92 #4331182 
 
  
Relative Expression = 2 – ((ΔCT TARGET 1) – (ΔCT TARGET 2)) 
 
Table 2.3: Table of primers used for qPCR. 
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2.3.3 Collecting DU145 Cell Conditioned Media or Vesicle Concentrates 
Obtaining Cell Conditioned Media 
DU145 control or lentiviral transduced cell lines were seeded into 6-well plates (Greiner Bio-
One), at equal densities (1 x 105) and cultured until 80% confluency. Media was removed 
from the flasks and replaced with 1.5ml of fresh RPMI-1640 media only. These plates were 
left at 37oC for 7 days, to allow the accumulation of vesicles in cell CM. Cell CM was collected 
and centrifuged at 400 x g for 7 minutes at RT, an additional 400 x g for 7 minutes at RT, 
followed by an additional at 2000 x g for 15 minutes at RT, to remove dead cells and cellular 
debris. The remaining CM were filtered using a 0.22µm millex GP syringe filter (Merck 
Millipore), to remove any remaining debris and larger vesicles. Filtered CM was used for 
experimental use or stored at -80OC until required. 
Obtaining Vesicle Concentrates 
The CM from above underwent ultracentrifugation at 200,000 x g for 2 hours at 4oC (fixed 
angle 70Ti rotor, Beckman Coulter). Vesicle concentrates were resuspended in PBS and 
stored at -80oC, until required for further experimental use. 
Normalisation of CM/Vesicle Concentrates to Cell Number 
One method of normalisation would be based on protein quantification (BCA Assay) of either 
cell CM or vesicle concentrates. Though, if the knockdown of interest did attenuate exosome 
secretion, normalisation based on protein content would not be a fair representation of 
vesicle loss and may negate its effect in downstream experiments. As protein normalisation 
would be based upon other vesicle subpopulations, this is not a fair representation of the 
impact of knockdown on vesicle secretion. As an alternative, we normalised lentiviral 
transduced DU145 cell CM/vesicle concentrates based on cell number, as this gives a fairer 
representation of secreted number of vesicle per cell.  
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First, cell counts were performed for the DU145 NM CTR, after collecting cell CM from T-
75cm2 culture flasks for ultracentrifugation. This gives an accurate count of cells that 
manufacture 100% of the control vesicle present in cell CM. 
Secondly, cell counts were performed for lentiviral transduced DU145 cells, after collecting 
cell CM from T-75cm2 culture flasks for ultracentrifugation. This give an accurate count of 
cells that manufacture a certain % of the vesicle present in cell CM following knockdown. 
As examples for correcting cell CM to cell number: 
  Control Knockdown 1 Knockdown 2 Knockdown 3 
Collected Cell CM 1ml 1ml 1ml 1ml 
Cell Counts 100000 50000 200000 140000 
Correction Factor 1x 2.0x 0.5x 0.71x 
Normalise Samples to Cell Number 
  Control Knockdown 1 Knockdown 2 Knockdown 3 
CM from Sample 0.5ml 1ml 0.25ml 0.35ml 
PBS 0.5ml 0ml 0.75ml 0.65ml 
Sample Normalised to 50,000 Cell Counts 
 
For characterisation or functional experiments, DU145 control vesicle concentrates was 
quantified to 20µg/ml or 200µg/ml by performing a MicroBCA Protein Assay (Thermo 
Scientific), as previously described. The vesicles derived from each DU145 CD9KD, Rab5aKD, 
Rab11bKD, Rab35KD, VAMP7KD or VPS25KD cell line would be adjusted to achieve an equivalent 
cell count versus controls. 
As examples for correcting vesicle concentrates to cell number: 
  Control Knockdown 1 Knockdown 2 Knockdown 3 
Vesicle 
Concentrates 
10μl = 
20μg/ml 
(Unknown) (Unknown) (Unknown) 
Correction Factor 1x 2.0x 0.5x 0.71x 
Normalise Vesicle Concentrates to Correction Factor 
 Control Knockdown 1 Knockdown 2 Knockdown 3 
Corrected Vesicle 
Concentrates to 
Use 
10μl 20μl 5μl 7.1μl 
Corrected Volume of Vesicle Concentrates 
 
Normalisation based on secreted vesicles per cell number would give an accurate count of 
the influence following knockdown has upon vesicle secretion. 
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2.4 Characterising and Phenotyping Cells and Vesicles 
2.4.1 Cell Viability Assay 
The cell viability reagent, water soluble tetrazolium (WST)-1 (Roche, Basel, Switzerland) was 
used to examine cell viability. In principle, the stable tetrazolium salt, WST-1, is cleaved to a 
soluble dependent on the NAD(P)H in viable cells. Thus, the amount of formazan dye formed 
directly correlates to the number of metabolically viable cells in culture. 
DU145 control or knockdown cells were seeded at 5,000 cells/well in 96-well flat-bottom 
plates (Greiner Bio-One) and incubated with 10µl of WST-1 reagent for 0.5 – 4 hours to 
determine the optimal time. Subsequently, seeded cells were left for 24, 48 and 72 hours 
respectively and plates were incubated up to 1 hour at 37oC. After this incubation period, the 
amount of formazan dye was quantitated by measuring absorbance at 420 nm by the 
PHERAstar FS Microplate Reader.  
2.4.2 Light Microscopy and Immunofluorescence Microscopy 
Light microscopy was used to examine general cellular morphology in vitro. DU145 cells, 
fibroblasts and HUVECs in 96-well plates, 25cm3 or 75cm3 culture flasks at 60 – 100% 
confluence, were visualised by phase contrast and images were captured using the Axio 
Observer Z1 (Zeiss, Oberkochen, Germany). 
For immunofluorescence analysis, a monolayer of lentiviral transduced DU145 cells were 
seeded at 20,000 cells/well in Nunc™ Lab-Tek™ 8-Well Chamber Glass Slides (ThermoFisher 
Scientific) and incubated until 70% confluent. Likewise, following various treatments, 
stromal cells, such as endothelial cells and fibroblasts were washed gently with pre-warmed 
PBS (Lonza) three times and fixed in ice-cold acetone-methanol (1:1 v/v) (ThermoFisher 
Scientific) for 5 minutes and allowed to air dry at RT. The cells were washed three times with 
PBS and blocked for 1.5 hours at RT in 1% BSA (R&D Systems, Minneapolis, USA) in Hanks’ 
Balanced Salt Solution (HBSS) (Sigma-Aldrich). The cells were washed three times using 0.1% 
BSA/HBSS (w/v) and were stained with unconjugated anti-mouse monoclonal antibodies 
(Figure 2.6), at 1µg/ml (in 0.1% BSA/HBSS) for 2 hours at RT. The cells were washed three 
times and stained with a goat anti-mouse secondary antibody (Alexa-488 conjugate) 
(ThermoFisher Scientific), at 10µg/ml for 45 minutes at RT, in the dark. Subsequently, 
following three washes, the cells were counterstained 4’,6-diamidino-2-phenylindole (DAPI) 
(14.3mM) (ThermoFisher Scientific), diluted 1:50,000 in 0.1% BSA/HBSS (w/v) for 5 minutes, 
followed by three further washes and the cells were visualised by wide-field fluorescence 
Axio Observer Z1 with apotome using the Zen Blue Software (Zeiss). 
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2.4.3 Flow Cytometry 
Lentiviral transduced DU145 cells were seeded in 6-well plates at 100,000 cells/well. Once 
confluent, cells were harvested using trypsin (Lonza) and centrifuged to obtain cell pellets, 
which were resuspended in PBS in form a homogenous cell suspension. The cells were fixed 
in IC Fixation Buffer (ThermoFisher Scientific), for 15 minutes at RT and washed twice with 
PBS. The resuspended cell pellets were incubated with unconjugated primary antibodies or 
matched isotype controls (Table 2.4) at 1µg/ml (in PBS) for 1 hour at RT, either with 2X 
Permeabilisation Buffer (ThermoFisher Scientific) or without. Following two washes, the cells 
were incubated with a goat anti-mouse secondary antibody (Alexa-488 conjugate) 
(ThermoFisher Scientific) at 10µg/ml for 45 minutes at RT, in the dark. Following a further 
two washes, cells were analysed using a FACSverse (BD Biosciences, New Jersey, USA). 
 
 
 
  
Primary Antibody 
Specificity: 
Isotype Catalogue 
Number 
Company 
α-SMA IgG1 Sc-166952 Santa Cruz 
CD9 IgG2B MAB1880 R&D Systems 
CD31 (PECAM-1) IgG1 Sc-6520 Santa Cruz 
CD63 IgG1 MCA2142 AbD Serotec 
CD81 IgG1 MCA1847EL BioRad 
EEA1 IgG1 610456 BD Bioscience 
LAMP1 IgG1 Sc-20011 Santa Cruz 
LAMP2 IgG1 Sc-18822 Santa Cruz 
Table 2.4: Table of primary antibodies used for flow cytometry and immunofluorescent 
microscopy. 
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2.4.4 Enzyme-Linked Immunosorbent Assay (ELISA) 
Quantification of FGF-2, HGF, uPA and VEGF-A in DU145 or treated fibroblasts cell CM was 
assayed using the DuoSet ELISA systems (R&D Systems). The manufacturer’s instructions 
were followed except for the detection of the colourimetric change in the substrate solution, 
that was substituted for europium streptavidin and amended to detect TRF. The FGF-2, HGF, 
uPA and VEGF-A capture antibody at a dose of 1µg/ml (mouse anti-human against FGF-2, 
HGF, uPA and VEGF-A) were added to a high protein binding ELISA strip 96-well plate (Greiner 
Bio-One), at 100µl per well and incubated overnight at RT. Wells were aspirated and washed 
three times with Delfia® Wash Buffer (1X in water) (Perkin Elmer) to remove unbound 
antibody. Blocking buffer (1% BSA in PBS) was added to wells for 2 hours at RT, where wells 
were washed three times with Delfia® Wash Buffer.  This was followed by the addition of a 
serial dilution human recombinant FGF-2, HGF, uPA and VEGF-A standard (diluted in 0.1% 
BSA in PBS) starting from 1000pg/ml (FGF-2), 2000pg/ml (VEGF-A), 4000pg/ml (uPA) or 
8000pg/ml (HGF), respectively to 0pg/ml to create an eight-point standard curve. 
Furthermore, DU145 or treated fibroblasts cell CM were added to the coated wells and 
incubated for 2 hours at RT, where wells were aspirated and washed. This was followed by 
the addition of the FGF-2, HGF, uPA and VEGF-A detection antibody (biotinylated goat anti-
human antibody against FGF-2, HGF, uPA or VEGF-A) at 100ng/ml (VEGF-A), 200ng/ml (HGF), 
250ng/ml (FGF-2), 400ng/ml (uPA), was added respectively for 2 hours at RT. Wells were 
washed 3 times, before adding a europium-streptavidin conjugate (Perkin Elmer) in a red 
buffer solution (Kaivogen) for 45 minutes at RT. Wells were washed 6 times, before adding 
enhancement solution (Kaivogen) for 5 minutes at RT; and the signal assessed by time 
resolved fluorescence (TRF) on a PHERAstar FS Microplate Reader. The absorbance values 
were extrapolated from the standard curve to calculate the FGF-2, HGF, uPA or VEGF-A 
protein concentration in each sample. 
TGF-β1 ELISA 
Quantification of TGF-β1 in treated fibroblasts cell CM was assayed using the DuoSet ELISA 
systems. The manufacturer’s instructions were followed except for the detection of the 
colourimetric change in the substrate solution, that was substituted for europium 
streptavidin and amended to detect TRF. The TGF-β1 capture antibody at a dose of 1µg/ml 
were added to a high protein binding ELISA strip 96-well plate (Greiner Bio-One), at 100µl 
per well and incubated overnight at RT. Wells were aspirated and washed three times with 
Delfia® Wash Buffer (1X in water) (Perkin Elmer), to remove unbound antibody. Blocking 
buffer (1% BSA in PBS) was added to wells for 2 hours at RT, where wells were washed three 
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times with Delfia® Wash Buffer. This was followed by the addition of a serial dilution human 
recombinant TGF-β1 standard (diluted in 0.1% BSA in PBS), starting from 2000pg/ml to 
0pg/ml to create an eight-point standard curve. 
To activate latent TGF-β1 to the immunoreactive form detectable by the TGF-β1 DuoSet 
ELISA kit, treated fibroblasts cell CM or vesicle concentrates were acid activated using 20µl 
of 1N hydrochloric acid (HCL), vortexed and incubated for 10 minutes at RT. The acidified 
samples were neutralised by adding 20µl of 1.2N sodium hydroxide (NaOH)/0.5 M HEPES, 
the pH was measured to ensure neutralisation was within 7.0 – 7.6. Once neutralised, 100µl 
of sample were added to the wells and incubated for 2 hours at RT, where wells were 
aspirated and washed. Biotinylated goat anti-human TGF-β1 detection antibody at 300ng/ml 
was added for 2 hours at RT. Wells were washed 3 times, before adding a europium-
streptavidin conjugate in a red buffer solution for 45 minutes at RT. Wells were washed 6 
times, before adding enhancement solution for 5 minutes at RT; and the signal assessed by 
TRF on a PHERAstar FS Microplate Reader. The absorbance values were extrapolated from 
the standard curve to calculate the TGF-β1 protein concentration in each sample. 
MMP-1 and MMP-13 ELISA 
Quantification of MMP-1 and MMP-13 in 3D spheroids cell CM was assayed using the 
RayBio® Human MMP-1 and MMP-13 ELISA kit (both from RayBio® Tech, Georgia, USA). The 
manufacturer’s instructions were followed except for the detection of the colourimetric 
change in the substrate solution, that was substituted for europium streptavidin and 
amended to detect TRF.  A serial dilution of human recombinant MMP-1 and MMP-13 
(diluted in 0.1% BSA in PBS) starting from 18000pg/ml (MMP-1) or 6000pg/ml (MMP-13) to 
0pg/ml created an eight-point standard curve in pre-coated MMP-1 and MMP-13 
microplates (RayBio® Tech). 100µl of 3D spheroids cell CM were added to the wells and 
incubated for 2.5 hours at RT, where wells were aspirated and washed three times with 
Delfia® Wash Buffer (1X in water). MMP-1 or MMP-13 detection antibody (biotinylated goat 
anti-human antibody against MMP-1 or MMP-13) was added at 1:80 dilution for both MMP-
1 and MMP-13 for 1 hour at RT. Wells were washed 3 times, before adding an europium-
streptavidin conjugate in a red buffer solution, for 45 minutes at RT. Wells were washed 6 
times, before adding enhancement solution for 5 minutes at RT; and the signal assessed by 
TRF on a PHERAstar FS Microplate Reader. The absorbance values were extrapolated from 
the standard curve to calculate the MMP-1 and MMP-13 protein concentration in each 
sample. 
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2.4.5 Protein Profiling Array 
Vesicle concentrates (20µl) from DU145 control, Rab11bKD or Rab35KD cells were subject to 
lysis (20µl of RIPA buffer); and analysed by a sensitive Proximity Ligation Assay Configure, in 
the form of a 92-Plex Array. Alternatively, cell CM normalised for cell number, without 
concentrating, were used. The Olink Proseek® Multiplex Inflammation I96x96 Panel comprises 
92 inflammation-related protein analytes as it gave a good coverage of potentially relevant 
factors (Olink Bioscience, Uppsala, Sweden). The Limit Of Detection (LOD) was defined as 1.5 
standard deviations above background and values below this limit were reported as <LOD. 
The data were filtered to remove analytes below the limit of detection and comparisons were 
made between control and knockdowns, based on fold change and t-test.
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2.5 Functional Experiments  
2.5.1 Growth Arrest 
Prior to all functional experiments, fibroblasts were growth-arrested in serum-free media for 
72 hours to allow fibroblast depletion of growth factors, otherwise any remanence of growth 
factors in the media would allow fibroblasts the potential capacity to express α-SMA. Seeded 
fibroblasts were washed with serum-free DMEM/F12 (Lonza) to remove any residual FBS. 
Fresh serum-free DMEM/F12 medium was added to fibroblasts for 72 hours and unless 
stated otherwise, fibroblasts were cultured in DMEM/F12 media. 
2.5.2 Fibroblast Differentiation  
Fibroblasts were cultured in Nunc™ Lab-Tek™ 8-Well Chamber Glass Slides (ThermoFisher 
Scientific) or 24-well plates (Greiner Bio-One) in DMEM/F12 media with supplement mixture 
(as described in 2.1.1) and once 80% confluent, the cells were growth-arrested for 72 hours. 
The fibroblasts were treated with either the equivalent of recombinant human TGF-β1 
(rhTGF-β1) (1.5ng/ml), 200µg/ml of purified DU145 exosomes, cell-number normalised 
vesicle concentrates (DU145 NM CTR, Rab11bKD or Rab35KD), in DMEM 10% exosome-
depleted FBS for 72 hours. In other experiments, fibroblasts were also treated in DU145 NM 
CTR, Rab11bKD or Rab35KD cell CM normalised to cell number. Treated fibroblasts cell CM 
after 72 hours treatment was used for ELISAs or to treat endothelial cells in a migration assay. 
The cells were fixed and subsequently stained for α-SMA (Santa Cruz) and visualised with the 
Axio Observer Z1 with apotome. 
2.5.3 Migration Assay 
A confluent monolayer of HUVEC cells was cultured in 96-well plates and serum-starved for 
24 hours in growth-factor free conditions. The confluent monolayer was subject to a single 
vertical scratch using a 200μl pipette tip. The wells were gently washed with PBS and treated 
with CM taken from fibroblast cultures and wells were microscopically monitored at 0, 6, 12, 
24 hours. The width of the scratch in triplicate wells was measured at 6 points for each well, 
using Image-J (National Institutes of Health, Bethesda, USA) and the rate of monolayer 
recovery plotted as relative to the original scratch width (% closure). 
2.5.4 Vessel-like Formation Assay 
Formation of endothelial vessel-like structures was performed with endothelial cells (20,000 
per well), serum-starved for 24 hours. These were added in triplicate to monolayers of 
fibroblasts (100,000 cells per well), that had been previously treated with rhTGF-β1, 
exosomes or vesicle concentrates for 72 hours. A 1:1 volume ratio of DMEM/F12:EGM-2 
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media in the absence of exogenous factors was used. After a further 4 days of culture, 
structures formed by endothelial cells were visualised by immunofluorescent labelling of 
CD31 (Santa Cruz). The total area occupied by CD31-positive structures was quantified using 
Zen Blue Software to calculate the area occupied by stained cells in each well. Data shows 
the average from triplicate wells per treatment and are representative of three such 
experiments. 
2.5.5 Spheroid Generation for Invasion and Growth Assessment 
Spheroid Generation 
Spheroids were generated in a 96-well u-bottom polyhydroxyethylmethacrylate (Poly-
HEMA)-coated plate (Sigma-Aldrich) or cell-repellent surface plate (Greiner Bio-One). To 
generate homotypic or heterotypic spheroids, tumour cells (DU145 NM CTR, Rab11bKD or 
Rab35KD) were incubated alone or together with fibroblasts at a ratio of 4:1 (tumour 
cells:fibroblast), in poly-HEMA or cell-repellent surface plates and centrifuged at 400 x g for 
10 minutes at RT. This ratio was previously used in vivo experiments specifically revealing a 
tumour growth benefit of fibroblasts (Webber et al., 2015). 10,000 cells were seeded in total 
per well for each generated spheroids and the medium consisted of RPMI-1640 in 10% 
exosome-depleted FBS. After 72 hours, the cell established 3D spheroidal structures. 
Growth Assessment 
3D cell spheroids were cultured in RPMI-1640 with 10% exosome-depleted FBS and every 
other day, 50% of the culture media was replaced by fresh media. Over a 24-day period, 
spheroid area and diameter was measured every 3-4 days by using Image J. 
Invasion Assay 
100µl of Matrigel™ (Corning, UK) was added to each well of a 24-well flat glass bottom plate. 
The basement membrane matrix consists of laminin, collagen IV, entactin and heparan 
sulphate proteoglycans. The matrigel-coated plates were set for 30 minutes at 37oC and 
medium was added. Spheroids were transferred to freshly matrigel-coated, 24-well plates to 
explore the potential invasive behaviours of these cells and the wells were monitored for 96 
hours thereafter. To evaluate the magnitude out from the spheroid, the free-hold selection 
tool in Image-J was used to draw the circumference of the central sphere. This was 
subtracted from the circumference of the region occupied by invading cells. This gives an 
approximation of Matrigel™ invaded by cells, as it does not consider the volumetric aspect 
of the 3D culture and is likely then to underestimate the true differences across the 
experimental groups. 
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2.6 In vivo Experiments 
2.6.1 Animal Maintenance 
In vivo experiments were conducted in accordance with the Animal (Scientific Procedures) 
Act 1986 and the United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) 
guidelines for the welfare of animals in experimental neoplasia. 8-week-old male CD1 
athymic mice were housed under standard laboratory conditions in a temperature controlled 
(22oC; 50-55% humidity) pathogen free environment, with a 12-hour light-dark cycle. 4 mice 
were used per experimental group. Food and water was supplied ad libitum. All procedures 
were performed under aseptic conditions and the body temperature of animals was kept 
constant using heated pads. 
2.6.2 Xenograft Establishment and Tumour Growth Delay  
For in vivo xenograft experiments, this was performed in collaboration with Prof. Jenny 
Worthington (Axis Bioservices, Coleraine, Northern Ireland). DU145 control or Rab11bKD or 
Rab35KD cells with fibroblasts xenografts (4 tumour cells:1 fibroblast ratio) were established 
on the dorsal flank by subcutaneous injection of 5 x 106 cells suspended in 100μl of matrigel 
with a 21g needle (Becton Dickinson, Oxford, UK). Once the tumour became palpable, 
dimensions were measured using Vernier calipers every two to three days, to determine the 
volume, up to the severity limits at day 46. Tumour volume was calculated using tumour 
volume = 0.523 x width2 x length. Total body weight was also taken and this did not change 
for any mouse during the procedures. At 46 days, tumours were excised and photographed. 
2.7 Statistical Analysis 
Statistical analyses were performed using Prism-5 Software V5.01 (Graph Pad, San Diego, 
USA). In experiments with more than two experimental groups, 1-way ANOVA with Tukey’s 
post-test was used, except for kinetic experiments where a 2-way ANOVA with Bonferroni 
post-test was used. Experiments with two experimental groups were evaluated using 
students t test. P values less than 0.05 were considered significant *p<0.05, **p<0.01, 
***p<0.001. Graphs depict mean±SEM, from one representative experiment of at least three 
similar experiments, unless stated otherwise.
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3.1 Characterisation of Exosomes from Wild Type DU145 Cells 
3.1.1 Introduction 
Cells communicate via soluble, secreted factors or via membrane vesicles, collectively 
referred to as EVs. Exosomes are endosome-derived EVs and correspond to the ILVs released 
into the extracellular space, by fusion of MVEs with the plasma membrane. The prostate 
cancer cell line chosen for this study were DU145 cells, derived from prostate 
adenocarcinoma metastatic to the brain (Stone et al., 1978), as they are commonly used for 
studying prostate cancer in several studies (Alimirah et al., 2006, Clayton et al., 2007, Webber 
et al., 2010); and their exosomes are well-characterised by the Clayton group.  
To broaden our understanding of exosomes, great efforts have been made for 
characterisation. In general, exosomes are isolated from either cell CM or biological fluids; 
and several protocols have been developed. This includes one that was used in initial studies 
describing exosomes (Johnstone et al., 1987, Raposo et al., 1996); and involves several 
centrifugation steps to separate vesicles (Théry et al., 2006): 400 x g and 2000 x g were used 
to eliminate unwanted cells and debris; and 10,000 x g to eliminate microvesicles, which are 
larger than exosomes (100 – 1000nm in diameter vs 30 – 150nm for exosomes). Exosomes 
are then pelleted at 100,000 – 200,000 x g. Alternatively, many variations are implemented 
in practice. Some protocols utilise serial filtration or others use 0.22µm filters prior to 
exosome pelleting, as this provides a quicker isolation step compared to additional spins. 
This protocol leads to a pellet that is concentrated with vesicles. Furthermore, density 
gradient-based isolation using the continuous sucrose gradient (Raposo et al., 1996, Caby et 
al., 2005), 30% sucrose cushion method (Lamparski et al., 2002) and iodixanol (OptiPrep™) 
(Cantin et al., 2008, Tauro et al., 2012), can be applied to obtain purer exosome preparations, 
by allowing separation based on density, rather than size or sedimentation rates by 
ultracentrifugation.  
Here, wild type DU145 exosomes were isolated based on a combination of 
ultracentrifugation and through a 30% sucrose cushion. Once isolated, characterisation of 
exosomes using a combination of techniques aimed at observing size/morphology and 
enrichment in exosomal-associated proteins (Western blotting or plate-based assays) was 
performed. These techniques fit the minimum experimental requirements for the definition 
of exosomes as set out by ISEV (Lotvall et al., 2014). NTA is a light-scattering technique, that 
is useful for size distribution and concentration measurements of exosomes (Dragovic et al., 
2011). In combination, cryo-EM was used to observe exosome morphology and 
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heterogeneity present within samples (Sokolova et al., 2011). Validation of exosomal-
associated markers include: the tetraspanins (CD9, CD63 and CD81); ESCRT-associated 
proteins (ALIX and TSG101); lysosomal-associated membrane proteins (LAMP1 and LAMP2); 
heat shock proteins (HSP70 and HSP90); and major histocompatibility complex-I (MHC-I). In 
addition, the presence of proteins not expected to be enriched in exosomes of endosomal 
origin should be determined and this simple aspect is often overlooked in the field. 
Contaminating soluble proteins such as calnexin (endoplasmic reticulum associated protein), 
cannot be detected by cryo-EM or NTA, and can be assessed by Western blot or other 
methods. One other method that discriminates purer vesicle preparations from those 
containing contaminating proteins is to compare the ratio of nanoparticle counts to protein 
concentration (P:P ratio) (Webber and Clayton, 2013). By being able to estimate purity and 
compare sample purity in relatively simple and general quantitative manner, will be useful. 
As this tool broadly defines what is an acceptably pure vesicle sample. A P:P ratio that is less 
than 1 x 1010 is considered to be unpure and will be used as a basis to quality control check 
exosome preparations. 
Here, in this Chapter, we will characterise wild type DU145 exosomes by using multiple 
approaches, which include cryo-EM, an immune-phenotyping plate assay, Western blot, NTA 
and by determining P:P ratios. These methods will form as a basis for analysing exosomes, 
by determining the quantity and phenotype of vesicles. These methods will act as a platform 
to examine whether exosome secretion is modulated by silencing putative regulators of 
exosome biogenesis and secretion. 
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3.1.2 Characterisation of DU145 Exosomes 
The DU145 cell line (originally derived from the metastatic site of the brain) was purchased 
from ATCC. A monolayer of DU145 epithelial cells were examined by phase contrast 
microscopy (Figure 3.1), revealing cells to be adherent to plastic and consisting of a flat 
polygonal shape in appearance; sometimes referred to as a cobble-stone like pattern when 
fully confluent (Stone et al., 1978). These morphological observations agreed with other 
studies on the DU145 cell line (Hayward et al., 2001, Alimirah et al., 2006). 
Isolating exosomes from DU145 cell CM by a combination of ultracentrifugation and 
purifying exosomes on a density-based gradient or cushion, based on their floatation 
property, is a commonly used analytical tool (Raposo et al., 1996, Théry et al., 2006). 
Traditionally, the continuous sucrose gradient is a commonly used method, however, it is 
labourious and there is variability with the exosome yields obtained (Lamparski et al., 2002). 
Alternatively, the sucrose cushion is a quicker method for isolating exosomes compared to 
the sucrose gradient method. This method utilises both ultracentrifugation and a 30% 
sucrose cushion to purify exosomes based on their flotational density in sucrose of 1.1 – 
1.2g/ml. Exosomes were captured in a small density cushion, composed of 30% sucrose/D2O. 
D2O can readily diffuse with H2O, which allows the formation of the minigradient between 
1.1 – 1.8g/cm3 and for enrichment and increased purity of exosomes because of the 
decreased soluble proteins present. The cushions containing exosomes were collected and 
went through an additional PBS wash. This resulted in an exosomal pellet which was 
characterised. 
First, the morphology of DU145 exosomes was examined by cryo-EM, in collaboration with 
Prof. Juan Manuel Falcon-Perez (CIC bioGUNE, Derio, Spain). This was carried out by 
resuspending exosome pellets in PBS and placed onto carbon grids. Grids were vitrified with 
the aid of a Vitrobot. Vitrified samples were imaged quickly at liquid nitrogen temperature 
to prevent the formation of ice crystals. The image reveal heterogeneous populations of 
rounded structures of vesicles with a thick outer boundary, indicative of a lipid bilayer (Figure 
3.2). The diameter of DU145 exosomes agrees with the typically observed diameter range 
for exosomes, often found between 30 – 150nm, as reported by other studies (Raposo et al., 
1996, Welton et al., 2010, Yuana et al., 2013).  
Additionally, the phenotype of DU145 exosomes was examined using a microplate immune-
phenotype assay. Exosomes were coated onto ELISA plates overnight and were assessed for 
their expression of proteins commonly found on exosomes. The expression of CD9, CD81 and 
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MHC-I on the DU145 exosomes were expressed at just over 3.5 x 106 TRF (Figure 3.3 A). The 
DU145 exosomes still showed expressed levels of CD63, but to a lesser extent compared to 
the other tetraspanins (3-fold less). The expression of other markers LAMP1, LAMP2, HSP70 
and HSP90 revealed DU145 exosomes exhibit a lower positive expression (< 5 x 105 TRF). 
However, it remained difficult to detect ALIX and TSG101 (ESCRT-related proteins) on the 
surface DU145 exosomes with this method, as these are ESCRT-related markers typically 
found on exosome’s internal side. Next, we attempted to refine this immune-phenotype 
assay by lysing exosomes coated onto ELISA plate to detect levels of ALIX and TSG101 (Figure 
3.3 B). The signal of ALIX and TSG101 was 4-fold greater when lysing exosomes with RIPA, 
compared to the standard method (P<0.001). Here we showed the isolated DU145 exosomes 
express proteins typically found on the exosome’s surface similar to other studies (Escola et 
al., 1998, Théry et al., 1999). 
To ensure that a specific protein is enriched in exosomes, a comparison in proteins between 
whole cell lysates and exosomes were prepared from the same parent cell (DU145) on the 
same gel. Cell lysates and exosomes from DU145 cells were compared by Western blot and 
probed with an assortment of antibodies. The expression of exosome-associated markers, 
such as ESCRT-related proteins (ALIX and TSG101) and MHC-I were highly enriched in 
exosomes, compared to cell lysates (Figure 3.4). LAMP1 and LAMP2 expression was found to 
be positively expressed in both cell lysates and exosomes, slightly enriched in the exosomes. 
In contrast, the endoplasmic reticulum protein, calnexin, was only present in the cell lysates. 
The expression of the cytosolic marker, GAPDH, was found in cell lysates and exosomes, as 
expected. By phenotyping the DU145 exosomes, these results agree with similar 
documented studies in characterising exosomal-associated proteins (Raposo et al., 1996, 
Escola et al., 1998). The method provides a means of differences in the endosomal/lysosomal 
origin of exosomes; and potentially as a means of defining if any change in their pathways 
arise if interferences with secretion. 
To provide an indication of the heterogeneity present within our purified DU145 exosome 
preparations, Nanosight™ NTA was used. First, we analysed the size distribution of vesicles 
present in DU145 cell CM and show a modal diameter of 99nm (Figure 3.5 A). This 
observation is comparable to the cryo-EM images presented in Figure 3.2, showing a 
heterogeneous population of exosomes with a diameter within the range of 30 – 150nm 
(Raposo et al., 1996, Filipe et al., 2010, Sokolova et al., 2011). Similarly, the isolated purified 
DU145 exosomes had a modal diameter of 131nm (Figure 3.5 B), comparable with the cryo-
EM images. No major differences in the modal size characteristics of exosomes were present 
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between both methods. Despite showing no presence of larger sized vesicles or cellular 
aggregates present (>500nm) in purified exosomes, there remains a broader range of 
detected vesicles (up to 500nm), compared to cell CM which ranges up to 300nm. This data 
suggests that characterising vesicles in cell CM gives similar size distribution profiles present 
in purified DU145 exosomes, with the benefit of having fewer peaks for larger size 
nanoparticles (>300nm). On the other hand, it is important to consider the purity of isolated 
exosomes from cell CM, as it is often dependent on the protocol utilised. 
Estimation of the exosome purity can be measured based on the P:P ratio, using a 
combination of NTA and a colourimetric BCA assay, to determine the particle per ml and 
protein concentration respectively (Webber and Clayton, 2013). A study has demonstrated 
that an exosome preparation containing protein contaminants, resulted in a reduced P:P 
ratio, compared to an exosome sample with no contamination. It was proposed that a P:P 
ratio that was below 1.0 x 1010 were impure and a P:P ratio >1.0 x 1010 were considered of 
low to high purity. The quality threshold of our exosome preparations were routinely used 
on isolated exosomes from the sucrose cushion preparation (Table 3.1). By characterising 
vesicles from cell CM alone, a P:P ratio of 1.78 x 108 was obtained and indicates the sample 
would be impure and could contain other soluble proteins that may not be vesicle-based 
(Figure 3.5 A). In contrast, a P:P ratio of 1.11 x 1010 was obtained from a purified DU145 
exosome preparation (Figure 3.5 B), passing the arbitrary threshold for a pure preparation. 
Many exosome preparations exceeded the quality threshold and were used for subsequent 
characterisation and functional experiments. In contrast, the preparations that failed the 
quality control were not used for experiments and this could be explained by some 
contamination of collecting the sucrose cushion containing exosomes during isolation. 
Exosomes isolated from prostate cancer DU145 cells using the sucrose cushion method are 
of good purity and largely free of contaminating proteins.  
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Figure 3.1: Morphology of prostate cancer cell line (DU145). Monolayer of live prostate 
cancer cell (DU145) were imaged using phase contrast microscopy to confirm 
cobblestone morphology of the epithelial cells. Scale Bar: 100µm. 
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Figure 3.2: Cryo electron microscopy images of DU145 exosomes. DU145 exosomes were adsorbed onto glow-discharging holey carbon 200-
mesh copper grids (QUANTIFOIL, Germany). Grids were blotted at 95% humidity and rapidly plunged into liquid ethane with the aid of VITROBOT 
(Maastricht Instruments BV, The Netherlands). Vitrified samples were imaged at liquid nitrogen temperature using a JEM-2200FS/CR 
Transmission Electron Microscope (JEOL, Japan), equipped with a field emission gun and operated at an acceleration voltage of 200 kV. Multiple 
samples were viewed under cryo-EM, confirming the presence of vesicle structures (white arrows) typical of exosomes. Scale bar: 100µm. 
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Figure 3.3: Characterisation of DU145 exosomes by an immune-phenotype plate assay. 
(A) DU145 exosomes were captured onto high protein binding ELISA plates (1µg/well). 
They were analysed for the expression exosome-associated proteins: tetraspanins (CD9, 
CD63 and CD81), MHC-I, lysosomal associated membrane proteins (LAMP1 and LAMP2), 
heat-shock proteins (HSP70 and HSP90), ESCRT-related proteins (ALIX and TSG101) with 
isotype controls. Graph shows mean + SEM, based on duplicate wells.  (B) DU145 
exosomes were lysed with RIPA and analysed for the expression of ALIX and TSG101. 
Time resolved fluorescence (TRF) is shown. Graph shows mean + SEM, based on duplicate 
wells. n.s: non-significant, **<0.01 and ***P<0.001. One-way ANOVA with Tukey’s 
multiple comparison test. 
(A) 
(B) 
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Figure 3.4: Characterisation of DU145 exosomes by Western blot. DU145 exosomes 
(20µg) and whole cell lysates (20µg), were subjected to SDS-PAGE and Western blotting. 
They were probed for exosomal associated proteins: ALIX, GAPDH, LAMP1, LAMP2, MHC-
I, TSG101. The presence of a protein not expected of endosomal origin was determined 
by calnexin a marker for the endoplasmic reticulum.  
 
 
 
  
Chapter 3. Characterisation of Exosomes from Wild-Type DU145 Cells 
 
86 
 
 
(A) 
Chapter 3. Characterisation of Exosomes from Wild-Type DU145 Cells 
 
87 
 
Figure 3.5: Isolated DU145 exosomes using the sucrose cushion are of high purity. (A) DU145 cell CM or (B) sucrose cushion purified exosomes 
were measured under flow conditions using Nanosight™ NTA. Data from each repeat measurement is shown, revealing the overall size 
distribution (histograms) and particle counts (particles/ml). 6 replicate measurements were carried out and overlaid to show the consistency 
across repeat measurements. BCA assay was used to quantify the protein concentration (µg/ml) of the exosomes. The purity of exosomes was 
assessed by the P:P ratio.  
 
 
  (B) 
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Table 3.1: Quality of isolated DU145 exosomes from the sucrose cushion. Protein and 
particle concentration of DU145 exosomes were measured using the BCA Assay and 
Nanosight™ nanoparticle tracking analysis respectively, to calculate the particle:protein 
(P:P) ratio. Isolated exosome samples with a P:P ratio of >1 x 1010 passed the arbitrary 
quality threshold for a pure exosome preparation (Webber and Clayton, 2013).  
Date Protein 
Concentration 
(µg/ml) 
Particle Concentration 
(particles/ml) 
Ratio 
(Particle/µg) 
Quality 
Control 
14/02/2014 3518 3.86 x 1013 1.09 x 1010 PASS 
26/03/2014 4239 1.48 x 1014 3.49 x 1010 PASS 
30/06/2014 6018 1.53 x 1014 2.54 x 1010 PASS 
30/07/2014 7281 2.20 x 1012 3.02 x 108 FAIL 
11/09/2014 6390 1.86 x 1013 2.91 x 109 FAIL 
18/11/2014 10273 2.51 x 1014 2.44 x 1010 PASS 
30/01/2015 2262 3.12 x 1013 1.38 x 1010 PASS 
20/02/2015 4456 6.87 x 1013 1.54 x 1010 PASS 
18/06/2015 9099 4.30 x 1014 4.73 x 1010 PASS 
17/08/2015 9748 2.27 x 1013 3.70 x 109 FAIL 
21/10/2015 5164 6.11 x 1013 1.18 x 1010 PASS 
04/11/2015 1760 3.73 x 1013 2.12 x 1010 PASS 
03/12/2015 903 8.31 x 1012 9.20 x 109 FAIL 
06/01/2016 677 8.54 x 1012 1.30 x 1010 PASS 
15/02/2016 2053 4.27 x 1013 2.07 x 1010 PASS 
10/03/2016 2758 3.63 x 1013 1.32 x 1010 PASS 
05/04/2016 2242 2.50 x 1013 1.11 x 1010 PASS 
24/05/2016 6398 6.40 x 1013 1.00 x 1010 PASS 
18/07/2016 11019 1.40 x 1014 1.27 x 1010 PASS 
04/10/2016 2003 3.86 x 1013 1.97 x 1010 PASS 
21/11/2016 3159 5.90 x 1013 1.77 x 1010 PASS 
22/12/2016 5014 7.02 x 1013 1.39 x 1010 PASS 
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3.2 Discussion 
In this Chapter, we used purified DU145 exosomes as a basis to characterise vesicles for 
future experiments, to determine whether silencing putative regulators of exosome 
biogenesis and secretion will impact vesicle secretion.   
Here, we showed that the prostate cancer cell line, DU145, was confirmed to have a cobble-
stone like morphology (Stone et al., 1978), similarly shown in other studies with prostate 
cancer cells (Hayward et al., 2001, Alimirah et al., 2006). Exosomes from DU145 cells were 
isolated using the sucrose cushion method and revealed circular structures, demonstrating 
the presence of a lipid bilayer. The DU145 exosomes were a heterogeneous population, in 
which the size of vesicles ranged between 30 – 150nm in diameter, in agreement with NTA 
analysis. The NTA enabled size distribution measurements of nanoparticles in fluid phase, as 
opposed to dehydrated and fixed exosome samples used in traditional (non-cryo) EM. This 
observation may give a greater representation of exosomes, as they are in their native state. 
The NTA data indicated a broad nanoparticle size ranging up to 500nm for purified DU145 
exosomes, despite passing through 220nm-pore filters. The purity of this method of isolating 
exosomes has been previously questioned as high molecular weight complexes and 
apoptotic blebs may co-sediment with these exosomes. Though, other studies have 
demonstrated the purity of these isolated exosomes contain minimal contaminating 
organelles (Mitchell et al., 2008, Webber and Clayton, 2013, Jeppesen et al., 2014). In 
contrast, we observed fewer size distribution peaks that are >300nm in size with 
nanoparticles in cell CM as detected by NTA. It could be possible that cell CM is less 
concentrated with EVs that may not co-isolate as many mixed EV populations. Both NTA and 
cryo-EM gave evidence that nanoparticles greater than >500nm were not present, 
suggesting the absence of apoptotic bodies or large organelles. Both these methods provide 
an indication of the heterogeneity present within samples that can characterise individual 
exosomes. NTA alone cannot distinguish EVs from co-isolated, non-membranous particles of 
similar size and should be compared with cryo-EM to acquire wide-field images of exosomes 
in question. Other methods to determine the presence of exosome-associated proteins must 
be considered to ascertain the isolated samples are in fact exosomes. 
Typically, a general overview of the protein composition of each exosome preparation should 
be provided in a semi-quantitative manner, with exosomal-associated proteins expected to 
be present and components not necessarily expected. Although numerous proteomics 
studies have highlighted proteins commonly found in exosome preparations, it is becoming 
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clear that these do not represent exosome ‘specific’ markers, but rather exosome ‘enriched’ 
proteins (Mathivanan and Simpson, 2009, Kalra et al., 2012). Within the literature, the 
relative proportion of exosomal-associated proteins varies with different EVs or cell types. It 
has been proposed that several proteins (three or more) in a semi-quantitative manner 
should be reported to characterise EVs (Lotvall et al., 2014). The expression of these 
tetraspanins: CD9, CD63, CD81 were detected on our purified DU145 exosomes, commonly 
found on the surface of exosomes from various cell types (Raposo et al., 1996, Escola et al., 
1998, Lamparski et al., 2002). These findings were similar to other studies with prostate and 
bladder cancer cells (Zoller, 2009, Welton et al., 2010). The microplate immune-phenotype 
assay and Western blot analysis revealed DU145 exosomes to be enriched with LAMP1 and 
LAMP2. The LAMP proteins are markers for lysosomes and could reflect the late endosomes 
containing ILVs, although the presence of LAMPs varies for most cell types. Some studies 
only demonstrate the presence of LAMP proteins in exosomes, as reported in tumour cells 
(Wolfers et al., 2001), but absent in DC-derived exosomes (Zitvogel et al., 1998). DU145 
exosomes also showed an enrichment of HSP70 and HSP90. These proteins are involved in 
antigen presentation and participate in loading peptides to MHC molecules (Srivastava, 
2002). Here, MHC-I was also present on exosomes and it is normally present in exosomes 
from most cell types. In general, the level of cellular contamination present within the 
exosome preparation was minimal, as the calnexin protein (ER marker) was absent in 
exosome samples. Within these DU145 exosomes, the presence of CD9, CD63, CD81, ALIX, 
TSG101, LAMP1, LAMP2, HSP70 and HSP90, in combination of the absence of calnexin, 
strongly suggests that the studied vesicles are exosomes. 
One other approach to determine sample purity of exosome preparations is by determining 
the levels of particle to protein (P:P) ratio (Webber and Clayton, 2013). It has been shown 
that vesicle preparation that are considered pure exhibit a relatively high ratio of particles to 
protein and thus contaminating protein within samples should have a negative effect on this 
ratio. Typically, an arbitrary P:P ratio of <1 x 1010 would be considered an impure isolated 
vesicle sample. From the data, isolated DU145 exosomes from the sucrose cushion method 
as one example, demonstrated a P:P ratio of 1.11 x 1010 compared to cell CM with a ratio of 
1.78 x 108. This suggests the exosome preparation from the sucrose cushion would be 
deemed purer. In contrast, analysing cell CM indicates an impure exosome preparation, 
possibly indicating a greater level of soluble proteins present.  Applying the ratio method 
provides a relatively simple and quantitative manner to estimate and compare purity. 
Though, there are some caveats using the P:P ratio as a sole method to analyse exosomes. 
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There it is difficulty in discriminating vesicles from non-vesicular particular material, there is 
an assumption that all detected particles are vesicles and there could be an overestimation 
of particles present within the sample. Furthermore, there is an assumption that each vesicle 
has a comparable and stable quantity of protein; though different disease states may alter 
the protein content to some degree, but this remains poorly understood. Nevertheless, 
bearing issues in mind, the P:P ratio method does provide an additional method to determine 
the purity of the vesicle preparation for future experiments. 
Other methods to isolate exosomes have claimed to isolate pure exosomes from cell CM, 
such the commercially available ExoQuick® (EQ) or Total Exosome Isolation Reagent (TEI). 
Though, the main caveat is that these reagents co-precipitates exosomes with non-vesicular 
proteins, leading to a low yield of impure exosomes (Van Deun et al., 2014). It has been 
shown that isolating vesicles based only on ultracentrifugation can retain a relatively 
moderate pure sample of vesicles, compared to density-based methods. One of the main 
advantages of ultracentrifugation method is it shows a greater protein yield, compared to 
other methods and remains enriched in exosomal-associated proteins. The ease of obtaining 
high overall yields of vesicles will be important for future experiments, as it will be utilised 
to not only be characterised by various methods, but also to perform functional experiments.  
In this Chapter, we have demonstrated different methods used to determine the phenotype 
of exosomes and the amount or concentration of exosomes present. All these methods act 
to analyse exosomes. By doing so, these methods act as a platform to evaluate whether 
exosomes are modulated by silencing putative regulators of exosome biogenesis and 
secretion in future Chapters.
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4.1 Generating Exosome-Deficient Cancer Cells 
4.1.1 Introduction 
Exosomes were first defined as EVs of heterogeneous sizes including one population with 
diameters between 500 and 1000nm (Trams et al., 1981); although this definition changes 
with exosomes originating from the endocytic pathway during early endosome maturation, 
to form MVEs (Harding et al., 1983, Pan et al., 1985). The formation of ILVs, within MVEs, 
involves inwardly budding vesicles with the incorporation of selected cargo. Once ILV 
formation is completed, fusion of MVEs with the plasma membrane secretes ILVs into the 
extracellular space; thus exosome secretion (Stoorvogel et al., 2002). However, MVEs that 
do not fuse with the plasma membrane can often be redirected to lysosomes for degradation 
(Futter et al., 1996). Currently, a great amount of effort has been made towards identifying 
the molecular machinery responsible for this process. 
One of the first mechanisms described for MVE formation was the ESCRT complex (Babst et 
al., 2002a). It contains four protein complexes (ESCRT-0, -I, -II and -III) and interacting 
accessory proteins, transiently engaged to the endosome’s limiting membrane. It is proposed 
that ESCRT-0, -I and -II are involved in clustering cargo in ILVs; and ESCRT-III in vesicle budding 
and scission (Wollert et al., 2009). The ESCRT-II complex contains two core VPS25 protein 
subunits, interacting heavily with both ESCRT-I and -III protein complexes (Wernimont and 
Weissenhorn, 2004). VPS25, as part of the ESCRT-II complex, appears to play a role in MVE 
formation (Katzmann et al., 2002); and localisation of ESCRT-III to late endosomes (Babst et 
al., 2002a). The formation of late endosome, ESCRT components (ALIX and TSG101), as well 
as ubiquitinated proteins, have been proposed to load cargo into ILVs. As examples, ALIX and 
TSG101 mediate epidermal growth factor (EGFR) and transferrin receptor loading into 
exosomes, respectively (Lu et al., 2003, Géminard et al., 2004); and are exosome-associated 
protein markers. Furthermore, the presence of cytosolic proteins into the ILVs can be due to 
co-sorting with other proteins. This mechanism is suggested for chaperones, such as HSP-70 
and HSP-90, found on exosome surfaces in some cell types (Théry et al., 1999, Gastpar et al., 
2005). 
In contrast, depletion of certain ESCRT subunits does not completely impair MVE formation, 
indicating other mechanisms independent of ESCRT may operate in ILV formation (Stuffers 
et al., 2009). It was demonstrated that inhibition of neutral sphingomyelinase, decreased the 
levels of PLP-associated exosome secretion (Trajkovic et al., 2008), independent of ESCRT 
function. Exosomes are often enriched with tetraspanins, such as CD9, CD63 and CD81, 
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dependent on cell type; although a recent report suggests that only CD81 is exosome-specific 
(Kowal et al., 2016). More recently, the tetraspanin, CD63, known to be expressed on the 
exosome surface, directly participates in ESCRT-independent sorting of the PMEL, as PMEL 
localises to CD63-containing ILVs, even in ESCRT-I depleted cells (van Niel et al., 2011). In the 
absence of functional CD63, ILV formation, PMEL sequestration and downstream 
melanosome biogenesis are severely reduced. Similarly, silencing another member of the 
tetraspanin family, CD9, results in a significant decrease in secreted exosomes from DCs 
(Chairoungdua et al., 2010) and Nalm-6 pre-B cells (Mazurov et al., 2013). Although CD9 is a 
commonly expressed tetraspanin on DU145 exosomes (Hosseini-Beheshti et al., 2012, 
Webber et al., 2014), the role they play on MVE biogenesis and exosome secretion is poorly 
understood. CD9 may function, in a similar manner to CD63 with melanosome secretion (van 
Niel et al., 2011). This suggests that distinct ESCRT-independent mechanisms might coexist 
with the ESCRT machinery on MVEs in different cells, reflecting multiple MVE subpopulations 
fated for degradation or exosome secretion (Buschow et al., 2009, Ostrowski et al., 2010, 
Hurley and Odorizzi, 2012).  
Rab proteins are small GTPases and essential regulators of transporting different endosomes 
between different endosomal compartments. Rabs can be involved endosomal budding, 
motility or tethering to the membrane of an acceptor compartment. The Rab family is 
composed of greater than 70 GTPases, each of which is potentially associated with one 
intracellular compartment, depending on cell type. Rab5 is proposed to be involved in early 
endosome formation and maturation of these compartments into late endosomes (Gorvel 
et al., 1991, Chen et al., 2009). It was first reported that silencing Rab11 in K562 cells 
attenuated exosome secretion (Savina et al., 2002); and their follow-up study showed Rab11 
to promote docking and fusion of MVE with the plasma membrane (Savina et al., 2005). 
These studies created an interest in Rab protein roles in exosome secretion. Rab27 was 
initially explored in HeLa cells, found to function in MVE docking at the plasma membrane 
(Ostrowski et al., 2010) and silencing Rab27a inhibited exosome secretion, as shown in 
various studies (Peinado et al., 2012, Bobrie et al., 2012, Ostenfeld et al., 2014, Webber et 
al., 2015). Similarly, silencing Rab35 demonstrated an accumulation of intracellular 
endosomes within the cell, whilst attenuating exosome secretion (Hsu et al., 2010). These 
proteins, Rab11, Rab27a and Rab35 are proposed to stimulate tethering and fusion of 
recycling or late endosomes to the plasma membrane, though it remains poorly understood 
whether Rab11 or Rab35 have the same role in trafficking MVEs with the plasma membrane 
in one given cell type. 
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In addition to Rab proteins, SNARE proteins localise to exosomes with CD63 and lipid rafts 
(Salaun et al., 2005, Perez-Hernandez et al., 2013). SNARE proteins are proposed to mediate 
membrane fusion, including transport between organelles (Jahn and Scheller, 2006). As a v-
SNARE protein, VAMP7 is suggested to assist in MVE docking and fusion with the plasma 
membrane; and subsequent release of exosomes into the extracellular space (Fader et al., 
2009). Some of these components are involved in MVE fusion with the plasma membrane 
during exosome release, although the specific SNARE complex has yet to be discovered.  
Here, we will transduce DU145 cells with lentiviral particles with a specific shRNA sequence 
targeting: CD9, Rab5a, Rab11b, Rab35, VAMP7 and VPS25. Confirmation of knockdown will 
be assessed at the mRNA and protein level; and possible cytopathic consequence of the 
knockdowns. Multiple approaches will be utilised to assess the outcome of knockdown on 
secreted vesicles; and be any distribution changes in endo/lysosomal compartments. 
Currently, there appears to few distinct mechanisms for exosome biogenesis, trafficking and 
release. It remains poorly understood whether different mechanisms may explain the 
heterogeneity of exosomes produced in each cell. However, one question that remains is 
whether it is possible to manipulate cells and force them to produce an altered repertoire of 
vesicle subpopulations, whilst understanding if there is a hierarchy of which mechanism is 
most relevant? As shown in Figure 4.1, the hypothesis is that blockade of one pathway 
(pathway A for example) may lead to a loss of a specific subpopulation. This may still enable 
the secretion of other vesicle subpopulations, pathway B and C as examples, that may impart 
a different cancer cell function. 
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Figure 4.1: Simplified diagram of MVE and vesicle heterogeneity. The cell has distinct 
pathways that generate complex heterogeneity in secretion of exosomes. Blockade of 
one pathway, for example pathway A, may result in a loss of subpopulation and impact 
the cancer cells function. 
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4.1.2 Puromycin Kill Curve for DU145 Cells 
For my initial studies, MISSION® shRNA lentiviral particles (Sigma-Aldrich) were used to 
transduce DU145 cells with a shRNA sequence against each respective target. Each lentiviral 
plasmid vector contains a puromycin resistance gene for mammalian selection. Therefore, 
puromycin was used in gene selection for mammalian host cells. First, a puromycin kill curve 
was performed to determine the minimum puromycin concentration required to kill all non-
resistant cells. Here, the WST-1 assay (measuring cell metabolic activity) was used to 
determine the minimum puromycin concentration required for efficiently selecting 
transduced cells. Incremental doses of puromycin (0 – 10µg/ml) were used to treat DU145 
cells (Figure 4.2). Absorbance was measured, based by the cleavage of the stable tetrazolium 
salt, WST-1, into a soluble formazan by cellular mitochondrial dehydrogenases present in 
viable cells. The quantity of released formazan dye correlates to the number of metabolically 
active cells in culture. Here, 1.25µg/ml was the minimal puromycin dose observed, that was 
sufficient to kill all DU145 cells. 
4.1.3 Confirmation of Knockdown at the mRNA and Protein Level 
Here, we used lentiviral particles with a specific shRNA sequence to silence targets putatively 
involved in exosome biogenesis and secretion to transduce DU145 cells. A multiplicity of 
infection (MOI) of 20 was used. MOI is defined as the number of transducing lentiviral 
particles per cell. DU145 cell were transduced with lentiviral particles containing shRNA, 
treated with puromycin for six passages before assessing levels of target mRNA and protein. 
We tested five different shRNA sequences for each target (Figure 4.3) that included: CD9, 
Rab5a, Rab11b, Rab35, VAMP7 and VPS25. Lentiviral particles delivering a shRNA sequence 
targeting a non-mammalian RNA was used as a control. Confirmation of each knockdown 
was carried using gene expression assays to show relative quantification (RQ) of the target 
mRNA to the control. For this, GAPDH mRNA was used as an internal control. 
The five shRNA sequences targeting CD9 showed variable mRNA knockdown, ranging from 
45% - 87% (Figure 4.3 A). Targeting Rab5a showed mRNA knockdown ranging from 85% - 
97% (Figure 4.3 B). Targeting Rab11b showed mRNA knockdown ranging from 71% - 95% 
(Figure 4.3 C). Targeting Rab35 showed mRNA knockdown ranging from 78% - 95% (Figure 
4.3 D). Targeting VAMP7 showed mRNA knockdown ranging from 87% - 92% (Figure 4.3 E). 
Lastly, targeting VPS25 showed mRNA knockdown ranging from 78% - 93% (Figure 4.3 F). 
These results indicated that we had successful knockdown of each target at the mRNA level. 
However, confirming knockdown at the mRNA level may not necessarily correlate to changes 
at the protein level.  
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Next, the protein level was investigated by Western blotting. First, analysis of whole cell 
lysates derived from each cell line demonstrated attenuated expression of target proteins. 
With the CD9 target, the clone #953 showed the greatest mRNA knockdown of 87% (Figure 
4.3 A), but did not show the greatest attenuation at the protein level (Figure 4.4 A). The clone 
#470 showed the greatest attenuation for CD9 at the protein level (Figure 4.4 A), despite 
only having a mRNA knockdown of 70%. All clones for the Rab5a target showed no detectable 
protein levels (Figure 4.4 B). The clone #466 was selected based on the mRNA knockdown at 
97%. With the Rab11b target, the clone #919 showed the greatest attenuation at the protein 
level (Figure 4.4 C), with a mRNA knockdown of 95%. Knockdown of Rab35 was less obvious 
when detecting levels of Rab35 protein (Figure 4.4 D). Although mRNA knockdown ranged 
from 78% - 95% for Rab35; the Rab35 clone #335 was selected based on 95% knockdown at 
the mRNA level. All clones for the VAMP7 target showed no detectable protein levels (Figure 
4.4 E). Therefore, clone #928 was selected based on the mRNA knockdown at 92%. For the 
VPS25 target, clone #757 showed the greatest attenuation at the protein level (Figure 4.4 F), 
with a mRNA knockdown of 93%. In Figures 4.3 and 4.4, the selected clones (denoted by a 
↓), CD9 (#470), Rab5a (#466), Rab11b (#919), Rab35 (#335), VAMP7 (#928) and VPS25 
(#757) were chosen for future experiments, based on a combination of both the mRNA and 
protein data. 
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Figure 4.2: Puromycin kill curve for DU145 cells. DU145 cells were seeded at a density of 
5,000 cells per well in a 96-well plate. Wells were subjected to a range of puromycin 
concentrations (0 -10µg/ml) and incubated for 2 hours. After this incubation period, cell 
viability was measured using the WST-1 assay. Wells were incubated with WST-1 for 1 
hour, to quantify the release of formazan by measuring absorbance at 420nm by the 
PHERAstar FS Microplate Reader. Graph shows mean + SEM, based on 5 wells. 
 
Chapter 4. Generating Exosome-Deficient Cancer Cells 
 
100 
 
Figure 4.3: Confirmation of knockdown of target mRNA by qPCR. DU145 cells were 
stably transduced with MISSION® shRNA lentiviral transduction particles expressing a 
non-mammalian control (CTR) or shRNA against the indicated target: (A) CD9, (B) Rab5a, 
(C) Rab11b, (D) Rab35, (E) VAMP7 and (F) VPS25. Relative expression of target mRNA 
was evaluated using qPCR, with GAPDH as the internal control. Arrows indicate selected 
clones demonstrating greatest knockdown at the mRNA level and subsequent protein 
level taken forward for experiments. Graph shows mean ± SEM, based on triplicate wells. 
***P<0.001. One-way ANOVA with Tukey’s post hoc test. 
(C) 
(E) (F) 
(D) 
(B) (A) 
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Figure 4.4: Confirmation of knockdown by Western blot. Cell lysates (20µg) from each 
cell lines was probed for their respective target protein: (A) CD9, (B) Rab5a, (C) Rab11b, 
(D) Rab35, (E) VAMP7 and (F) VPS25. GAPDH was used as a protein loading control. 
Arrows indicate the selected clones which showed greatest knockdown at both the 
mRNA and protein level. 
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4.1.4 The Impact of Knockdowns on Cell Viability 
We next explored some of the general properties of cells, to understand if the knockdowns 
have any cytopathic impact. A monolayer of lentiviral transduced DU145 cells were seeded 
and examined by phase contrast microscopy (Figure 4.5). All the cells display a flat polygonal 
morphology typically shown in DU145 control cells, forming discrete islands when sub-
confluent (shown) and a cobblestone-monolayer pattern, when confluent. This was indeed 
the case regardless of attenuated target proteins. The knockdowns, therefore, did not impart 
gross effects on cell shape or the capacity to attach or form monolayers. 
Next, we examined the proliferation properties of these lentiviral transduced cells, using the 
cell proliferation reagent, WST-1. DU145 cells were seeded equally and incubated with the 
WST-1 reagent for 0.5 – 4 hours.  This determined the optimal incubation time required to 
detect formazan levels above the background and below the maximum thresholds (Figure 
4.6 A). Here, we observed that doubling of DU145 cell numbers, indicated by the absorbance 
values showed a sigmoidal curve with a signal plateau at 50,000 cells/well or greater; 
although there was a dose-dependent relationship within a range of 6,000 – 50,000 cells. 
Here, there is no advantages in signal strength when incubating for different times. 
Therefore, a time of 1 hour was chosen to incubate cells to ensure the signal is present or 
does not plateau.  
Next, we seeded 5,000 lentiviral transduced DU145 cells into 96-well plates and monitored 
cell proliferation over 72 hours. WST-1 was incubated for 1 hour at each timepoint to 
measure formazan absorbance. Here, knockdown of CD9 and Rab5a in DU145 cells appeared 
to show weak inhibition of cell proliferation (Figure 4.6 B and C) over 72 hours, compared to 
controls. Knockdown of Rab11b and Rab35 (Figure 4.6 D and E) in DU145 cells appears to be 
negligible on cell proliferation over 72 hours compared to the control. In contrast, 
knockdown of VAMP7 in DU145 cells appeared to show a modest increase in cell 
proliferation (Figure 4.6 F). On the other hand, there was a significant decrease in cell 
proliferation with the knockdown of VPS25 (Figure 4.6 G), compared to controls. The 
majority of knockdowns showed a minimal impact upon cell viability, except for VPS25. 
Therefore, any observed changes with vesicle secretion with the VPS25 knockdown will be 
difficult to assess, as the impact on vesicle secretion may be accounted for by toxic, rather 
than specific effects on vesicle biogenesis/traffic function.  
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Figure 4.5: Transduced DU145 cells maintain cobblestone-like morphology. Monolayer 
of live transduced DU145 cell lines were imaged using phase-contrast microscopy, to 
visualise the cobblestone-like morphology within the epithelial cells. Scale bar: 100µm. 
Representative fields are shown. 
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Figure 4.6: Confirmation of lentiviral transduced DU145 cell viability. (A) Lentiviral 
transduced DU145 cell lines were seeded at various cell densities (0 – 200,000 cells per 
well) in a 96-well plate; and subjected to different incubation times (30 - 240 minutes) 
with WST-1 reagent. After incubation, absorbance was measured at 420nm, quantifying 
formazan release, using the PHERAstar FS Microplate Reader. 5,000 cells were seeded 
into 96-well plates for each lentiviral transduced DU145 cell lines: (B) CD9, (C) Rab5a, (D) 
Rab11b, (E) Rab35, (F) VAMP7 and (G) VPS25. Cells were subjected to the WST-1 reagent 
at 24, 48 and 72 hours. Graph shows mean ± SEM, based on quadruplicate wells. n.s: 
non-significant, *P<0.05, **P<0.01 and ***P≤0.001. Two-way ANOVA with Bonferroni 
post hoc test. 
 
(A) 
(B) (C) (D) 
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4.1.5 Confirmation of Knockdown Cell Stability  
Previously, we demonstrated that puromycin selection eliminated non-transduced DU145 
cells and knockdown of CD9, Rab5a, Rab11b, Rab35, VAMP7 and VPS25 was validated at both 
the mRNA and protein levels. Selected sequences with successful knockdown demonstrated 
a mRNA reduction between 70% - 97%. However, if shRNA-mediated depletion of the target 
caused a growth disadvantage over time, the cells bearing knockdowns might be overgrown 
with cells not exhibiting the knockdown from this heterogeneous cell population. This may 
limit the experimental timeframe available to us, if loss of the knockdown phenotype over 
time is apparent. To test the stability of each knockdown within the populations of 
transduced DU145 cells, we compared target mRNA expression between two time-points. 
Newly transduced DU145 cell lines, free from lentiviral particles at week 6, were compared 
to cells maintained in continuous culture for 15 weeks, longer than any other experiments 
conducted in this study. 
The CD9 mRNA transcript expression levels were decreased by 86% in DU145 CD9KD cell 
populations at 15 weeks after transduction (Figure 4.7 A), compared to a 70% decrease at 
week 6. Transduction of other targets showed decreased expression of target mRNA that still 
maintained very good knockdown stability, as in all cases, the target mRNA remains >78% 
decreased below controls, although this shows a slight increase in target mRNA expression 
levels than at the initial 6-week time-point, for Rab5a, Rab11b, VAMP7 and VPS25 (Figure 
4.7 B – C and E – F). For Rab35, however, the cloning levels was faster for wild type, showing 
expression levels at 5% at week 6 and 45% at week 15; but remained significantly down 
(Figure 4.7 D). In all cases, besides CD9, the mRNA knockdown decayed over time, indicating 
cells can maintain their stability over a given time, although all experiments were performed 
prior to week 15.  
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Figure 4.7: Confirmation of shRNA silencing stability in lentiviral transduced DU145 
cells. mRNA was extracted from lentiviral transduced DU145 cell lines at week 6 or 15, 
to confirm the stability of each target at the mRNA level. Relative expression of target 
mRNA; (A) CD9, (B) Rab5a, (C) Rab11b, (D) Rab35, (E) VAMP7 and (F) VPS25 were 
evaluated using qPCR, with GAPDH as the internal control. Graph shows mean ± SEM, 
based on triplicate wells. ***P<0.001. One-way ANOVA with Tukey’s post hoc test. 
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4.1.6 Characterisation of Vesicles Derived from Lentiviral Transduced DU145 Cells 
We investigated whether silencing CD9, Rab5a, Rab11b, Rab35, VAMP7 or VPS25 attenuated 
exosome secretion. We characterised the number and size of nano-particulate material 
present in cell CM using the Nanosight™ NTA platform for each lentiviral-transduced DU145 
cells. First, cell CM was collected from DU145 CD9KD, Rab5aKD, Rab11bKD, Rab35KD, VAMP7KD 
and VPS25KD cells, cultured at identical densities. Cellular debris was removed by serial 
centrifugation (400 x g for 7 minutes, 2000 x g spins for 15 minutes); and the removal of large 
non-exosomal particles by filtration (0.22µm filter). The resultant cell CM was analysed by 
NTA. Otherwise, cell CM underwent ultracentrifugation (200,000 x g for 2 hours), to obtain 
vesicle concentrates that were characterised for exosomal-associated proteins. 
Traditionally, estimates of the relative expression of proteins of interest are often made by 
comparison against the signal observed by internal standards (housekeeping proteins). 
Conventionally, such proteins are considered to be ubiquitously and constitutively expressed 
in every tissue, presumed necessary for normal cellular function. Classical examples include 
GAPDH or β-actin. This allows normalisation of signals so that expression of genes/proteins 
between samples can be compared, eliminating variations arising from technical reasons, 
such as sample loading or transfer. However, there is currently no ubiquitously and 
constitutively expressed housekeeping protein on exosomes, derived from various cell types. 
Here, by investigating multiple targets putatively implicated in exosome biogenesis and 
secretion, comparisons made between secreted exosomes from lentiviral transduced DU145 
cells were difficult. Normalisation of the secreted exosomes based on protein concentration 
would not give a true representation of the knockdown effect, as this may incorporate other 
exosome subpopulations. Thus, the cell CM or vesicle concentrate pellet were corrected for 
cell number. By normalising for cell number, we can analyse the exosome quantity arising 
from each lentiviral transduced DU145 cells, that will give a fair comparison between the 
exosome subpopulations.  
First, we performed size distribution measurements of vesicles by NTA in the DU145 control, 
CD9KD, Rab5aKD, Rab11bKD, Rab35KD, VAMP7KD and VPS25KD cell CM, corrected for cell number 
(particle/cells). We observed that nanoparticle size distribution profiles were similar 
irrespective of knockdown; and revealed a population of particles ranging between 50 – 
200nm in diameter, while not exceeding 300nm (Figure 4.8 A). The histogram mode of the 
control cells was around 110nm and this was comparable with other knockdowns, with a 
tendency for larger nanoparticles in the VAMP7KD (125nm) and VPS25KD (135nm) (Figure 4.8 
B). When examining the quantity of particles per cell, some significant differences were 
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present. We observed no significant differences in the CD9KD, but surprisingly an elevation 
(24%) in particles/cell (P<0.01) was evident in the Rab5aKD. In contrast, there was a modest 
attenuation in particles/cell with respect to the Rab11bKD (24%) (P<0.01), Rab35KD (23%) 
(P<0.05), VAMP7KD (32%) (P<0.001) and VPS25KD (20%) (P<0.01), respectively (Figure 4.8 C). 
The selected knockdowns, therefore, appeared to have an impact on the cell-derived, 
nanoparticles produced, except for the CD9KD. 
Solely relying on NTA to characterise vesicles based on size distribution profiles is not 
sufficient, as it does not discriminate vesicles from other nanoparticles or any other non-
vesicular aggregates of protein/cell debris. Therefore, other related assays (Western blot or 
plate-based assays) are used to confirm the vesicle levels in the total secretome. To confirm 
vesicle loss from DU145 control, CD9KD, Rab5aKD, Rab11bKD, Rab35KD, VAMP7KD and VPS25KD 
cells, we used ultracentrifugation to concentrate vesicles in bulk. For the following 
experiments, cell counts were used as a basis for correcting differences in cell numbers at 
the CM harvesting time. Pelleted vesicle concentrates were obtained from cell CM, as 
previously described. Western blot was performed to observe the presence of any exosomal-
associated proteins in the vesicles derived from knockdowns. Membranes were probed for 
ESCRT-related proteins; ALIX and TSG101; lysosomal associated membrane proteins, LAMP1 
and LAMP2; heat shock proteins HSP70 and HSP90; and GAPDH. Data for the CD9KD in terms 
of Western blot, matched the NTA dataset to some degree, where we observed little change 
in the levels of ALIX, GAPDH, HSP90 and TSG101, despite a modest reduction in intensity for 
HSP70, LAMP1 and LAMP2 (Figure 4.9). Following Rab5aKD, the Western blots pointed to a 
general increase in intensity for ALIX, GAPDH, HSP90, LAMP1 and LAMP2, despite little 
change in HSP70 or TSG101, consistent with NTA data showing an increase in particles/cell. 
In contrast, the Western blots revealed a general reduction in levels of ALIX, HSP70, HSP90, 
GAPDH, LAMP1, LAMP2 and TSG101 for the Rab11bKD, Rab35KD or VPS25KD. This agreed with 
the NTA data and would be consistent with a partial attenuation in exosome secretion. 
Similarly, VAMP7KD followed this trend, despite showing little change in ALIX and TSG101 
protein. Despite these trends, it remains difficult to assess changes in protein target levels, 
as it depends on the knockdown target.  
Next, we characterised these vesicle concentrates from the DU145 control, CD9KD, Rab5aKD, 
Rab11bKD, Rab35KD, VAMP7KD and VPS25KD cell CM (described previously), using a plate-based 
assay to examine surface expressing tetraspanins (CD9 and CD81). Vesicle concentrates were 
corrected to cell number, as previously described. We examined the relative level of 
tetraspanin positive vesicles, compared to controls. Vesicles derived from the CD9KD, 
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demonstrated a significant reduction in CD9 signal (P<0.001); as expected (Figure 4.10). 
Similarly, there was an attenuation (<50%) in CD9 signal with the Rab11bKD, Rab35KD and 
VAMP7KD (P<0.01); and likewise, with the VPS25KD (P<0.001), compared to controls. 
Consistently, there was an increase (80%) in CD9 signal for the Rab5aKD (P<0.001), similar to 
the Western blot and NTA data. Despite showing no significant differences in CD81 signal, 
we observed the same trends with each knockdown, as we saw for CD9-signal (Figure 4.10). 
In summary, stable knockdown of at least >70% was achieved for each target, without 
unleashing gross cytopathic or toxic effects. Although the mRNA was effectively diminished, 
exosome concentrates for Rab11b or Rab35 resulted in a modest 23% decrease only. 
VAMP7KD was similar, but gave no changes in levels of ALIX or TSG101. These are difficult to 
interpret, whether indicative of a protein and/or a vesicle effect. The CD9KD demonstrated 
little changes in vesicle number, but may have some effect in controlling protein-cargo 
loading onto vesicles, although this remains difficult to understand. In contrast, Rab5aKD 
showed increased levels of exosome concentrates, though this is unknown whether this is 
due to increased exocytosis or blockade of endocytosis. Silencing VPS25, however, remains 
difficult to assess, whether this is due to the toxic cellular effect or genuine vesicle function. 
Based on our evidence, we decided to explore the importance of Rab11b and Rab35, in terms 
of vesicle structure and endosomal/lysosomal distribution in cells. 
 
  
 
Chapter 4. Generating Exosome-Deficient Cancer Cells 
 
110 
 
 
 
 
 
Figure 4.8: Characterising vesicles from lentiviral transduced DU145 cell CM by NTA. Cell CM was collected from DU145 control, CD9KD, Rab5aKD, 
Rab11bKD, Rab35KD, VAMP7KD and VPS25KD cells, cultured for 7 days. CM was analysed by NTA and six replicate measurements, revealing (A) the 
overall size distribution (histogram), (B) modal particle size and (C) the number of particles, adjusted for cell number (particles per cell: p/cell) is 
shown. The background of particles in the culture medium has been subtracted. These data are from a contiguous experiment and are 
representative of three such experiments. Graph shows mean ± SEM, based on 6 replicates. n.s: non-significant, *P<0.05, **<0.01 and 
***P<0.001. One-way ANOVA with Tukey’s post hoc test. 
(A) 
(B) (C) 
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Figure 4.9: Characterising vesicles from lentiviral transduced DU145 cell CM by Western 
blot. Cell CM was collected from DU145 control, CD9KD, Rab5aKD, Rab11bKD, Rab35KD, 
VAMP7KD and VPS25KD cells, cultured for 7 days. CM underwent a basic differential 
ultracentrifugation method, followed by filtration through a 0.22µm filter, before 
ultracentrifugation at 200,000 x g for 2 hours in a fixed angle 70Ti rotor to obtain vesicle 
concentrates. Vesicle concentrates corrected for cell number were loaded. Six different 
exosomal-associated proteins (ALIX, HSP70, HSP90, LAMP1, LAMP2 and TSG101) were 
probed by Western blot. 
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Figure 4.10: Characterising vesicles from lentiviral transduced DU145 cell CM by a plate-
based assay. Cell CM was collected from DU145 control, CD9KD, Rab5aKD, Rab11bKD, 
Rab35KD, VAMP7KD and VPS25KD cells, cultured for 7 days. CM underwent a basic 
differential ultracentrifugation method, followed by filtration through a 0.22µm filter, 
before ultracentrifugation at 200,000 x g for 2 hours in a fixed angle 70Ti rotor to obtain 
vesicle concentrates. Vesicle concentrates corrected for cell number were captured onto 
high protein binding ELISA plates. Expression of (A) CD9 and (B) CD81 were analysed and 
plotted as relative levels, compared to control cells. Graph shows mean + SEM, based on 
duplicate wells, due to the limitation of sample availability. n.s: non-significant, **<0.01 
and ***P<0.001. One-way ANOVA with Tukey’s post hoc test. 
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4.1.7 Characterising Vesicle Structures by Cryo-EM From DU145 Control or Rab11bKD or 
Rab35KD Cells 
To understand the structure of nanometre sized vesicles, direct imaging would be a preferred 
characterisation technique. However, due to the limitation of their nanometre size, vesicles 
are at the lower limit of resolution for conventional light microscopy techniques. Although 
confocal or fluorescence microscopy can detect the larger nanometre-sized vesicles 
(>200nm), the fine details cannot be resolved (Piccin et al., 2007); although attempts have 
been made, but none seem quite successful. One of the commonly used methods to 
determine vesicle’s size and structure is TEM. Though some concerns about the reliability of 
analysis of pelleted vesicles (dehydration and fixation) for TEM may alter vesicle size and 
morphology. Other ‘newer’ methods, such as cryo-EM, led to finding that the ‘cup-shaped’ 
morphology of exosomes was an artefact related to fixation for TEM (Théry et al., 2006). 
Despite these concerns, cryo-EM is the only method by which the nature of the vesicles size 
and structure may be determined at the same time. Here, the morphology of vesicles derived 
from DU145 control, Rab11bKD or Rab35KD cell CM were examined using cryo-EM in 
collaboration with Prof. Juan Manuel Falcón-Pérez (CIC bioGUNE, Derio, Spain). To perform 
this, vesicle concentrates were resuspended in PBS and placed onto glow-discharged holey 
carbon grids. Grids were blotted at 95% humidity and rapidly plunged into liquid ethane with 
the aid of VITROBOT. Vitrified samples were imaged at liquid nitrogen temperature, using a 
JEM-2200FS/CR cryo-TEM (JEOL, Japan), equipped with a field emission gun and operated at 
an acceleration voltage of 200 kV. Vesicle samples were viewed, revealing circular vesicle 
structure with a thick outer boundary, typical of a lipid bilayer.  
Representative images are presented from DU145 control, Rab11bKD- or Rab35KD- derived 
vesicle concentrates, showed the presence of exosomes (Figure 4.11 A - C). The vesicles were 
heterogeneous in size, demonstrating that the population of vesicles from either control or 
knockdowns are not uniform as expected; and comparable to other reports of vesicle 
analysis by others (Caby et al., 2005, Yuana et al., 2013, Royo et al., 2017). From these 
representative images, there appeared to be fewer smaller sized (<50nm) vesicles in the 
Rab11bKD images (Figure 4.11 B), compared to controls. Though, there appears to be an 
increase in smaller sized vesicle-like structures (<20nm) in the Rab35KD (Figure 4.11 C), that 
may reflect the impact of knockdown on vesicle heterogeneity. Overall, these representative 
images appear to show the presence of vesicles, with all well recognised within the 
established diameter range of exosomes at 30nm - 150nm reported by various studies 
(Raposo et al., 1996, Escola et al., 1998, Yuana et al., 2013). 
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Figure 4.11: Characterisation of vesicles from DU145 control, Rab11bKD or Rab35KD cells by cryo-EM. CM from (A) control, (B) Rab11bKD or (C) 
Rab35KD cells were concentrated by 200,000 x g ultracentrifugation into vesicle pellets, that were resuspended in PBS and placed onto glow-
discharged holey carbon grids. Grids were blotted at 95% humidity and rapidly plunged into liquid ethane with the aid of Vitrobot. Samples were 
imaged at liquid nitrogen temperature using a JEM-2200FS/CR cryo-TEM (JEOL), equipped with a field emission gun. The vesicles were viewed 
under cryo-EM, confirming the presence of lipid-bounded vesicle structures typical of exosomes. Scale bar: 100nm.  
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4.1.8 Distribution of Endosomal/Lysosomal Markers in DU145 Rab11bKD or Rab35KD Cells 
Previous studies have demonstrated that silencing Rab27a (Ostrowski et al., 2010) or Rab35 
(Hsu et al., 2010), results in an accumulation of MVEs within the cell, because of attenuated 
exosome secretion. These alterations are often associated in distribution changes with 
endosomal/lysosomal compartments, revealing MVE accumulation that may otherwise be 
exosomally-secreted. We next investigated the impact of knocking down Rab11b and Rab35 
upon the endosomal compartments in DU145 cells. These following experiments involved 
immunofluorescent microscopy and flow cytometry staining for the tetraspanins (CD63 and 
CD81) and LAMP2. We also included early endosome antigen 1 (EEA1), as a marker for the 
early endosome. For assessing whole cell populations, flow cytometry was carried out on 
fixed/permeabilised cells for the markers, as described. 
Here, we examined the impact of Rab11bKD or Rab35KD, in relation to any alteration in size or 
distribution and accumulation of proteins in late endosomes/lysosomes. There was clear 
evidence for an elevation in intracellular CD63, LAMP1 and CD81, following knockdown of 
Rab11b or Rab35 (Figure 4.12 A - C), compared to controls. The weak and diffuse punctate 
staining of CD63, LAMP1 and CD81 in control cells became more intense, with increased peri-
nuclear accumulation. On the other hand, staining for EEA1 (Figure 4.12 D) remained 
punctate and diffuse within the cytosol with no significant alteration in intensity or 
distribution, suggestive of the early endosomes remaining unaffected following knockdown.  
Next, we performed flow cytometric analysis on control and knockdown cells, showing 
similar results to immunofluorescent staining. However, the results indicated the median 
fluorescent intensity (MFI) are weak and this may be due to sub-optimal staining or sub-
optimal cell permeabilisation (Figure 4.13 A - C). Nevertheless, we observed a significant 
elevation (40%) in the MFI of CD63 (Figure 4.13 D) was observed in both Rab11bKD and 
Rab35KD (P<0.001), compared to controls. This was also true for LAMP1 staining 
accumulation (40% increase) (Figure 4.13 E), in Rab11bKD (P<0.05) and Rab35KD (P<0.01). 
Interestingly, data for CD81 (Figure 4.13 F), showed a significant difference in Rab11bKD 
(P<0.05), but not for Rab35KD. Consistently, EEA1 (Figure 4.13 G) MFI remained not 
significantly altered following either knockdown, suggesting that early endosomes are not 
affected. Here, the cells demonstrate that knockdown of Rab11b or Rab35 impacts the 
organisation of the late endosomal or lysosomal compartments and not early endosomes, 
consistent with the previous published data related to attenuated exosome secretion.   
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Figure 4.12: Immunofluorescent staining of endosomal/lysosomal markers in DU145 
control, Rab11bKD or Rab35KD cells. Fixed-permeabilised DU145 control or Rab11bKD or 
Rab35KD cells were stained for markers of late endosomes/lysosomes: (A) CD63, (B) 
LAMP1, (C) CD81, or a marker of early/recycling endosomes EEA1 (D) and labelled with 
Alexa-488, and DAPI. Wide-field fluorescence microscopy, with structured illumination 
was performed, and images show representative microscopic fields, as Z-axis sections 
overlaid to generate maximum projection images. The grey box shows selected regions 
at higher magnification. Scale bar: 20µm and 5µm respectively. Representative fields are 
shown. 
(B) 
(C) (D) 
(A) (A)
A) 
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Figure 4.13: Flow cytometric analysis of endosomal/lysosomal markers in DU145 control, Rab11bKD or Rab35KD cells. Flow cytometry analysis of 
fixed-permeabilised DU145 control, Rab11bKD or Rab35KD cells. (A) Representative dot plot image of size and granularity distribution of cells. Region 
of interest (P1) was selected to include single and viable cell populations. Representative histograms shows an example of LAMP1 staining in 
fix/permeabilised DU145 control and (B) Rab11bKD and (C) Rab35KD cells. Median fluorescent intensities (MFI) were plotted after isotype subtraction 
(based on 5,000 events), based on other primary antibodies against: (D) CD63, (E) LAMP1, (F) CD81 and (G) EEA1. Graph shows mean + SEM, based 
on duplicate samples. n.s: non-significant, *P<0.05, **<0.01 and ***P<0.001. One-way ANOVA with Tukey’s post hoc test. 
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4.1.9 Protein Profiling of Vesicles or the Soluble Secretome Following Rab11b or Rab35 
Knockdown 
The Rab proteins are known to function collectively in regulating a myriad of membrane 
transport processes. However, disrupting the intracellular traffic regulators may have 
unexpected effects on the secretome. In one report, silencing Rab27a resulted in effective 
exosome attenuation, although, this also impacted on the secretion of a subset of cytokines. 
For example, the secretion of pro-MMP-9 were significantly reduced, or in contrast cells 
displayed increased tendencies to secrete granulocyte-colony stimulating factor (G-CSF); but 
none were secreted in associated with vesicles (Bobrie et al., 2012). These results highlight 
silencing Rab27a not only impacts the secretion of MVE derived exosomes, but also regulates 
the secretion of a subset of soluble proteins.  
Here, we investigated whether the secretion of non-exosome associated secreted factors 
present in cell CM (total secretome) and changes arising in the vesicle concentrates, could 
also be affected upon knockdown of Rab11b or Rab35. We performed a sensitive Proximity 
Ligation Array (Proseek® Multiplex Immuno-Onc I96x96) for this experiment, which measured 
the expression of 92 proteins across various samples, to sub picogram sensitivity. This 
sensitive array was performed because soluble factors are often at low concentrations that 
are difficult to detect by the Array. From the Array, many proteins were reported below the 
LOD, whilst detectable signal was present for 46 proteins in the total secretome. With 
respect to the vesicle concentrates a total of 38 proteins were detected (Figure 4.14). 
First, we compared the profile of vesicle-rich pellets from DU145 control cells, compared to 
vesicle pellets from Rab11b or Rab35 knockdowns. The data is presented as fold-changes 
compared to control cells; and revealed around 18 analytes exhibiting greater than 2-fold 
changes in relative abundance following knockdown (Figure 4.15 A). Though the extent of 
change was dissimilar, the direction of change was similar for both Rab11b and Rab35 
knockdowns, all except for some cases. For example, CXCL6 was >3.8 fold decreased in 
vesicles derived from the Rab11b knockdown, compared to >2 fold increased from the Rab35 
knockdown. The factors were significantly different (P<0.05) compared to control cells, as 
shown in the volcano plot (Figure 4.15 B). This highlights a reduction in MMP-1, but an 
elevation in CXCL6, IL18R1, TGFα, TNFRSF3, TRAIL and VEGF-A in vesicle pellets derived from 
Rab35 knockdowns. In contrast, vesicle concentrates from the Rab11b knockdown 
demonstrated decreased levels of AXL1N, CXCL6, TRAIL and TWEAK; and showed an 
elevation in 4E-BP1. This data revealed that despite showing similarities across vesicle 
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samples, there are examples where the vesicle populations following knockdown of Rab11b 
or Rab35, are not identical. 
Similar comparisons were made comparing with cell CM (Figure 4.15 C). We observed 
numerous changes with the DU145 Rab11bKD and Rab35KD cells, compared to controls. As 
examples, LIF (>30 fold) and IL-6 (>36 fold) expression were significantly elevated in the 
Rab35 knockdown cell secretome, but were not a feature of the vesicle-rich pellets. This 
suggests that these are present as soluble rather than in association with vesicles. Changes 
in CXCL6 and 4E-BP1 in the Rab11b knockdown, or CXCL6, IL18R1 in the Rab35 knockdown 
(Figure 4.15 D), however, agreed in both the general secretome and vesicle pellets; which 
were at least partially vesicle-related. Protein profiling the secretome highlights several 
examples of dissimilarity and showed Rab11b or Rab35 knockdown imparts distinct effects 
on the general secretome and which are not vesicle exclusive. 
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Figure 4.14: Venn diagram depicting the Protein Array in CM and vesicle pellets. The 
Venn diagram depicts the entire Proseek® (Multiplex Immuno-Onc I96x96) Protein Array 
menu (of 92 analytes); and shows those identified with signal above the limits of 
detection in cell conditioned media and vesicle pellets (green, 38 analytes), or those 
found in cell conditioned media but reported with no signal in vesicle pellets (orange, 8 
analytes). Half of the menu (blue, 46 analytes), were below detection limits. Specific 
identifications in each category are shown. 
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Figure 4.15: Knockdown of Rab11b or Rab35 alters the protein profile of vesicle concentrates and the general secretome. Cell CM from control 
or knockdown cells were concentrated by 200,000 x g ultracentrifugation and pellets normalised for protein, were analysed using the Proseek 
Multiplex Proximity Ligation Array, with coverage of 92 analytes related to inflammation. Analysis represent differences in levels of those 38 
analytes reporting with signals above the assay limits of detection (LOD), comparing the vesicle-pellets derived from RAB11b or Rab35 relative 
to control. (A) The waterfall plot lists the analytes, and plots log10-fold change compared to control levels. (B) The volcano-plot identifies 
differentially expressed analytes with a fold change>2 and a P value<0.5 (T-test). Similarly, cell conditioned media was analysed (without 
concentrating vesicles), representing the secretome, showing (C) waterfall and (D) a volcano-plot as above for the 48 analytes reporting with 
signals above the LOD. 
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4.2 Discussion 
In this Chapter, we investigated whether our choice of factors putatively implicated in 
exosome biogenesis and secretion can be successfully knocked down using lentiviral particles 
delivering specific shRNAs. Puromycin was used in gene selection for mammalian host cells 
and identified the minimal puromycin concentration to kill all non-resistant cells, which was 
used to conditioned transduced DU145 cells with specific shRNA clones. 
RNA-mediated silencing is an evolutionary conserved mechanism, through which dsRNA 
induces inactivation of specific gene sequences. The discovery of RNAi provided researchers 
with a rapid rise in identified genes underlying many biological processes and produced 
phenotypes that revealed gene function (Moffat et al., 2006). Its success is attributed to an 
evolutionary endogenous pathway present in all cell types, that regulates gene expression 
commonly achieved by siRNA or shRNA. The use of exogenously supplied siRNA that mimic 
the functions of miRNAs, but are designed to have a greater specificity to their targets by 
having complementary sequences, can assemble with RISC and have siRNA-mediated target 
recognition; thus mRNA cleavage and degradation (Brennecke et al., 2005). One drawback 
to using this is the depletion of siRNA over a few days and a loss of effect, with recovery of 
cells to the wild-type phenotype. As an alternative to this method, we used shRNA and its 
delivery through a lentiviral vector-expressing plasmid, which contains a selection marker 
(puromycin). This produces a dsRNA structure that is similar to the pri-miRNA of the cell and 
is produced accordingly to the miRNA mimic, the siRNA. Hence, we achieved continuous 
stable expression of shRNA for suppressing the target gene (Lee et al., 2003, Sigma, 2016). 
Many studies have utilised shRNA as a powerful tool to study gene function in both in vitro 
and vivo models (Stewart, 2003, Van den Haute et al., 2003, Singer and Verma, 2008, Wilson 
et al., 2013). Similarly, our knockdowns still remain stable over 15 weeks and all 
characterisation and functional experiments were performed, prior to 15 weeks. 
Our results initially confirmed that knockdown targets were reduced (70 - 97%) at the mRNA 
level; and we evaluated if these knockdowns would translate into attenuated protein levels. 
We demonstrated attenuated expression of target proteins in lentiviral transduced DU145 
cells, with an overall agreement of the mRNA knockdown. As one example showing mRNA 
expression was strongly decreased by 86% in DU145 CD9KD (#711 clone) cells, it’s impact on 
protein was not similar, compared to the #470 clone. Since biological processes are typically 
driven by proteins, mRNA expression signatures results are thought of as a proxy for 
functional pathway changes, involving changes in protein levels. This requires the 
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assumption that global differences in mRNA levels reflect differences in protein levels. 
Comparisons attempting to directly determine how closely mRNA expression levels reflect 
those corresponding to proteins, have revealed weak to moderate correlations between 
both mRNA and protein markers (Anderson and Seilhamer, 1997, Tian et al., 2004, Pascal et 
al., 2008, Koussounadis et al., 2015). Differences in the mRNA vs protein correlation show a 
surprisingly weak correlation of 0.40; signifying that only ~40% of protein concentration can 
be explained by knowing mRNA abundance (de Sousa Abreu et al., 2009, Schwanhausser et 
al., 2011). The other ~60% of the variation could be explained by a combination of post-
transcriptional and post-translational regulation, half-life of different proteins varying from 
minutes to days; and by measurement errors (Maier et al., 2009, Vogel and Marcotte, 2012). 
Thus, we felt it was important to evaluate and select our knockdowns sequences on a 
combination of diminished mRNA and protein levels. 
We next determined whether the phenotypic consequence of gene knockdown would 
impact cell proliferation or morphology. Similar cobblestone-like cell morphology was 
observed in all lentiviral transduced DU145 cells. There was slightly reduced cell proliferation 
seen with knockdown of CD9 and Rab5a in DU145 cells; and this was more pronounced with 
the knockdown of VPS25. The connection between VPS25 knockdown and cell proliferation 
extends to fungal species, where VPS25 inhibition interrupts the division of cells and invasive 
growth (Sarode et al., 2011). In Drosophila models, many of the mutations related to VPS-
related proteins and in particular VPS25 mutant cells, are very sensitive to apoptosis (Herz 
et al., 2006). With this evidence, we proposed that VPS25 have roles in reducing cell 
proliferation and a slower rate of reaching confluency. However, to assess vesicle secretion, 
DU145 VPS25KD cells experienced some toxicities, which is extremely difficult to assess, as 
these cells are undergoing cell death that can produce apoptotic blebs and cellular debris to 
confound analysis of exosome secretion. We did not, therefore, evaluate the remaining 
vesicle population in detail for this cell line. 
CD9 was first documented in exosomes derived from dendritic cells (Théry et al., 1999). 
Several studies describe CD63 and CD81 as the most frequently identified proteins in 
exosomes, which are considered classical markers (Kobayashi et al., 2000, Caby et al., 2005, 
Logozzi et al., 2009). Here, silencing CD9 showed a partial decrease in protein content of 
LAMP1, LAMP2 and HSP70, whilst no significant changes in particles/cell. There are, 
however, some conflicting studies. In one report, exosome release from dendritic cells 
generated from CD9 knockout (CD9KO) mice was reduced, compared to wild type dendritic 
cells (Chairoungdua et al., 2010). In a different model, knockdown of CD9 in Nalm-6 pre B-
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cells resulted in a decrease in CD10-associated vesicles (Mazurov et al., 2013). In a similar 
tetraspanin model, in the absence of CD63 expression, ILV formation and downstream MVE 
biogenesis were severely reduced, but not any MVEs requiring sphingomyelinase expression 
or activity (van Niel et al., 2011). The results we observed differs from other studies and 
suggests that knockdown of CD9 has little effect on vesicle number, but some effect in 
controlling the protein-cargo loading onto the vesicle. Perhaps, CD9 may contain a 
population of vesicles that are independent of ALIX and TSG101, but are important for 
LAMP1, LAMP2 and HSP70. This data reveals there is a full complex mechanism for vesicle 
manufacture by the cells and the data do not possess a definite explanation yet of the CD9 
role. 
Also, we next investigated the impact of the SNARE protein (VAMP7) in exosome secretion 
by DU145 cells. Silencing VAMP7 caused a modest decrease in particles/cell and other 
exosomal-associated markers (CD9, LAMP1 and LAMP2) in the remaining vesicle pellet. With 
a role in membrane fusion between intracellular endosomal compartments, VAMP7 is 
potentially involved in the final steps of exosome secretion. Currently, there are few studies 
to address the requirement of SNAREs in exosome secretion. Our results are consistent with 
the finding that VAMP7 is involved in exosome secretion by K562 cells (Fader et al., 2009). 
Expression of the N-terminal domain of VAMP7, which impairs the formation of the SNARE 
complex, induced the accumulation of enlarged MVEs at the cell periphery and reduced 
exosome secretion, similar to other studies targeting exosome secretion by other means 
(Bobrie et al., 2012, Webber et al., 2015). Likewise, YKT6 is another SNARE protein implicated 
in membrane fusion, YKT6 inhibition led to a reduction in exosome release in lung cancer 
models (Ruiz-Martinez et al., 2016). There are some conflicting studies demonstrating that 
VAMP7 is not required for exosome secretion (Rao et al., 2004). In one report, expression of 
the longin domain (N-terminus) of VAMP7 inhibits the secretion of lysosomes, but not of 
exosomes (Proux-Gillardeaux et al., 2007). These findings indicate that different SNARE 
complexes may function differently in specific cell types and might be involved in fusion of 
certain endosomal compartments. Therefore, different SNARE complexes could mediate 
only a certain subpopulation of MVEs within a single cell type, as highlighted by another 
group (Colombo et al., 2013); and VAMP7 downregulation might only affect a specific 
exosome subpopulation. Our data shows quantification of some exosomal-associated 
markers (ALIX and TSG101) remains unaltered in the knockdown of VAMP7, compared to 
controls. The results we observe differ from other studies, and suggests that knockdown of 
VAMP7 attenuates vesicles secretion by 31%, but show little changes in the levels of ALIX 
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and TSG101. Perhaps VAMP7 may contain a population of vesicles that are dependent of 
ESCRT-related proteins, but not important for LAMP1, LAMP2, HSP70 and HSP90. It could be 
possible that VAMP7 may govern a specific MVE subpopulation, though this data reveals the 
complex mechanism for vesicle secretion and does not provide a definitive role of VAMP7.  
In contrast, silencing Rab5a induced an increase in exosome secretion by 25%, which may be 
a potential candidate for enhancing the extracellular vesicle content, either through 
enhanced accelerated secretion, or equally by dysregulating the cell’s capability to 
endocytose and process vesicles through an autocrine fashion. Some studies reveal 
overexpression of Rab5 impairs early intra-endosomal trafficking and causes MVEs to 
enlarge, severely reducing exosome secretion and respective markers (ALIX, CD63 and 
syntenin) in MCF-7 cells (Baietti et al., 2012). Likewise, knockdown of endogenous Rab5 
increased the number of secretory granules per mast cell in the immunological setting (Azouz 
et al., 2014). These findings conflicted with other observations, where exosome secretion is 
decreased upon Rab5a targeting (Ostrowski et al., 2010). Multiple studies, however, have 
documented that knockdown of Rab5 decreased uptake levels of horseradish peroxidase in 
NIH3T3 cells (Su et al., 2006), low-density lipoproteins in primary mouse hepatocytes 
(Zeigerer et al., 2012) and Staphylococcus aureus (S. aureus) uptake in Cos-7 cells (Hagiwara 
et al., 2014). These studies suggests Rab5 plays potential roles in endocytic uptake. Other 
studies have also shown the role for Rab5a-mediated autophagy, together with a key 
autophagic protein (Beclin-1), between the early stages of autophagosome-mediated fusion 
with the lysosome (Maroni et al., 2016, Tan et al., 2016). Different Rab5 isoforms for 
endosomal trafficking show that in HeLa cells, Rab5aKD or Rab5bKD impairs and delays EGFR 
degradation and consequently delays early to late endosome trafficking, whereas Rab5cKD 
does not affect EGFR degradation (Chen et al., 2009). With no direct evidence to these 
speculations, it could be hypothesised that cargo in the early endosome is typically fated for 
Rab5a-mediated autophagic degradation. Rab5a inhibition could potentially redirect 
endosomal compartments to a different pathway (exocytosis), hence increased exosome 
secretion, yet this should be investigated in further detail.  
From our data, silencing either Rab11b and Rab35 appears to have attenuated exosome 
secretion from DU145 cells, confirmed by a reduction in exosomal-associated proteins (ALIX, 
HSP70, HSP90, LAMP1, LAMP2 and TSG101) and tetraspanins (CD9 and CD81) within the 
remaining vesicle pellet and a modest reduction (20%) in particle/cell. Supporting these 
findings, other studies focusing on Rab11 in K562 cells and Rab35 in oligodendrocytes, have 
demonstrated that silencing either protein appears to attenuate exosome secretion (Savina 
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et al., 2002, Hsu et al., 2010). Given the amount of evidence available, we generated 
knockdowns of Rab11b or Rab35 to give a genuine, but modest, perturbation on exosome 
secretion and provided the basis of selected target for future investigation. 
There was no general failure in trafficking machinery following Rab11b or Rab35 knockdown, 
as early endosomes appeared unaffected and the knockdowns showed only a limited impact 
on exosome secretion. Silencing Rab11b or Rab35 also accumulated levels of CD63, LAMP1 
and CD81 around the nuclei, signifying an accumulation of potential MVEs in the cells, which 
agreed with other studies in a similar Rab27a knockdown model (Ostrowski et al., 2010, 
Webber et al., 2015, Grimsey et al., 2016). Similarly, it was noted that knockdown of Rab27a 
demonstrated reduced MVE docking, despite an increase in MVE size (Ostrowski et al., 2010). 
This could be explained by a lack of motor linkage resulting in enlarged compartments. 
Myosin Va is a widely expressed actin-based protein, binding only to a subset of Rab proteins 
(Rab8, Rab11b and Rab27a), associated with either endocytic recycling and post-golgi 
secretory systems (Desnos et al., 2003, Lindsay et al., 2013). In contrast, myosin Va does not 
directly bind to Rab35 (Rahajeng et al., 2012). However, Rab35 promotes the recruitment of 
Rab8 with MICAL-L1, a multiple Rab-binding protein mediating exocytosis (Kobayashi et al., 
2014). This may explain that a myosin Va-driven specific-Rab exchange mechanism is only 
conceivable during the late stages of exocytosis, as is the case for Rab11b or Rab35, 
transporting MVEs to the cell periphery by a kinase-driven mechanism; thus modulating 
exosome secretion. 
Visualisation of the nanometre-sized structures of the vesicles derived from either DU145 
control, Rab11bKD or Rab35KD cells was performed by cryo-TEM. As observed for controls, the 
200,000 x g vesicle pellet showed the presence of different populations of vesicles with 
different sizes ranging from 30nm-150nm. The existence of morphologically different 
exosome subpopulations among secreted vesicles is in agreement with other reports, 
showing the presence of different MVEs in a single cell (Möbius et al., 2003, White et al., 
2006, Bobrie et al., 2012, Willms et al., 2016), as these distinct exosomes may be formed in 
diverse MVEs. Alternatively, smaller sized vesicle-like structures (<10nm), exhibit a dense 
centre without a distinctive bilayer membrane was observed in the knockdown of Rab35. It 
was demonstrated that mutant Rab35 redirects many receptors to be found in smaller sized 
vesicles (<30nm in diameter), suggesting an accumulation in transport intermediates (Sato 
et al., 2008). In contrast, no smaller size vesicles were detected in the knockdown of Rab11b. 
From these images, there could possibly be an underestimation of the particle/cells in the 
knockdown of Rab35. NTA enables the analysis of nanoparticles around 20nm, provided the 
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samples have a high refractive index (Gardiner et al., 2014), but biological samples are often 
complex and in reality, the limit of detection is often around 40 - 50nm. Despite showing the 
differences behind the knockdown of Rab35 in generating <20nm vesicles, the mechanism 
behind this remains unknown and has not been addressed, but these images show the 
presence of distinct vesicle subpopulations as a result from each respective knockdown.  
Because of the similarities in data for Rab11bKD and Rab35KD, in terms of a partial attenuation 
of exosome secretion, characterised by exosomal-associated markers and NTA analysis, 
described above; the hypothesis is whether both Rab11b and Rab35 co-regulate an identical 
pathway. Here, a highly sensitive multiplexed proximity-ligation array was used to address 
this. There were significant changes in the protein profile of DU145 Rab11bKD-derived 
vesicles, with many overlapping similarities following knockdown of Rab35, but the 
phenotype between vesicles were not identical. The Array showed that CXCL6, TRAIL and 
TWEAK are proteins found in the DU145 Rab35KD-derived vesicles, compared to their 
decrease in DU145 Rab11bKD derived vesicles. These observations support the concept that 
different endosomal compartments and subsequent secreted vesicles, display different 
protein compositions (Bobrie et al., 2012, Colombo et al., 2013), governed by these Rab 
proteins. It remains difficult, however, to characterise specific markers to analyse different 
vesicle populations, either based on different isolation techniques or different endosomal-
derived vesicles. Published reports have highlighted the presence of vesicle heterogeneity 
(Lazaro-Ibanez et al., 2014, Smith et al., 2015, Willms et al., 2016); and one study has 
attempted to distinguish different vesicles by a proteomic comparison, attempting to define 
new markers (Kowal et al., 2016). Here, our data reveals vesicle heterogeneity, with respect 
to remaining vesicles enriched with distinct proteins, following knockdown of Rab11b or 
Rab35 in DU145 cells. 
Inhibition of Rab11b or Rab35, however, for assessing subsequent exosome function should 
be taken with a degree of caution, as this may impact secretion of soluble factors. It is not 
completely understood what interplay between vesicles that are truly separate from the 
soluble secretome. However, many databases, such as ExoCarta (Mathivanan and Simpson, 
2009) and Vesiclepedia (Kalra et al., 2012), highlight vesicle association with various 
cytokines, eicosanoids and growth factors. Hence, the loss of a vesicle subpopulation may 
impact on the soluble secretome, as these are no longer available to tether molecules to 
their surface as a manner of sequestration. In a breast carcinoma model, secretion of other 
non-exosome-associated proteins, such as MMP-9, was decreased, with the Rab27a 
knockdown model (Bobrie et al., 2012). Likewise, other secreted soluble factors such as PDGF 
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and placental growth factor (PGF), in melanoma cells were decreased following Rab27a 
knockdown (Peinado et al., 2012). Control of MVE trafficking by Rab GTPases have potential 
broad effects on exocytic events, that cannot be assumed to be exosome-selective. 
In this Chapter, we have successfully transduced DU145 cells with specific shRNA and 
validated these DU145 knockdown cell lines at the mRNA and protein level. We have 
demonstrated that Rab11b and Rab35 play minor roles in terms of overall secretion of 
exosomes and abrogate distinct subpopulations of exosomes.  We will take forward both 
DU145 Rab11bKD and Rab35KD cells, to explore the functional impact of a loss of these 
exosome subpopulations has upon the cancer-associated stroma.
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5.1 The Impact of Exosome-Deficient Tumour Cells on the Stroma 
5.1.1 Introduction 
Tumours are complex structures of malignant cancer cells surrounded by stroma, pivotal for 
cancer growth and progression (Hanahan and Weinberg, 2011). The tumour stroma consists 
of cellular and non-cellular components. Cellular components include immune cells, 
endothelial cells, mesenchymal stem cells and fibroblasts, whereby non-cellular components 
include growth factors and other signalling molecules (Kalluri and Zeisberg, 2006). While 
none of these cells are themselves malignant, their complex reciprocal interaction with each 
other and tumour cells, creates a tumour microenvironment that supports local growth, 
invasion and ultimately dissemination. Exosomes plays large roles in intercellular 
communication, between cancer and stromal cells, resulting in tumour microenvironment 
maturation, aiding tumour growth in a variety of systems (Chowdhury et al., 2015, Saleem 
and Abdel-Mageed, 2015, Webber et al., 2015, Baglio et al., 2017). 
Fibroblasts are one of the dominant cell types within the tumour microenvironment of many 
solid cancers and then play pivotal roles in dictating the nature of cancer-activated stromal 
tissues. For this study, we relied on an extensively well-characterised primary cell as a model, 
to assess stromal-fibroblast phenotypes under the influence of cancer cells. The AG02262 
normal diploid adult lung fibroblasts (from Coriell Institute) were used, as these have limited 
population doubling levels and become senescent post-passage 10. They have previously 
been studied for their capacity to differentiate to myofibroblasts (Webber et al., 2009, 
Webber et al., 2010, Midgley et al., 2013, Chowdhury et al., 2015, Webber et al., 2015). These 
fibroblasts can differentiate into myofibroblasts under the control of recombinant human 
TGF-β1 (rhTGF-β1) and have been used in studying exosome-controlled differentiation 
(Webber et al., 2010, Webber et al., 2015). Myofibroblasts are determined by the acquisition 
of alpha-smooth muscle actin (α-SMA), together with cell contractility (Hinz et al., 2012). 
Since the classic observations of many histological similarities between the tumour 
microenvironment and wound healing, it has been proposed that the tumour stroma is 
“wound healing gone awry” (Dvorak, 1986). During normal wound healing, coagulation of 
extravasated blood initiate an intricate cascade of signals that recruit inflammatory cells, 
stimulate fibroblasts and epithelial cell proliferation, direct cell migration and induce 
angiogenesis to restore tissue integrity (Kalluri and Zeisberg, 2006). This permits re-
epithelialisation of the injured region and the myofibroblasts undergo apoptosis when the 
injured site is fully covered by a new epidermis (Shaw and Martin, 2009). In the context of 
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carcinomas, this process is not self-limiting. As it is often associated with the chronic 
persistence of α-SMA positive myofibroblasts (Orimo et al., 2005), increased proliferation 
and invasion of epithelial cells, resulting in uncontrollable tumour growth and eventual 
metastatic spread (Coussens and Werb, 2002). 
For the metastatic spread of cancer tissue, the formation of a supportive vascular network is 
important. Tumour cells can penetrate into newly-formed and poorly organised blood or 
lymphatic vessels, pass through the lymphatic or peripheral circulation and then localise at 
other sites (Folkman, 1971). Angiogenesis occurs in a multi-step process involving 
endothelial cell activation by angiogenic factors, migration, proliferation and organisation of 
endothelial cells into vessel-like structures (Carmeliet and Jain, 2000). Tumour angiogenesis, 
however, relies on many of the same processes involved in physiological angiogenesis. This 
is associated with excessive growth-promoting signals and a lack of sufficient cues to spatially 
and temporally coordinate vessel growth, remodelling and maturation, fuelled in part by 
tumour-secreted factors and tumour hypoxia (Carmeliet and Jain, 2000, Trojan et al., 2004). 
The blood vessels produced by tumours are typically aberrant, where the tumour 
neovasculature is marked by distorted and enlarged vessels, leakiness and abnormal 
endothelial cell proliferation (Nagy et al., 2010). Numerous studies have demonstrated that 
angiogenesis directly associates with aggressive carcinomas and increasing incidences of 
tumour metastasis (Weidner et al., 1993, Jaeger et al., 1995, Parangi et al., 1996). Therefore, 
angiogenesis is considered an important aspect for primary tumour growth that provides a 
continual supply of nutrients, as one of the hallmarks for cancer (Hanahan and Weinberg, 
2011).  
A host of pro-angiogenic growth factors secreted from cancer epithelial and stroma cells 
have been identified. The VEGF family and their receptors (VEGFR) are powerful angiogenic 
mediators in cancerous tissues and adjacent stroma. Elevated expression of VEGF and VEGFR 
correlates with aggressive metastatic cancer, compared to non-metastatic tumours 
(Takahashi et al., 1995, Hoeben et al., 2004, Caballero et al., 2007). Expression of hepatocyte 
growth factor (HGF), has been shown to positively correlate with enhanced vessel formation 
in various in vitro and in vivo models (Xin et al., 2001, Abounader and Laterra, 2005). Basic 
fibroblast growth factor (bFGF) and epidermal growth factor (EGF) were expressed in 
malignant carcinomas, associating with increased CD31 (endothelial cell marker) expression, 
compared to non-tumour tissues (Dunn et al., 2000, Bajou et al., 2002, Trojan et al., 2004, 
van Cruijsen et al., 2005). Various studies showed that different growth factors are released 
from epithelial cells, or cells within the stroma, such as endothelial cells, mast cells or 
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fibroblasts (McNeil et al., 1989, Leon et al., 1994, Stadnyk, 1994, Grugan et al., 2010). These 
cellular components may therefore play a role in support of vessel formation, but the 
principal source of these growth factors should be explored. 
Fibroblasts within the tumour stroma have an activated phenotype, known to produce 
growth factors and chemokines, supporting ECM remodelling and facilitating the angiogenic 
recruitment of endothelial cells (Kalluri and Zeisberg, 2006). Breast cancer cells co-cultured 
with tumour-associated myofibroblasts demonstrated extensive vascular formation in vivo 
(Orimo et al., 2005). However, capillaries were far less established when tumour cells were 
co-cultured with normal fibroblasts. In intestinal tumours, tumour-associated myofibroblasts 
strongly stimulated the migration and vessel formation of vascular endothelial cells (Shao et 
al., 2006); and this has also been shown in gastric cancer in vivo models (Guo et al., 2008). 
However, not all myofibroblasts are pro-angiogenic. Current studies have shown that α-SMA 
positive myofibroblasts generated from rhTGF-β1 induced fibroblasts did not elevate 
angiogenic growth factors or support formation of endothelial vessel-like structures in vitro 
(Webber et al., 2015). In contrast, prostate cancer exosomes induced myofibroblasts, which 
were pro-angiogenic, exhibited elevated HGF and VEGF secretion and encouraged formation 
of endothelial vessel-like structures in vitro (Webber et al., 2015). In the in vivo setting, co-
administration of diseased prostate stromal myofibroblasts with tumour cells in mice 
enhanced tumour growth, in contrast to rhTGF-β1-treated fibroblasts or exosome-activated, 
normal stromal fibroblasts (Webber et al., 2015). These findings show the role of exosomes 
in communicating between tumour cells and the surrounding stroma, directing stromal 
differentiation to a tumour supporting phenotype. 
Previously, I have demonstrated that knockdown of Rab11b or Rab35 appeared to impact a 
distinct subpopulation of exosomes from DU145 cells. It remains unknown, however, 
whether the effect has any functional relevance in terms of cancer cell influence on stromal 
fibroblasts. The hypothesis is that the remaining vesicles, following Rab11b or Rab35 
attenuation, lose their stromal activating potency.  
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5.1.2 The Cancer Cell Secretome Triggers a Poor Fibroblast Differentiation Response 
We first measured secreted growth factor levels from the cancer conditioned media (CM) 
(control or Rab11bKD or Rab35KD), corrected for cell number (as described in Chapter 4). There 
were no significant differences in secreted levels of FGF-2, HGF, uPA and VEGF-A (Figure 5.1 
A-D) in either Rab11bKD or Rab35KD in comparison to controls. These observations are 
important, as it demonstrates that exocytic modulation by knocking down Rab11b or Rab35 
does not have a major effect on these important angiogenic factors. 
Next, we determined the fate of fibroblast differentiation in response to cancer cell CM 
(control or Rab11bKD or Rab35KD). Fibroblasts were grown until 70% confluent and growth-
arrested for 72 hours. Subsequently, fibroblasts were grown in DMEM-F12 media alone or 
with a single stimulation with rhTGF-β1 (1.5ng/ml), purified DU145 exosomes at an 
equivalent TGF-β1 dosage (200µg/ml) or cell CM (control or Rab11bKD or Rab35KD), corrected 
for cell number. After 72 hours, fibroblasts were fixed, stained and analysed by 
immunofluorescent microscopy, to explore α-SMA expression. The number of α-SMA 
positive cells was assessed over 6 microscopic fields and in duplicate treatments. Fibroblasts 
treated with either rhTGF-β1 or purified DU145 exosomes increased the number α-SMA 
positive cells, compared to untreated fibroblasts (Figure 5.2). Control cell CM had a negligible 
effect on α-SMA onset, where weak staining was evident in a small proportion of cells. There 
was a total absence of α-SMA-positivity in fibroblasts treated with Rab11bKD or Rab35KD cell 
CM. Thus, unlike rhTGF-β1 or purified exosomes, the soluble secretome appears insufficient 
to trigger a robust fibroblast differentiation response into α-SMA positive myofibroblastic 
cells under these conditions. 
The levels of growth factors, FGF-2, HGF, uPA and VEGF-A, secreted by untreated fibroblasts 
or fibroblasts treated with cancer CM were investigated (Figure 5.3). There was a significant 
reduction in HGF levels, following treatment with CM from Rab11bKD (P≤0.01) or Rab35KD 
(P≤0.001) cells, compared to the control (Figure 5.3 B). Similarly, levels of activated VEGF-A 
secretion followed the comparable trend of HGF and did not quite reach statistical 
significance when using knockdown cell CM (Figure 5.3 D). In contrast, levels of activated 
FGF-2 and uPA secretion (Figure 5.3 A & C), exhibited negligible changes in both control and 
knockdown conditions. These observations are important, as the cell CM effects are 
apparent following knockdown of Rab11b or Rab35. A full-blown differentiation was not 
observed and there were indeed, documented differences in the functional influence of the 
CM, following knockdown. For example diminished HGF and VEGF levels, suggestive that 
Rab11b or Rab35 must have a role in attenuating growth factor release. 
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Figure 5.1: Assessment of growth factor secretion from exosome competent and 
deficient tumour cells. Cell CM from DU145 control or knockdowns (Rab11b or Rab35; 
corrected for cell number), after 5 days of culture were analysed by ELISA for (A) FGF-2, 
(B) HGF, (C) uPA and (D) VEGF levels. Graph shows mean ± SEM, based on triplicate wells. 
n.s: non-significant. One-way ANOVA with Tukey’s post hoc test. 
(A) (B) 
(C) (D) 
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Figure 5.2: Cancer cell secretome triggers a poor fibroblast differentiation response. Fibroblasts at passage 7 were growth-arrested (72 hours) 
and were either left untreated, or treated in the presence of rhTGF-β1 (1.5ng/ml), purified DU145 exosomes (200ug/ml) or DU145 (CTR, 
Rab11bKD or Rab35KD) cell CM, corrected for cell number in DMEM-F12 media. Fibroblasts were examined by immunofluorescent microscopy for 
the expression of α-SMA (green) and DAPI (blue). Scale bar: 50μm. α-SMA positive cells over 6 microscopic fields were examined in duplicate 
wells per treatment. Representative fields are shown. Data are representative of three independent experiments. 
Data as representative of three independent experiments. 
Chapter 5. The Impact of Exosome-Deficient Tumour Cells on the Stroma 
 
137 
 
 
 
 
 
Figure 5.3: Fibroblasts treated with DU145 Rab11bKD or Rab35KD cell CM generate 
reduced pro-angiogenic growth factors. Fibroblasts at passage 7 were growth arrested 
(72 hours) and were either left untreated, or treated in the presence of the DU145 
(control, Rab11bKD or Rab35KD) cell CM, corrected for cell number in DMEM-F12 media. 
CM collected from different treated fibroblast conditions was analysed by ELISA for levels 
of (A) FGF-2, (B) HGF, (C) uPA and (D) VEGF. Graph shows mean ± SEM, based on triplicate 
wells. n.s: non-significant, **P≤0.01 and ***P≤0.001. One-way ANOVA with Tukey’s post 
hoc test. Data are representative of three independent experiments. 
 
(B) (A) 
(C) (D) 
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5.1.3 Vesicle Concentrates From Rab11bKD or Rab35KD Cell CM Lose Their Stroma-
Activating Potency 
Previously it was shown that the cell CM influenced fibroblast secretion. As such, we 
proposed that this may be due to a vesicle-driven process, as demonstrated with cancer 
exosomes holding the capacity to drive stromal fibroblast differentiation into myofibroblasts 
(Webber et al., 2010, Webber et al., 2015). We, therefore, concentrated vesicles from cell 
CM and examined the effects on fibroblasts, as we did for the treatment of cell CM.  
Fibroblasts were grown in DMEM-F12 media alone, with a single stimulation with rhTGF-β1 
(1.5ng/ml) or purified DU145 exosomes at an equivalent TGF-β1 dosage (200µg/ml). Vesicle 
concentrates (control or Rab11bKD or Rab35KD) corrected for cell number also were 
compared. Untreated fibroblasts exhibited low level/negligible staining of α-SMA, whilst 
purified exosomes from wild-type DU145 cancer cells stimulated the onset of α-SMA in the 
entire cell population (Figure 5.4). Similarly, stimulation with rhTGF-β1 generated a robust 
differentiation response. Vesicle concentrates obtained from control cell CM triggered a 
strong differentiation response, involving the majority of the fibroblasts in the population. In 
contrast, treating fibroblasts with remaining vesicle concentrates deriving from Rab11bKD or 
Rab35KD cells, revealed a poorly convincing differentiation response; whilst some of the α-
SMA was detectable, this was weaker in intensity and not all cells had responded (Figure 5.4). 
Hence, we proposed that the remaining vesicles from Rab11bKD or Rab35KD cells resulted in 
an attenuated fibroblast differentiation response. 
We next explored levels of FGF-2, HGF, uPA and VEGF-A, secreted by treated fibroblasts 
(Figure 5.5). We observed a significant increase in both HGF and VEGF secretion when using 
vesicle concentrates from control cells (Figure 5.5 B & D). In contrast, there was a significant 
reduction in secreted HGF (Figure 5.5 B) in treated conditions for Rab11bKD (P≤0.001) and 
Rab35KD (P≤0.01). Also, levels of VEGF secretion (Figure 5.5 D) followed this pattern, when 
using either Rab11bKD (P≤0.05) or Rab35KD (P≤0.01). Levels of FGF-2 increased with the 
Rab11bKD (P<0.01) (Figure 5.5 A), secreted uPA levels were reduced with the Rab35KD 
(P<0.05) (Figure 5.5 C). This highlights that the fibroblasts treated with distinct vesicle 
concentrates following knockdown of Rab11b or Rab35 are different in the effects on 
fibroblasts. It supports the idea of vesicle subpopulations dictate distinct functions. 
Overall, there appears to be a significant attenuation when using vesicles concentrated from 
either Rab11bKD or Rab35KD, in terms of the acquisition of the α-SMA positive phenotype and 
in terms of the secretory phenotype of the fibroblasts. 
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Figure 5.4: Vesicle concentrates from Rab11bKD or Rab35KD cell CM triggers a poor fibroblast differentiation response. Fibroblasts at passage 7 
were growth arrested (72 hours) and were either left untreated, treated in the presence of rhTGF-β1 (1.5ng/ml), purified DU145 exosomes 
(200µg/ml), or DU145 vesicle concentrates (control, Rab11bKD or Rab35KD) corrected for cell number in DMEM-F12 media. Fibroblasts were 
examined by immunofluorescent microscopy for the expression of α-SMA (green) and DAPI (blue). Scale bar 50μm. Images of α-SMA positive 
cells over 6 microscopic fields were examined in duplicates per treatment. Representative fields are shown. 
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Figure 5.5: Vesicle concentrates from Rab11bKD or Rab35KD cell CM fail to fully induce 
fibroblast secretion of pro-angiogenic factors. Fibroblasts at passage 7 were growth 
arrested (72 hours) and were either left untreated, or treated in the presence of the 
DU145 vesicle concentrates (control, Rab11bKD or Rab35KD) corrected for cell number in 
DMEM-F12 media. CM collected from undifferentiated and differentiated fibroblasts was 
analysed by ELISA for levels of (A) FGF-2, (B) HGF, (C) uPA and (D) VEGF. Graph shows 
mean ± SEM, based on triplicate wells. n.s: non-significant, *P<0.05, **P≤0.01 and 
***P≤0.001. One-way ANOVA with Tukey’s post hoc test. 
(A) 
(C) (D) 
(B) 
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5.1.4 Quantification of Remaining TGF-β1 Positive Vesicles following Knockdown 
Previously, as we observed a different fate in α-SMA expression, following treatment with 
vesicles following knockdown of Rab11b or Rab35, we examined if there were any changes 
in vesicle-associated TGF-β1 which accounted for this. 
Vesicles derived from control or knockdown cells were treated with HCl, to activate the 
latent TGF-β1 on the vesicle’s surface to the immunoreactive form, detectable by the TGF-
β1 ELISA (Figure 5.6). A consistent expression of TGF-β1 was observed among the control 
vesicle, in which 7.2pg of TGF-β1 was expressed per µg of DU145 vesicles, similar to previous 
studies (Clayton et al., 2007, Webber et al., 2010). We, therefore, questioned if perturbation 
of the Rab GTPases would interfere the TGF-β1-positive signal on vesicles. We revealed there 
was 4.8pg of TGF-β1 expressed per µg of DU145 Rab11bKD derived vesicles (33% decrease) 
(P<0.01), compared to controls. Similarly, 4.1pg of TGF-β1 was detected in DU145 Rab35KD 
derived vesicles (44% decrease) (P<0.001), compared to controls. This suggests that the 
presence of Rab11b or Rab35 must be required for vesicles that are expressing high TGF-β1 
content, in relation to the entire vesicle population. 
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Figure 5.6: Reduced TGF-β1 expression on vesicles derived from DU145 Rab11bKD or 
Rab35KD cells. CM underwent a differential ultracentrifugation method, followed by 
filtration through a 0.22µm filter, before ultracentrifugation at 200,000 x g for 2 hours in 
a fixed angle 70Ti rotor to obtain vesicle concentrates. Vesicle concentrates from DU145 
control or Rab11bKD or Rab35KD cells (20µg/well) and corrected for cell number were 
added to a 96-well plate coated with a TGF-β1 capture antibody. Vesicles were subjected 
to acid activation and expression of active TGF-β1 were measured using a TGF-β1 ELISA. 
Graph shows mean ± SEM, based on duplicate wells. **P≤0.01 and ***P≤0.001. One-way 
ANOVA with Tukey’s post hoc test. 
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5.1.5 Rab11b- and Rab35-Dependent Vesicles are Required for Stromal Activation 
Previously we have shown that knockdown of Rab11b or Rab35 results in a loss of TGF-β1 
positive vesicles from DU145 cells, which results in a poor differentiation response. We, 
therefore, examined if this functionality is dependent on the exosome dose required to 
trigger a fibroblast differentiation response or if it were due alterations in the vesicle’s 
phenotype following knockdown.  
Fibroblasts were grown and growth-arrested as described previously. Briefly, fibroblasts 
were grown in DMEM-F12 media alone or with a single stimulation with rhTGF-β1 (1.5ng/ml) 
or purified DU145 exosomes at an equivalent TGF-β1 dosage (200µg/ml). Importantly, unlike 
our previous experiments, the vesicle concentrates were added at equal quantities 
(200µg/ml) to the fibroblasts, to negate any effects on knockdown on vesicle secretion 
amount. Untreated fibroblasts exhibited low level/negligible staining of α-SMA and positive 
control exosomes from wild-type DU145 cancer cells stimulated the onset of α-SMA in the 
entire cell population (Figure 5.7). Similarly, stimulation with rhTGF-β1 generated a robust 
differentiation response. Vesicle concentrates obtained from DU145 control cell CM 
triggered a strong differentiation response, involving the majority of the fibroblasts in the 
population. Treating fibroblasts with vesicle concentrates derived from knockdown of 
Rab11b showed a moderate differentiation response; whilst some α-SMA was detectable. 
Though, vesicles derived from knockdown of Rab35 showed a poor differentiation response. 
Whilst some α-SMA was detectable, this was weaker in intensity and not all cells had 
responded. Here, adding the identical quantity of vesicle from the cancer cell CM gives a 
different fibroblast response. We concluded that the knockdowns modulate a distinct vesicle 
phenotype and this results in defective cancer cell stromal influence. 
We also observed a significant increase in both HGF and VEGF secretion when using vesicle 
concentrates from control cells. In contrast, there was a significant reduction in secreted HGF 
(Figure 5.8 A) in treated conditions for Rab11bKD (P≤0.01) and Rab35KD (P≤0.05). Also, levels 
of VEGF secretion (Figure 5.8 B) followed this trend, when using either knockdown of Rab11b 
(P≤0.05) or Rab35 (P≤0.05). By equalising vesicle quantity, it was not sufficient to negate the 
effects of the knockdowns. These effects, therefore, must be due to the changes occurring 
in the vesicle’s molecular phenotype, following attenuation of Rab11b or Rab35.
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Figure 5.7: Rab11b- or Rab35-dependent vesicles are still required for stromal activation. Fibroblasts at passage 7 were growth arrested (72 
hours) and were either left untreated, treated in the presence of rhTGF-β1 (1.5ng/ml), purified DU145 exosomes (200µg/ml), or DU145 vesicle 
concentrates (control, Rab11bKD or Rab35KD) corrected for protein (200µg/ml) in DMEM-F12 media. Fibroblasts were examined by 
immunofluorescent microscopy for the expression of α-SMA (green) and DAPI (blue). Scale bar 50μm. Images of α-SMA positive cells over 6 
microscopic fields were examined in duplicates per treatment. Representative fields are shown. 
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Figure 5.8: Normalised vesicle concentrates by quantity from Rab11bKD or Rab35KD CM, 
reduces fibroblast secretion of pro-angiogenic factors. Fibroblasts at passage 7 were 
growth arrested (72 hours) and were either left untreated, or treated in DU145 vesicle 
concentrates (control, Rab11bKD or Rab35KD) corrected for protein (200µg/ml) in DMEM-
F12 media. CM collected from undifferentiated and differentiated fibroblasts was 
analysed by ELISA for levels of (A) HGF and (B) VEGF. Graph shows mean ± SEM, based 
on duplicate wells. *P<0.05 and **P≤0.01. One-way ANOVA with Tukey’s post hoc test. 
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5.1.6 Fibroblasts Treated with Vesicles From Knockdown of Rab11b or Rab35 are not 
Pro-Motile 
One key aspect of tumour-associated myofibroblasts is their influence on an angiogenic 
response. Previously, our group demonstrated that purified cancer exosomes can generate 
a pro-angiogenic stromal microenvironment (Webber et al., 2015). For angiogenesis to 
occur, endothelial cell migration is crucial and a simple method to quantify this, is the 
‘scratch’ migration assay (Liang et al., 2007). The creation of an artificial gap to an endothelial 
cell monolayer so called ‘scratch’, allows the cells on the newly created edge to migrate to 
close the ‘scratch’, until new cell-to-cell contacts are re-established. This motility may be 
heightened by a particular stimulus.  Here, we assessed the effects of CM from fibroblasts 
following treatments with either cancer cell secretome or vesicle concentrates (control or 
Rab11bKD or Rab35KD derived) on endothelial cell motility, using a monolayer scratch assay. 
A monolayer of HUVEC cells, cultured in EBM-2 media was established. Once fully confluent, 
these were growth-arrested for 24 hours to remove pro-motility factors in the supplemented 
media, followed by formation of a vertical scratch by a 200µl pipette tip. The endothelial cell 
media was replaced with CM from either untreated (EBM-2 only) or fibroblasts treated with 
the cell secretome (control or Rab11bKD or Rab35KD). Endothelial cell motility in response to 
the different treatments was examined by imaging and measuring scratch closure over the 
24-hour period (Figure 5.9 A). From an early timepoint of 6 hours, the endothelial scratch 
closure in response to untreated or CM from treated fibroblasts with knockdown cell 
secretome was less than 10% (Figure 5.9 B). In contrast, the endothelial cell response to the 
CM from fibroblasts treated with the control cell secretome showed an accelerated response 
of 30% closure by 6 hours; achieving almost 70% closure within 24 hours. In contrast, 
untreated or knockdown-treated CM was slower in closure, reaching only around 30% 
closure in the same timeframe (P<0.001).  
Next, we, therefore, questioned if CM from vesicle-treated fibroblasts would accelerate 
endothelial cell motility, compared to the cancer cell secretome-treated fibroblasts. HUVEC 
monolayers were established, as described previously, but endothelial cell media was 
replaced with CM, from untreated or DU145 vesicle concentrates (control or Rab11bKD or 
Rab35KD) treated fibroblasts (Figure 5.10 A). Endothelial cell motility was markedly quicker 
(30%~) at 6 hours in response to CM from vesicle-treated fibroblasts, compared to the cancer 
cell secretome-treated fibroblasts (~10%) (Figure 5.9 B). From an early timepoint at 6 hours, 
endothelial scratch closure in response to CM from untreated or CM from treated fibroblasts 
with Rab11bKD or Rab35KD vesicle concentrates was less than 30% (Figure 5.10 B). In contrast, 
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the endothelial cell response to CM from normal vesicle-treated fibroblasts marked an 
accelerated response of 60% closure, achieving full closure by 18 hours; quicker than 
fibroblasts treated with the cancer cell secretome (50%) (Figure 5.9 B). In contrast, the 
closure rate was slower at 18 hours, reaching only <40% in untreated (P<0.001) and <60% in 
knockdown of Rab11b and Rab35 in the same timeframe (P<0.001). 
Therefore, the soluble factors secreted from fibroblasts treated with vesicles accelerated 
endothelial cell migration, compared to fibroblasts treated with the cancer cell secretome; 
indicating this stimulus is enhanced by vesicles. This influence, suggests that to promote a 
highly pro-motile influence over endothelial cell, stromal cells activated by vesicles is 
required and the effect is strongly attenuated using knockdown of Rab11b or Rab35.
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Figure 5.9: CM from fibroblasts treated with Rab11bKD or Rab35KD cell secretome, slows endothelial cell motility. (A) Growth-arrested primary 
fibroblasts were treated with the control or Rab11bKD or Rab35KD cancer cell secretome, normalised for input cell number. After 3 days, the 
fibroblast CM was harvested and added to monolayers of human endothelial cells that had been freshly scratched using a 200µl pipette tip. The 
closure of the scratch was monitored microscopically up to 24 hours thereafter. Representative images of wells at scratch initiation and at 24 
hours are shown and the margin of the scratch emphasised by the white lines. Scale bar: 100µm. (B) Measurements of scratch gap were taken 
throughout the time course and are plotted as the proportion of scratch width relative to that at 0 hours, at each time point. Graph shows mean 
± SEM, based on quadruplicate wells. ***P≤0.001. Two-way ANOVA with Bonferroni post hoc test. 
(B) (A) 
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Figure 5.10: CM from fibroblast treated with vesicles from Rab11bKD or Rab35KD cells, slows endothelial cell motility. (A) Growth-arrested 
primary fibroblasts were treated with vesicles from control or Rab11bKD or Rab35KD cells, normalised for input cell number. After 3 days, the 
fibroblast CM was harvested and added to monolayers of human endothelial cells that had been freshly scratched using a 200µl pipette tip. The 
closure of the scratch was monitored microscopically up to 18 hours thereafter. Representative images of wells at scratch initiation and at 18 
hours are shown and the margin of the scratch emphasised by the white lines. Scale bar: 100µm. (B) Measurements of scratch gap were taken 
throughout the time course and are plotted as the proportion of scratch width relative to that at 0 hours, at each time point. Graph shows mean 
± SEM, based on quadruplicate wells. ***P≤0.001. Two-way ANOVA with Bonferroni post hoc test. 
 
 
(A) (B) 
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 5.1.7 Rab11bKD- or Rab35KD- Derived Vesicles Fail to Trigger Angiogenesis-Promoting 
Stroma 
The formation of blood vessels coordinates a combination of endothelial cell proliferation, 
migration and structural organisation into vessel-like structures (Adams and Alitalo, 2007). 
To investigate the potential for endothelial cells to not only migrate, but to organise into 
vessel-like structure, was performed through co-culture of pre-treated fibroblasts with 
endothelial cells (Sheldon et al., 2010). Fibroblasts were left untreated with DMEM-F12 
media alone or treated for 72 hours with a single stimulation with rhTGF-β1 (1.5ng/ml), 
purified DU145 exosomes at an equivalent TGF-β1 dosage (200µg/ml) or vesicle 
concentrates (control or Rab11bKD or Rab35KD) corrected for cell number. After stimulation, 
endothelial cells were added in a random drop-wise fashion to the wells and left untreated 
for 96 hours. The cells were fixed and stained for the endothelial cell marker, CD31, absent 
in fibroblasts.  
The data demonstrated in either untreated or rhTGF-β1 treated fibroblasts, there were rare 
clusters of CD31-positive cells formed, with little evidence of newly developed structures 
(Figure 5.11). In contrast, purified wild type DU145 exosomes showed the generation of 
often thick, elaborate CD31-positive structures, comprising hundreds of individual cells. 
There was little evidence of structures generated with the fibroblasts treated with the 
control cell secretome or with knockdown of Rab11b or Rab35. It suggested that although 
the CM could support motility, their influence is limited and fails to promote a more 
sophisticated and mature endothelial structure, with limited effects on vessel formation. We, 
therefore, questioned whether vesicles dependent on Rab11b or Rab35, can support these 
vessel-like structures to form. 
Similarly, untreated or rhTGF-β1 treated fibroblasts gave rare clusters of CD31-positive cells, 
with little evidence of endothelial cell structures (Figure 5.12 A). In contrast, purified wild 
type DU145 exosomes and control vesicle concentrates showed the generation of often 
thick, elaborate CD31-positive structures comprising hundreds of individual cells and 
occupying most of the microscopic field. There were a relative lack of structures generated 
with either DU145 Rab11bKD- or Rab35KD- derived vesicles. These were comprised of tens, 
rather than hundreds, of cells. Measuring the area occupied by the CD31-positive structures 
allowed for a straightforward means of quantifying this pro-angiogenic behaviour (Figure 
5.12 B). This revealed a significant increase in CD31-positive surface area in response to 
controls, compared to the knockdown of Rab11b or Rab35 (P<0.001). Therefore, the vesicles 
which remain following knockdown of Rab11b or Rab35 are insufficient in numbers and/or 
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molecular composition, to trigger formation of a fibroblast with a positive influence on vessel 
forming capacity of endothelial cells. Together, these findings suggest that Rab11b- or 
Rab35-dependent vesicles play roles in activating the stroma, in terms of fibroblast 
differentiation and supporting the formation of vessel-like structures.
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Figure 5.11: Cancer cell secretome fails to stimulate fibroblasts to support endothelial vessel-like structure formation. Growth-arrested 
primary fibroblasts were treated with the cancer cell secretome derived from control or Rab11bKD or Rab35KD cells, normalised for input cell 
number. Similarly treated fibroblasts at day 3 were subject to the addition of endothelial cells (20,000 cells/well), in a randomly placed, drop-
wise fashion. Co-cultures were maintained undisturbed for a further 4 days, before fixation and immunofluorescent staining with antibody 
against CD31. Images of CD31 positive cells were examined in duplicates per treatment are shown. Scale Bar: 100µm. Data are representative of 
three independent experiments. 
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Figure 5.12: DU145 Rab11bKD- or Rab35KD- derived vesicles render the stroma poorly 
angiogenic. (A) Growth-arrested primary fibroblasts were treated with vesicle 
concentrates derived from control or Rab11bKD or Rab35KD cells, normalised for input cell 
number. Similarly, treated fibroblasts at day 3 were subject to the addition of endothelial 
cells (20,000 cells/well), in a randomly placed, drop-wise fashion. Co-cultures were 
maintained undisturbed for a further 4 days, before fixation and immunofluorescent 
staining with antibody against CD31. Fluorescence (CD31-alexa-488) images of 
representative microscopic fields are shown. Selection from image showing endothelial 
vessel-like structures comprising of hundreds or tens of endothelial cells (inset). Scale 
Bar: 100µm. (B) The regions of CD31-positivity were measured using intensity 
thresholding in the Alexa-488 channel (Zeiss Zen software), to calculate the area occupied 
by endothelial cells. This was done on 4-microscopic fields in each well. Graph shows 
mean ± SEM, based on triplicate wells. n.s: non-significant ***P≤0.001. One-way ANOVA 
with Tukey’s post hoc test. 
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Figure 5.13: Diagram of the importance of Rab11b- or Rab35-dependent tumour vesicles on the stroma. Wild type exosomes can drive 
fibroblast differentiation into α-SMA positive myofibroblasts, secreting growth factors, accelerating endothelial cell motility and vessel-like 
structure formation. Here, we propose that in the absence of either Rab11bKD/Rab35KD derived vesicles, a reduction in α-SMA positive 
myofibroblastic cells are present, showing a reduction in secreted pro-angiogenic growth factors from myofibroblasts, thus slower endothelial 
motility and a lack of vessel like-structures formed. 
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5.2 Discussion 
In this Chapter, we investigated the functional importance of tumour-derived Rab11b- and 
Rab35-dependent, vesicle subpopulations, by highlighting the vesicle populations following 
Rab11b or Rab35 knockdown and their interaction with the stroma, in terms of fibroblast 
differentiation and promotion of angiogenic properties. 
Traditionally, TGF-β1 is an established cytokine essential for regulating fibroblast 
differentiation (Desmoulière et al., 1993, Sime et al., 1997, Thannickal et al., 2003). rhTGF-
β1 treated fibroblasts, resulted in high levels of α-SMA positive cells, but secrete low levels 
of both HGF and VEGF (Chowdhury et al., 2015, Webber et al., 2015). In contrast, purified 
prostate cancer exosomes had the potent capacity to trigger fibroblast differentiation, as 
noted by the onset of α-SMA stress fibres, consistent with a previous study (Webber et al., 
2010). Furthermore, exosome-treated fibroblasts secreted elevated levels of pro-angiogenic 
growth factors, HGF and VEGF, consistent with features akin to myofibroblastic stromal cells 
extracted from prostate cancer tissues, that have been ‘educated’ in vivo under the direction 
of the cancer milieu (Webber et al., 2015). These findings agree with lung cancer-derived, 
vesicles stimulating the stromal cells to produce factors that induce the expression of several 
pro-angiogenic factors, such as VEGF and MMP-9, that can enhance metastatic spread 
(Wysoczynski and Ratajczak, 2009). Similarly, melanoma derived vesicles, promoted 
fibroblast differentiation to myofibroblasts, that potentially regulates VCAM-1 and activates 
extracellular signal-regulated kinase 1/2 (ERK1/2) signalling pathways, promoting 
endothelial cell proliferation and migration during angiogenesis (Srinivasan et al., 2009, Zhao 
et al., 2015, Shin et al., 2016). Likewise, pancreatic cancer cell-derived vesicles, containing 
miR-155, also can trigger fibroblast differentiation (Pang et al., 2015). Taken together, the 
literature suggest that cancer-derived exosomes are crucial for generating tumour-
associated myofibroblasts, conditioning the tumour microenvironment in promoting 
angiogenesis and metastasis.  
Growing evidence suggests that the cancer cell secretome itself containing cancer exosomes, 
can promote fibroblast differentiation into myofibroblasts. CM taken from aggressive breast 
tumour cells induces fibroblast differentiation by potentiating TGF-β1 signalling, in both in 
vitro and in vivo models (Valenti et al., 2001, Avgustinova et al., 2016). Similarly, fibroblast 
treatment with ovarian cancer cell secretome resulted in α-SMA positive myofibroblastic-
like cells, secreting elevated levels of HGF and VEGF (Yao et al., 2009). The cancer cell 
secretome from ovarian and cancer cells appear sufficient to trigger fibroblast 
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differentiation. Equally, with the prostate cancer model, our group have previously shown 
that the cell secretome is sufficient to trigger fibroblast differentiation and secreting 
elevated growth factors (Webber et al., 2015). However, our data demonstrates the cell 
secretome appears insufficient to trigger fibroblast differentiation, despite differences in the 
secretory profile. One explanation for this, could be the collection of the cancer cell CM was 
from densely seeded cell numbers in other studies, therefore a concentrated cell secretome, 
sufficient to trigger these responses. In contrast, our experiments may have been conducted 
using lower density of cell numbers, producing therefore a diluted cell secretome, 
insufficient to trigger the onset of fibroblast differentiation. 
Initially, the first indications for Rab GTPases in exosome secretion were from reticulocyte 
cell lines, which required the function of Rab11 for exosome secretion (Savina et al., 2002). 
In an RNAi screen in HeLa cells targeting a host of Rab GTPase family members, silencing 
Rab27a reduced MVE docking, which significantly reduced the levels of secreted exosomes 
(Ostrowski et al., 2010). However, other studies using the Rab27a knockdown model have 
demonstrated that silencing Rab27a does not exclusively affect exosome secretion, but 
impacts other secretory routes for the cell, such as pro-MMP-9 secretion (Bobrie et al., 2012). 
Similarly, observations in another Rab27a knockdown model, reveal attenuated levels of 
exosome secretion, which also reduced secretion of pro-angiogenic soluble factors (PDGF-
AA and osteopontin), derived from tumour cells, hindering bone marrow derived cells 
mobilisation and tumour growth (Peinado et al., 2012). Therefore, this makes interpretation 
of the data difficult, as findings may be due to soluble factors and not due to loss of vesicles. 
However, I found much of the stromal-activating activity is focused to the vesicular content 
of the secretome, observing stronger differentiation effects and a stronger angiogenic 
promoting phenotype. This demonstrates the effects on the soluble-secretome are not solely 
responsible for the functional defect arising (Webber et al., 2015). In our data, concentrating 
vesicles from the cell secretome triggered fibroblast differentiation, in much of the fibroblast 
population. The knockdowns, however, could not trigger differentiation similar to the 
control, even following vesicle concentration. Myofibroblastic differentiation is 
predominantly a vesicle-mediated effect and not governed by other factors derived from 
cancer cells. For this critical activation of tumour-associated myofibroblasts, we showed that 
vesicle secretion controlled by Rab11b or Rab35 is required. 
Understanding precisely how myofibroblastic traits of the cancer-associated stroma are 
initiated, altering stroma from a normal homeostatic function towards a malevolent, or 
indeed, a protective phenotype; remains unclear. Although TGF-β, secreted by tumour cells 
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has remained a principal factor, studies from our group (Webber et al., 2010, Chowdhury et 
al., 2015, Webber et al., 2015), and others (Gu et al., 2012, Borges et al., 2013), have reported 
exosomes delivering TGF-β1 elicit robust stromal modulation in cancer. In our data, we 
demonstrate a 20% loss of vesicles following knockdown of either Rab11b or Rab35, that 
demonstrates defective α-SMA differentiation. Attenuating the vesicle population even by 
20% may be sufficient to disrupt the required threshold for differentiation. The vesicles 
following knockdown of Rab11b or Rab35 show a loss of 30 – 40% of TGF-β1 positive vesicles, 
and it appears that these are needed to generate the robust differentiation response. 
Alternatively, there could be alterations in the vesicle’s phenotype following knockdown of 
Rab11b or Rab35, that renders the remaining population deficient in fibroblast 
differentiation. In a simple experiment, normalising vesicles to a quantity to reach a 
threshold for activation was shown; and knockdown of Rab11b were still capable of driving 
differentiation. However, vesicles following knockdown of Rab35 remained deficient in 
differentiation ability, irrespective of normalisation. The data highlights that the vesicles 
following Rab11b knockdown are distinct in protein profile and differentiation capacity, 
compared to vesicle produced following Rab35 knockdown. This suggests that the Rab35-
dependent vesicle subpopulation are required for fibroblast differentiation to 
myofibroblasts. 
Angiogenesis is a complex process in which growth of new blood vessels can be described by 
multiple steps. Firstly, angiogenic stimuli cause increased endothelial cell permeability and 
cellular proliferation, which is followed by proteolysis of the basement membrane and ECM. 
Endothelial cell migration into the stroma of the neighbouring tissue, requires the 
cooperative MMP and plasminogen activator system, before endothelial cells trigger lumen 
formation as the sprout forms a vessel-like structure (Hoeben et al., 2004). 
In this Chapter, I have demonstrated that CM from fibroblasts treated with the DU145 
knockdown (Rab11b or Rab35) cell secretome can significantly slow endothelial cell 
migration, in comparison to controls. Here, the in vitro scratch assay is a frequently used 
technique to investigate endothelial cell motility (Xu and Deng, 2006, Shi et al., 2013, 
Chronopoulos et al., 2016). One downfall is that it does not replace well-established 
chemotaxis studies, such as the Boyden Chamber assay (Liang et al., 2007) and there is little 
physiological relevance. Still, the in vitro scratch assay is an inexpensive and straightforward 
method to study cell migration. Here, we show endothelial cells cultured in CM from 
untreated fibroblasts were poorly motile. This effect was similar to CM from fibroblasts 
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treated with vesicle concentrates from knockdown of Rab11b or Rab35, only achieving 50%~ 
closure by 18 hours; in contrast where full closure was seen in the control. 
Endothelial cell migration is one essential aspect of angiogenesis and many different 
cytokines are involved in chemotactic endothelial cell migration. Some of the main 
promoters of actin-based motility include HGF, VEGF, bFGF, angiopoietins and other 
contributing factors, such as: PDGF, EGF, TGF-β, uPA and many more (Lamalice et al., 2007). 
VEGF is a potent inducer of endothelial cell proliferation and migration in vitro and in vivo 
(Ferrara, 1993, Bernatchez et al., 1999). Endothelial cell sensitivity to VEGF is exemplified, by 
the lethal vascular abnormalities that result from disrupting a single VEGF allele in mice 
(Carmeliet et al., 1996). Furthermore, VEGF-A is capable of binding onto multiple VEGFRs 
including VEGF-R1 and VEGF-R2. Upon VEGF binding, phosphorylation of tyrosine kinase 
residues on VEGF-R, activates the ERK pathway and p38/mitogen-activated protein kinase 
(MAPK) which induces cell proliferation, migration and increases vascular permeability 
(Murphy et al., 2006).  Furthermore, HGF is a powerful motility factor in different cells, acting 
through the tyrosine kinase receptor, encoded by the MET oncogene (Bussolino et al., 1992). 
In various studies, heightened HGF levels interacts with its cognate receptor, c-Met; and 
promotes angiogenesis by elevating VEGF expression; and by stimulating endothelial cell 
migration and growth (Cai et al., 2000, Duan et al., 2004, Usatyuk et al., 2014). Interestingly, 
analysis of tumour-associated myofibroblasts showed elevated levels of both PDGF and 
PDGFR in a colorectal cancer model (Pena et al., 2013). PDGF appears to play a critical role 
in increasing endothelial cell migration during angiogenesis in vitro, by activating protein 
kinase A (PKA), increasing downstream vasodilator-stimulated phosphoprotein (VASP) 
phosphorylation; thus, increasing endothelial cell migration (Thommen et al., 1997, Zhang et 
al., 2010).  
At the molecular level, HGF/c-Met signalling is proposed to activate multiple signal 
transduction pathways, including the p120/STAT3, the PI3K/Akt pathway, the Ras/MEK 
pathway and phosphorylating annexin-1 supporting angiogenesis. The p120/STAT3 pathway 
stimulates branching morphogenesis of cells (Boccaccio et al., 1998), the PI3K/Akt pathway 
activates cell motility and survival (Potempa and Ridley, 1998, Xiao et al., 2001),  the Ras/MEK 
pathway mediates HGF-induced scattering and proliferation of cells (Ivan et al., 1997) and 
phosphorylating annexin-1 induces endothelial cell proliferation and migration (Pin et al., 
2012). Therefore, these pathways may directly or indirectly stimulate endothelial cells: 
directly by morphogenic effects and indirectly by regulation of other angiogenic factors. As 
demonstrated in various studies, tumour-associated myofibroblasts can secrete various 
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growth factors and cytokines supporting angiogenesis (Kalluri and Zeisberg, 2006, Clark et 
al., 2013, Webber et al., 2015, Chowdhury et al., 2015). Therefore, we demonstrate that 
targeting the Rab11b or Rab35 vesicle secretion pathway, triggering a weakened fibroblast 
differentiation response with decreased levels of secreted HGF and VEGF; and possibly other 
related growth factors, thereby, slowing endothelial cell motility. The extent by what the 
fibroblast secretes by sub-optimal stimulation due to Rab vesicles is not yet understood, but 
a worthwhile avenue for more expansive studies.  
As angiogenesis is a complicated event that requires interactions among different cells, 
growth factors and matrix components, a single “gold standard” assay to capitulates all these 
events is currently unavailable. More commonly used, the ex vivo explant assay involving a 
3D mouse aortic ring, is considered more physiological relevant, because the system includes 
the surrounding non-endothelial cells (pericytes and smooth muscle cells) and a supporting 
matrix, in contrast to traditional cell-based assays (Bellacen and Lewis, 2009). Also, the 
endothelial cells have not been altered by repeat passaging, thus making them quiescent at 
the beginning of explantation, hence, more representative of the in vivo situation, where 
angiogenesis is stimulated and quiescent endothelial cells respond by migration, 
proliferation from existing vessels and differentiating into tubules (Staton et al., 2004). 
However, this method has its downfalls, including the necessity for fresh mouse tissue, 
species differences compared to humans, a lack of non-aortic tissues; and vessel regression 
over time giving them a restricted time for analysis (Baker et al., 2011). Also, endothelial cells 
derived from veins, such as HUVECs, are more applicable for studying angiogenesis, as they 
are prone to generating capillaries, albeit ideally the source should be microvascular 
endothelial cells best derived from the tissue organs, similar to those found at tumour sites, 
unlike endothelial cells from aortic vessels (dela Paz and D'Amore, 2009). 
Here, we used the co-culture method (fibroblasts with endothelial cells), which allowed us 
to assess the specific stromal influence on the formation of vessel-like structures, unlike the 
aortic ring model. Fibroblasts provide critical support for the proliferation and migration of 
endothelial cells, in part, this is mediated through the secretion of pro-angiogenic growth 
factors (Jain, 2003, Nagy, 2003). Furthermore, similar observations showed endothelial cell 
migration, forming branching vessel-like structures that was dependent upon the presence 
of fibroblasts. Tumour cells that released VEGF could not replace fibroblasts in these 
interactions (Velazquez et al., 2002). Here, exosome-generated myofibroblasts can secrete 
pro-angiogenic growth factors, aiding the formation of endothelial vessel-like structures. 
This was shown in a similar gastric cancer exosome model, inducing VEGF expression in 
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stromal fibroblasts, which accelerated the vessel formation assay in HUVECs in vitro and vivo 
(Guo et al., 2008). Yet, vesicles remaining following attenuation of the Rab11b or Rab35 
secretory pathway could only trigger weakened stromal activation, with decreased levels of 
secreted HGF and VEGF, thus reflecting the failure of these vesicles to promote a pro-
angiogenic function in stromal cells. The cancer cell secretome derived from knockdown of 
Rab27a, also failed to trigger fibroblast differentiation and lacked pro-angiogenic effects, in 
terms vessel-forming capability (Webber et al., 2015).  
Therefore, in this Chapter, I have shown that targeting the Rab11b or Rab35 vesicle sub-
population has major effects on cancer to stroma communication. Although there remains 
notable vesicles secretion (80%) by these cells, this remaining subpopulation is dysfunctional 
in driving fibroblast differentiation into myofibroblasts. The stromal cells that arise also 
exhibit attenuated support for angiogenesis. Therefore, the production of vesicle that 
dependent on Rab11b or Rab35 are important elements in stromal regulation by cancer cells. 
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6.1 The Impact of Exosome-Deficient Tumour Cells and Fibroblasts in a 3D 
Co-Culture Model 
6.1.1 Introduction 
Cancer develops in a complex tissue environment, which depend upon continuous growth, 
invasion and metastasis. Studies have shown that tumour-derived exosomes are capable of 
“re-educating” fibroblasts within the stroma to an activated phenotype, supporting ECM 
remodelling and tumour invasion (Yang and Robbins, 2011, Webber et al., 2015). For 
example, myofibroblasts isolated from breast carcinomas compared to normal mammary 
fibroblasts from the same patient, contribute to enhanced tumour invasion and growth in 
vivo (Olumi et al., 1999). An altered stromal microenvironment is a feature of many 
aggressive tumours and consistently, myofibroblasts are commonly found in the stroma of 
carcinomas, often concentrated at the invasive margin of the tumour (Lewis et al., 2004, 
Karagiannis et al., 2013, Li et al., 2016). CM from these tumour-associated myofibroblast 
contains elevated levels of HGF, VEGF or MMPs, suggested to promote the invasive capacity 
of myofibroblast and carcinoma cells through collagen and matrigel matrices (De Wever et 
al., 2004, Cat et al., 2006, Ding et al., 2015). This highlights the importance of myofibroblasts 
in tumour invasion. In particular, interactions between tumour cells and the associated 
disease stroma represents a powerful relationship that influences disease progression and 
poor prognosis (Joyce and Pollard, 2009). Currently, information on exosomal 
communication, controlling the interplay between cancer cells and stromal myofibroblasts 
remains limited in vivo, as it is difficult to recapitulate this exact environment in vitro. 
Evidence has suggested that three dimensional (3D) cell culture models represent the 
microenvironment accurately, where cells resides in tissue, compared to 2D culture systems 
(Kim, 2005). Within 3D culture conditions, there exists a pathophysiological gradient this is 
representative of that in vivo, compared to 2D culture (Benya and Shaffer, 1982, Nelson and 
Bissell, 2005, Baharvand et al., 2006). This added dimensionality leads to quite different 
cellular responses, because not only does it influence physical constraints of the cell, but it 
also promotes the spatial orientation of cell surface receptors engulfed in surrounding cells. 
These physical and spatial features in 3D culture affects the signal transduction from outside 
and into the cell, ultimately influencing gene expression and cellular behaviour in a profound 
manner (Takahashi et al., 2015). 
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Previous studies have reported the importance of cancer exosomes in activating the stroma 
(Webber et al., 2010), that can provide a tumour-supporting environment to support tumour 
invasion in vitro (Chowdhury et al., 2015) and growth in vivo (Webber et al., 2015). It remains 
unclear whether a Rab11b- or Rab35-dependent vesicle subpopulations from tumour cells 
can maintain this crosstalk to fibroblasts within a 3D cell culture model. The previous Chapter 
provided evidence that the Rab11b- or Rab35-dependent vesicle subpopulations can play 
roles in stroma activation, that can support a pro-angiogenic phenotype. Whether these 
functional in vitro assays can be recapitulated within a 3D microenvironment will be 
explored. 
In this Chapter, we will first characterise 3D cell spheroid generation methods with tumour 
cells alone, or co-cultured with fibroblasts. We hypothesise that the remaining vesicle 
subpopulations, following knockdown of Rab11b or Rab35, can exert an influence on 3D 
culture models, in terms of spheroid generation and growth as examples. The invasive 
capacity of these 3D cell spheroids will be explored and their potential mechanism of action 
will be investigated. The hypothesis is that the vesicles remaining following knockdown of 
Rab11b or Rab35 in tumour cells, will severely attenuate the capacity for tumour growth in 
a 3D structure and propose these findings may be recapitulated in vivo.  
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6.1.2 Optimisation of 3D Co-Culture with Tumour Cells and Fibroblasts 
3D spheroid growth of established tumour cell lines is regarded as a stringent and 
representative model when performing in vitro drug screening. They possess several in vivo 
features of aggressive solid cancer, such as cell-to-cell interaction (Baker and Chen, 2012), 
hypoxia (Doublier et al., 2012), production/deposition of ECM (Kimlin et al., 2013) and 
tumour invasion (Weiswald et al., 2015). Here, homotypic (tumour cells alone) or heterotypic 
(tumour cells with fibroblasts) spheroids were used to evaluate spheroid growth and the 
influence of DU145 Rab11b or Rab35 knockdowns. 
The DU145 CTR or Rab11bKD or Rab35KD cells were incubated alone or together with 
fibroblasts at a ratio of 4 tumour cells : 1 fibroblast in cell-repellent plates. Here, two 
methods were used to generate and characterise 3D spheroid cell culture: a Poly-HEMA 
coated plate (cell repellent) or CELLSTAR® cell-repellent surfaces, obtained from Greiner Bio-
One (GBO, UK). The spheroids were cultured in RPMI-1640 in 10% exosome-depleted FBS 
and every other day, 50% of the culture media was replaced with fresh media, as other 
methods used to generate spheroids (Hirschhaeuser et al., 2010, Vinci et al., 2012, Weiswald 
et al., 2015).  
Spheroids were fully established at day 3 (Figure 6.1 A), with cells seeded at a density of 
either 1,000, 5,000 or 10,000 cells (4 tumour control cell: 1 fibroblast) on a poly-HEMA-
coated 96-well round-bottomed plates. Some cellular debris was present around the 
spheroid’s periphery, in different cell seeded conditions. The free hand tool on Image J was 
used to measure spheroid’s diameter and area. The morphology of different cell seeded 
spheroids looks spherical, comparing day 3 to day 13 images. Cells seeded at 1,000 cells had 
an average diameter of 220µm; a diameter of 400µm at 3,000 cells; and a diameter of 580µm 
at 10,000 cells (Figure 6.1 B). In terms of area, a 1,000-cell spheroid had an average area of 
50,000µm2; an area of 100,000µm2 at 3,000 cells; an area of 260,000µm2 at day 3 and an 
area of 200,000µm2 at day 13 (P<0.001) at 10,000 cells (Figure 6.1 C). This showed that as 
more cell numbers were seeded, diameter and area both increased. It was observed that in 
replicate 10,000 cell spheroids, they were robust and stable generated spheres that could be 
handled, compared to smaller cell numbers as they would become fragile, when assessed for 
other functional experiments. Such smaller sized spheroids that were fragile could not be 
modelled without disrupting their structure. Therefore, we proceeded seeding 10,000 cells 
to generate 3D spheroids.  
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As an example of spheroid generation, time-lapse imaging of cells aggregating together over 
72 hours is shown (Figure 6.2). Cells seeded at a density of 10,000 cells (tumour:fibroblast) 
can aggregate into a compact 3D spheroid, with the spheroid’s core becoming darker, 
compared to the spheroid’s periphery by 16 hours. Possibly, the larger seeded cell numbers 
are shrinking and becoming compact within the inner spheroid core, as light must travel 
through more thickness. 
Next, we measured spheroid growth over a 24-day period, either in spheroids containing 
DU145 control, Rab11bKD or Rab35KD cells, or in the presence or absence of fibroblasts (Figure 
6.3 A) by the Poly-HEMA method. All tumour or tumour:fibroblast spheroids were stable 
upon generation. By day 4, the spheroid’s diameter (Figure 6.3 B) was smaller (650µm) in 
spheroid’s containing fibroblasts, compared to tumour cells alone (750µm). There was a 35% 
decrease in area (~250,000µm2), in spheroid’s containing fibroblasts (Figure 6.3 C), compared 
to tumour cells alone (~380,000µm2) (P<0.05). By day 13, all spheroid’s diameter and area 
had shrunk by 20%-30% (~500µm:~200,000µm2). However, from day 17, all spheroids 
increased in spheroid size by 20% (~600µm:~250,000µm2). There were no significant 
differences in size between spheroids containing exosome-deficient or competent tumour 
cells, or in the absence or presence of fibroblasts in spheroids. Though, the observed biphasic 
changes in a 3D sphere was unexpected and is difficult to interpret. Perhaps, this may be 
related to the uneven coating poly-HEMA to these plates that may explains these changes. 
In contrast, spheroids generated with the GBO cell-repellent surfaces plates, coated with a 
polymer still induced spheroid formation. This method maintained a steady spheroid size 
increase, showing a darker inner core over 24 days (Figure 6.4 A). Possibly, larger spheroids 
over time have greater inner quiescent cells that die through necrosis; thus a darker necrotic 
core. By day 4, the diameter and area (Figure 6.4 B & C) of spheroids were 10%-15% smaller 
in size (575µm:275,000µm2), in the presence of fibroblasts, compared to tumour cells alone 
(675µm:305,000µm2). By day 24, the diameter and area on average increased by 5%-20% 
(690µm:350,000µm2), in fibroblast containing spheroids and similarly shown in spheroids 
containing tumour cells only. We failed to observe any significantly differences in spheroid 
growth by comparing spheroids containing or lacking fibroblasts, or the presence or absence 
of DU145 Rab11bKD or Rab35KD cells. Hence, we failed to discriminate each homotypic or 
heterotypic spheroid by size alone. 
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Next, we compared both spheroid generation methods (Poly-HEMA vs GBO). There was a 
consistent increase in spheroid size by using the GBO method (Figure 6.5), compared to Poly-
HEMA. Furthermore, fluctuations in spheroid size by the Poly-HEMA method remained 
difficult to ascertain, whether this was due to the knockdown effect or spheroid generation 
method. Over time, we observed a consistent increase in spheroid size with the GBO method 
and a dark spheroid inner core, proposed to be a necrotic cell core similar with other 3D cell 
spheroid studies (Hirschhaeuser et al., 2010, Godugu et al., 2013, Takahashi et al., 2015). 
Therefore, the reliability issues with generating spheroids, together with minimal 
fluctuations in size parameters, parallel with other studies the GBO method will be 
implemented for future experiments within this Chapter.
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Figure 6.1: Optimising cell number to generate 3D cell spheroids. Cells were seeded at 
a density of 1,000, 5,000 or 10,000 cells (4 tumour control cell: 1 fibroblast) on poly-
HEMA-coated (cell repellent), 96-well round-bottomed plates. After 72 hours, seeded 
cells aggregated into a compact 3D cell spheroid. (A) Representative images of 3D co-
cultured spheroids (a single spheroid per well) at day 3 and day 13. Scale bar: 250µm. 
Representative fields are shown. (B) Diameter and (C) area measurements were carried 
out using Image J software at day 3 and 13. Graph shows mean ± SEM, based on 15 wells. 
n.s: non-significant and ***P<0.001. One-way ANOVA with Tukey’s post hoc test. Data 
are representative of three independent experiments. 
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Figure 6.2: Time-lapse images of 3D spheroid generation. Cells were seeded at a density 
of 10,000 cells (4 tumour cell: 1 fibroblast). Over time, cells suspended on a cell-repellent 
plate aggregated into a compact 3D cell spheroid. Time-lapse brightfield images were 
obtained every hour, up to 72 hours by the CytoSmart™ Lux 10X System (pictured: every 
hour up to 16 hours, and daily up to 72 hours). Representative images are shown. Scale 
bar: 250µm. Data are representative of three independent experiments. 
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Figure 6.3: Spheroids containing DU145 control, Rab11bKD or Rab35KD cells alone or co-
cultured in fibroblasts maintain tumour growth over time (Poly-HEMA method). (A) 
Starting from day 3 post- initiation, representative images of DU145 control, Rab11bKD or 
Rab35KD +/- fibroblasts spheroids grown on Poly-HEMA plates, were obtained at 
indicated time points. Scale bar: 250µm. Representative fields are shown. (B) Diameter 
and (C) area measurements were carried out using ImageJ software. Graph shows mean 
± SEM, based on 10 wells. n.s: non-significant. Two-way ANOVA with Bonferroni post hoc 
test. Data are representative of three independent experiments. 
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Figure 6.4: Spheroids containing DU145 control, Rab11bKD or Rab35KD cells alone or co-
cultured in fibroblasts maintain tumour growth over time (GBO method). Starting from 
day 3 post initiation, representative images of DU145 control, Rab11bKD or Rab35KD +/- 
fibroblasts spheroids grown on CELLSTAR® cell-repellent surfaces from Greiner-Bio One 
(GBO) plates were obtained at indicated time points. Scale bar: 250µm. Representative 
fields are shown. (B) Diameter and (C) area measurements were carried out using ImageJ 
software. Graph shows mean ± SEM, based on 15 wells. n.s: non-significant. Two-way 
ANOVA with Bonferroni post hoc test. Data are representative of three independent 
experiments. 
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Figure 6.5: Comparing two spheroid generation methods (Poly-HEMA vs GBO) over 
time. Measurements of (A) diameter and (B) area of 3D spheroids between the Poly-
HEMA and the GBO spheroid method over 24 days. Line graph showing diameter and 
area of Poly-HEMA spheroids fluctuating compared to GBO’s spheroids gradually 
increasing over time. Graph shows mean ± SEM, based on 15 wells. n.s: non-significant 
and ***P<0.001. Two-way ANOVA with Bonferroni post hoc test. 
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6.1.3 Loss of Rab11b- or Rab35-Dependent Tumour Exosomes Attenuates Invasion in 3D 
Culture 
Myofibroblasts orchestrate processes aiding tumour invasion and progression, through 
paracrine interactions involving the secretion of several soluble growth factors, such as EGF, 
FGF-2, HGF, VEGF-A (Orimo et al., 2005, Kalluri and Zeisberg, 2006, Webber et al., 2015). 
Furthermore, myofibroblasts can also secrete MMP enzymes to aid ECM modelling that can 
potentially recruit cells to facilitate an aggressive invasive functional change of tumour cells. 
Here, we explored if loss of Rab11b- or Rab35-dependent exosomes can have any effect on 
invasivity in 3D culture models. We established 3D tumour (DU145 control or Rab11bKD or 
Rab35KD cells) spheroids with or without fibroblasts by day 4. Once these spheroids were 
established, these were transferred to matrigel-coated plates acting as a 3D basement 
membrane mimic (Figure 6.6 A). Each well contained RPMI-1640 media with 10% exosome-
depleted FBS. Each spheroid was examined microscopically daily, up to 96 hours, to 
determine whether cells escape from the spheroid into the surrounding matrix. Cell 
outgrowth was observed from the spheroid (DU145 control + fibroblast) as early as 8 hours, 
growing beyond the field of view (x10 objective) at 32 hours (Figure 6.6 B).  
Control tumour cells, in the absence of fibroblasts readily formed compact spheroids, but 
cells within exhibited a poor capacity to escape into the surrounding matrix. This was true 
for both knockdown of Rab11b (Figure 6.7 A) or Rab35 (Figure 6.7 C). In contrast, when 
incorporating fibroblasts into these spheroids, we observed notable cell invasion into the 
matrix as early as 24 hours; and beyond the x10 field of view as time progressed. By tiling 
multiple images, we could assess invasion up to 96 hours and quantify % increase in area 
difference from day 0 spheroid. The formula used to calculate this: 
% increase in area difference = Total area of outgrowth (day n) / Total area of spheroid at 
day 0 
When measuring these outgrowths, we took into consideration these 3D spheroid structures 
are viewed as 2D images. Therefore, we are not accounting for any movement in the z-axis. 
Nonetheless, spheroids comprising fibroblasts and exosome competent tumour cells 
demonstrated a significant increase in area occupied by extra-spheroid cells (Figure 6.7 B & 
D), compared to tumour cells containing the Rab11bKD (150% decrease) (P<0.01) (Figure 6.7 
B) or Rab35KD (350% decrease) (P<0.001) (Figure 6.7 D) at 96 hours. Outgrowths were 
drastically less extensive by 96 hours, with a clear attenuation of invasive capacity in the 
absence of Rab11b or Rab35 tumour-derived vesicles. Fibroblasts, therefore, are important 
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mediators of this invasive behaviour. Tumour cells exhibiting knockdown of Rab11b or Rab35 
still exhibited an attenuated invasive capacity, even in the presence of fibroblasts, suggesting 
these regulators are important in communicating between tumour and stromal cells in the 
context of a 3D spheroid environment, as they are relevant regulators of invasive behaviour.
Chapter 6. The Impact of Exosome-Deficient Tumour Cells in a 3D Co-Culture Model 
 
175 
 
Figure 6.6: Time-lapse imaging of the 3D spheroid invasion assay. (A) Schematic 
diagram of 3D spheroid matrigel invasion assay: a single day 4 established 
tumour:stroma spheroid was transferred to each well of a matrigel matrix-coated 24-
well, flat bottomed plate. (B) Representative time-lapse brightfield images of the 3D 
spheroid cell outgrowths (pictured: every 4 hours up to 60 hours) were obtained by the 
CytoSmart™ Lux 10X System. Scale bar: 250µm. Data are representative of three 
independent experiments. 
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Figure 6.7: DU145 Rab11bKD/Rab35KD cells attenuate aggressive invasion in 3D culture. Spheroid cultures were established, composed of DU145 
control and (A and B) Rab11bKD or (C and D) Rab35KD cells, or a combination of DU145 cells with fibroblasts (at a ratio of 4:1 respectively), at 104 
total cells/spheroid. The area occupied by extra-spheroidal cell outgrowths was measured daily for up to 96 hours. For late time-points, multiple 
images of the spheroid-outgrowths were taken and these were tiled to form a composite representation of the full extent of outgrowth. Scale bar: 
100µm. Graph shows mean ± SEM, based on 5 spheroids per group. ** P≤0.01 and ***P≤0.001. Two-way ANOVA with Bonferroni post hoc test. 
Data shown as representative of three experiments. 
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6.1.4 Tracking Fluorescently Labelled Tumour Cells and Fibroblasts in the Invasion Assay 
The tumour margin is an important aspect for invasion, where stromal cells are pivotal in 
supporting this complex tumour microenvironment. Notably, many tumour cells do not 
degrade the surrounding matrix and do not secrete high levels of proteases, but are able to 
disseminate and invade aggressively (Cao et al., 2015). The population of myofibroblasts may 
provide a significant stromal remodelling capacity, leading the way for invasive tumour cells. 
However, it remains poorly understood whether tumour cells or fibroblasts concentrate at 
the leading edge to support cancer invasion. Here, DU145 cells labelled with green 
fluorescent protein (GFP) and fibroblasts labelled with quantum dots (qDot) were used, to 
track cells in the spheroid invasion assay. 
Previously, we transduced DU145 cells with MISSION® lentiviral particles (Chapter 4) with 
the pLKO.1-puro vector, allowing stable gene silencing of selected targets. Here, we selected 
the best knockdowns and used lentiviral particles with an alternative vector backbone; Neo-
CMV-tGFP, to fluorescently express our selected DU145 cells with GFP allows for selection of 
transduced cells using Geneticin® (G418). The 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay was used to determine the lowest G418 dose 
(eukaryote antibiotic) required for efficiently selecting transduced cells. Here, incremental 
G418 doses were used to treat DU145 cells (Figure 6.8). 2000µg/ml was the minimal G418 
dose observed, sufficient to kill the majority of DU145 cells. These transduced DU145 cells 
successfully fluorescently expressed GFP. 
We initially proposed to use a Neo-CMV-tRFP to fluorescently label our fibroblast cell line 
with red fluorescent protein (RFP); though this would be redundant as these primary 
fibroblasts have a limited number of passages. If fibroblasts were RFP positive and be 
deemed free of lentiviral particles, they would undergo senescence if available for use. An 
alternative to fluorescently label fibroblasts would be utilising quantum dots (qDots), as one 
study reported to successfully track MSCs in vitro and vivo with long photostability (Muller-
Borer et al., 2007). First, we explored the effect of qDot-labelling on fibroblasts, to 
understand if qDot-labelling has any cytopathic impact on fibroblasts. A monolayer of 
unlabelled and labelled fibroblasts was seeded and counted daily, over the 144-hour time 
course. We observed no significant differences in cell number between labelled and 
unlabelled conditions over time (Figure 6.9 A), which suggests qDot-labelling does not cause 
any cytopathic effect on fibroblast cell growth. 
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Next, we labelled fibroblasts with qDots and assessed intracellular qDot labelling over a 96-
hour time course by flow cytometry (Figure 6.9 B). 24 hour labelled qDot fibroblasts 
demonstrate a greater fluorescent signal, compared to unlabelled fibroblasts. Though by 72 
hours and until 144 hours, the qDot signal was weakened and we saw some overlap with 
unlabelled fibroblasts; suggestive of a faint signal. As the fibroblasts incorporated qDots, this 
declining signal may be explained by the cells undergoing cell division, that potentially divides 
the signal in half with every division.  
Nevertheless, we next incorporated these fluorescently-labelled cells into our 3D spheroid 
invasion assay, to determine whether the periphery of cell outgrowths is concentrated with 
just tumour cells, fibroblasts or a combination of both. Cell outgrowth was observed from 
the spheroid (DU145 control cells + fibroblasts) as early as 8 hours (Figure 6.10 A). Cells were 
proliferating and growing beyond the field of view at x20 microscope objective at 30 hours, 
with evidence of tumour cells proliferating between 16-22 hours. We observe weakly GFP-
labelled tumour cells present in the cell outgrowth at 0 and 12 hours (Figure 6.10 B). 
Similarly, qDot-labelled fibroblast signal was present at the periphery of cell invasion at 0 
hour, but the signal faded by 12 hours. As some examples, individual qDots are present 
within cell outgrowth, as determined by the zoomed in images; indicative of fibroblasts, 
albeit very faint. These results give some indication that tumour cells are present in these 
outgrowths, supporting cancer invasion at the leading edge. Fibroblasts are likely to be 
present, as some qDot positive cells were present with tumour cells at the invading front, 
but the signals were weak and difficult to detect over time.  
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Figure 6.8: Optimisation of G418 cytotoxicity profile for DU145 cells. Cells were seeded 
at a density of 5,000 cells per well and incubated with a range of G418 concentrations 0-
4000µg/ml. After 48 hours, cell viability was measured using the WST-1 assay. DU145 
cells were stably transduced with MISSION® lentiviral transduction particles expressing 
GFP. Graph shows mean, based on 5 wells. 
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Figure 6.9: Growth curve and quantification of qDot-labelled fibroblasts over time. (A) 
Fibroblasts were labelled with qDots for 24 hours, prior to seeding cells at a density of 
7,500 cells per well in DMEM-F12 media. The growth curve of fibroblasts was monitored 
daily, up to 72 hours and at 144 hours, determined by cell counts. Graph shows mean ± 
SEM, based on triplicate wells. n.s: non-significant. Two-way ANOVA with Tukey’s post 
hoc test. (B) Flow cytometry results of qDot labelled fibroblasts at 24, 48, 72 and at 144 
hours.  
 
(A) 
(B) 
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Figure 6.10: Tracking GFP-positive DU145 cells and qDot-labelled fibroblasts in the invasion assay. (A) Representative time-lapse images of 
GFP-positive DU145 cells (green) and qDot-labelled fibroblasts (red) images of the 3D spheroid cell outgrowths. Representative images (pictured: 
every 2 hours up to 30 hours) obtained hourly up to 96 hours (not shown) by the Zeiss Z1 observer. Image of spheroid cell outgrowth at 0 hour 
and 12-hour time points with (B) GFP-labelled tumour cells and qDot-labelled fibroblasts at the periphery of cellular invasion. Scale bar: 250µm. 
White arrows: GFP or qDot labelled cells.  
(A) 
(B) 
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6.1.5 Loss of Rab11b- or Rab35-Dependent Exosomes Attenuates MMP Levels in 3D 
Culture  
Previous results revealed that DU145 Rab11bKD or Rab35KD cells significantly reduced the 
invasive capacity of 3D spheroids, failing to give any advantageous invasion even in the 
presence of fibroblast. Invasion requires a complex actin-based tumour cell migration 
machinery that works in tandem with the secretion of MMPs. Here, we explored the 
potential mechanism of action underlying these invasive differences proposed to be 
alterations in MMP levels, capable of degrading the ECM to support cellular invasion. 
RNA was extracted from 3D spheroids at day 4. The relative levels of mRNA for MMP-1, 
MMP-13 and tissue inhibitor of matrix metalloproteinase-3 (TIMP-3) were compared among 
the different homotypic and heterotypic spheroids using Taq-Man PCR assays. Relative 
quantification using the comparative Ct method (2-ΔΔCt), was used to analyse differences in 
gene expression of MMP-1, MMP-13 or TIMP-3 among the spheroids. MMP-1 or MMP-13 
expression was measured relative to the DU145 control, Rab11bKD or Rab35KD cells alone. 
TIMP-3 expression was measured relative to DU145 control cell co-cultured with fibroblasts. 
The mRNA for MMP-1 and MMP-13 was significantly up-regulated by 1.7-fold (P<0.001) and 
1.6-fold (P<0.01) respectively, in DU145 control cells with fibroblasts compared to control 
tumour cells alone (Figure 6.11 A & B). In contrast, DU145 Rab11bKD or Rab35KD cells, with or 
without fibroblasts, showed no significant differences in MMP-1 and MMP-13. Though, 
TIMP-3 was up-regulated by 1.5-fold in DU145 Rab11bKD (P<0.05) and Rab35KD (P<0.05) cells 
in the presence of fibroblasts respectively, compared to controls (Figure 6.11 C). Overall, at 
the transcript level, TIMP-3 was undetectable in the tumour cell only spheroids. 
At the protein level, the pattern is similar to the mRNA data (Figure 6.12), revealing increased 
concentrations of both MMP-1 (4.7-fold increase) (P<0.01) and MMP-13 (1.6-fold increase) 
(P<0.05), in the DU145 control and fibroblast spheroid’s CM, compared to control tumour 
cells alone. This influence is lost when using either DU145 Rab11bKD or Rab35KD cells (Figure 
6.12 A & B). Loss of either Rab11b- or Rab35-dependent vesicles appear to shows disruptive 
effects on the cross-talk between tumour cells and fibroblasts. These rendered the spheroid 
environment lower in MMPs and elevated in TIMP-3 at the transcript level; and this may 
explain the differences observed in invasivity. 
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Figure 6.11: Exosome-deficient tumour spheroids have reduced transcripts for MMP-1 
and MMP-13; and elevated TIMP-3.  RNA was isolated from spheroids containing DU145 
control, Rab11bKD and Rab35KD cells, with or without fibroblasts, at day 4. Quantification 
of mRNA expression levels for (A) MMP-1, (B) MMP-13 and (C) TIMP-3 in the different 
spheroids were measured, relative to the DU145 tumour cells alone or with fibroblasts, 
using qPCR. Graph shows mean ± SEM, based on triplicate wells. n.s: non-significant, 
*P<0.05, **P<0.01 and ***P<0.001. One-way ANOVA with Tukey’s post hoc test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
(A) (B) 
(C) 
Chapter 6. The Impact of Exosome-Deficient Tumour Cells in a 3D Co-Culture Model 
 
185 
 
Figure 6.12: Exosome-deficient tumour cell spheroids secrete reduced levels of MMP-
1 and MMP-13. Cell CM was collected from spheroids containing DU145 control, 
Rab11bKD and Rab35KD cells, with or without fibroblasts, at day 4. Quantification of 
protein levels for (A) MMP-1 and (B) MMP-13 in the different spheroids were measured 
by ELISA. Graph shows mean ± SEM, based on duplicate wells. n.s: non-significant, 
*P<0.05 and **P<0.01. One-way ANOVA with Tukey’s post hoc test.  
 
 
 
 
  
(A) 
(B) 
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6.1.6 Knockdown of Rab35 Impacts Tumour Growth, but not Rab11b 
Previously, our group has demonstrated that administration of DU145 control cells with 
fibroblasts accelerated tumour growth in mice, compared to DU145 Rab27aKD cells with 
fibroblasts (Webber et al., 2015). Our results revealed that knockdown of Rab11b or Rab35 
leaves a vesicle population that remains insufficient for driving fibroblast differentiation into 
myofibroblast, leading to diminished angiogenesis and attenuated behaviour in 3D in vitro 
models. Here, we explored whether we could recapitulate these in vitro findings into the in 
vivo setting, in terms of tumour growth. 
Tumour:fibroblast xenografts consisted of DU145 (control or Rab11bKD or Rab35KD) cells co-
cultured together with fibroblasts in a ratio of 4 tumour cells:1 fibroblast (Figure 6.13 A). 
These xenografts were established on the dorsal flank of CD1 athymic mice and administered 
by subcutaneous injection of 5 x 106 total cells suspended in matrigel. Once tumours became 
palpable, dimensions (height and width) of tumours were measured using vernier callipers 
every 2 to 3 days. These measurements were used to calculate tumour volume (Jensen et 
al., 2008, Faustino-Rocha et al., 2013), using the formula:  
tumour volume (mm3) = width2 x length x 0.5. 
For each condition, tumours became palpable at day 7, with steady growth thereafter (Figure 
6.13 B). Knockdown of Rab11b showed little difference in tumour growth rates, compared 
to controls, reaching a large volume of in excess of 330mm3 by day 46, compared to 389mm3 
by the controls. In contrast, knockdown of Rab35 showed a significant attenuation of tumour 
growth from day 35 onwards (P<0.001) and at day 46, the tumour volume was less than 
100mm3. Representative images of excised tumours are shown (Figure 6.13 C), 
demonstrating restricted growth of the Rab35 knockdown tumour. We were surprised to see 
that knockdown of Rab11b did not show similar results as the Rab35 knockdown. Possibly, 
this may be due to other responses that we have not explored, perhaps phenotypic 
differences in the secretome. Though these reasons will be discussed in greater detail in the 
Discussion. 
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Figure 6.13: Rab35 knockdown attenuates growth in vivo, but not Rab11b. (A) 
Schematic diagram of experimental outline. A total of 5 x 106 cells comprising of tumour 
cells (DU145 control or Rab11bKD or Rab35KD) with fibroblasts, at a ratio of 4:1 were 
administered subcutaneously to the dorsal flank of CD1 athymic mice. Three groups were 
compared; including control tumour cells, Rab11bKD or Rab35KD. (B) When tumours were 
palpable, day 7 onwards, tumour growth was assessed using external callipers every 2 to 
3 days and the graph shows tumour volume (mm3) for up to 46 days. Graph shows mean 
± SEM, (n=4). n.s: non-significant and ***P<0.001. Two-way ANOVA with Bonferroni post 
hoc test. (C) Tumours were excised, and photographed to represent the differences in 
volume at the experimental endpoint. 
(B) (C) 
(A) 
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6.2 Discussion 
In this Chapter, we investigated the implications of spheroids containing DU145 Rab11bKD or 
Rab35KD cells, co-cultured with fibroblasts on spheroid growth and invasion in vitro and 
tumour growth in vivo. First, spheroids generated with DU145 control, Rab11bKD or Rab35KD 
cells alone, or with fibroblasts, were cultured for 24 days. Numerous factors including 
spheroid generation method, culture media and cell lines can affect spheroid formation 
(Kelm et al., 2003, Kim, 2005). During the growth of these homotypic and heterotypic 
spheroids, we observed a dark dense cell core suggestive of a necrotic centre. This was 
commonly observed in all spheroids containing either DU145 control, Rab11bKD or Rab35KD 
cells. This feature was also observed in other 3D cell spheroids cultured in vitro (Folkman and 
Hochberg, 1973, Sherar et al., 1987, Hirschhaeuser et al., 2010). A necrotic core is recognised 
to be enclosed by a shell of quiescent cells and an outermost layer of live proliferating cells. 
Studies have described spheroids with diameters larger than 500µm, accumulating 
metabolic waste in the inner core which deprives cells of oxygen and nutrients, thus a 
necrotic centre (Anada et al., 2012, Beauchamp et al., 2015).  
Analysis of these DU145 control, Rab11bKD or Rab35KD cells alone, or and tumour:fibroblast 
spheroids, revealed a reduction in size with the Poly-HEMA method, before increasing in size 
over time. Although Poly-HEMA coated plates can generate spheroids, it remains difficult to 
control a homogenous Poly-HEMA coating (Ke et al., 2004). Where uneven coating can occur, 
this may result in impurities or poor ethanol evaporation in Poly-HEMA, that may affect 
spheroid formation and growth (Atala and Lanza, 2001). There was great difficulty in using 
poly-HEMA generated spheroids for functional invasion assays, as spheroids became fragile 
and brittle. This led to companies, such as GBO, to manufacture CELLSTAR® cell-repellent 
surfaces plates that have a homogenously coated polymer to induce spheroid formation. 
Similar to Poly-HEMA, these coated polymers are proposed to prevent cell adherence, due 
to the negative electrostatic reduction of the polystyrene surface (Folkman and Moscona, 
1978). Based on the GBO-spheroid method, an increase spheroid growth for homotypic and 
heterotypic spheroids was consistent with other studies (McMillan et al., 2016, Wang et al., 
2016b). In contrast, the presence of tumour cells and especially fibroblasts showed an initial 
smaller spheroid, compared to tumour cells alone. This initial smaller spheroid may be due 
to cell re-organisation and cellular contraction of fibroblasts (Sodek et al., 2009, Nyga et al., 
2013). However, even in the presence of exosome deficient tumour cells, this did not seem 
to hinder spheroid growth. Similar to other reports, there is a finite limit to the maximum 
size a spheroid can grow to, regardless of how frequent media is replenished or the 
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availability of space for spheroid growth (Folkman and Hochberg, 1973). This could be 
explained the spheroid’s total number of cells reaches a point where their aggregate surface 
area is insufficient to allow adequate diffusion of catabolites. These spheroids enter a 
‘dormant’ phase and would perhaps require vascularisation that would begin exponential 
growth. Furthermore, measurements of these 3D spheroids are based on 2D measurements, 
which is not an accurate representation of tumour growth, as we assume spheroids are 
perfect spheres but the surface composition may differ. Spheroids which look small, might 
nevertheless be complex biologically; and differences other than this may exist. Analysis of 
spheroid tumour growth revealed that the single parameter of size (diameter and area) was 
not able to show differences in experimental groups, as we initially hoped.  
During tumour invasion, the stroma plays a fundamental role in secreting growth factors and 
matrix degrading enzymes to support tumour invasion (Hanahan and Weinberg, 2011). 
Therefore, we examined the invasive behaviour as a feature affected by the Rab 
knockdowns. Matrigel was used for in vitro invasion assays to mimic basement membrane 
matrices, which cancer cells penetrate during tumour metastasis (Albini et al., 1987, Albini, 
1998). From our data, cell outgrowth from 3D spheroid into the surrounding ECM occurs 
readily. By observing GFP-positive tumour cells and qDot-labelled fibroblasts, there was 
some evidence of tumour cells at the leading invasive edge. Although, some qDot 
fluorescence was present at the time of invasion (12 hours), qDot fluorescent signal was lost 
over time. An improved approach would have been to transduce fibroblasts with lentiviral 
particles with a fluorescent tag (mCherry/RFP), similar to GFP-positive tumour cells. This 
would have sustained fluorescent signal over a longer duration, whilst addressing whether 
fibroblasts are present at the leading edge or within the invading mass. In other studies, 
fibroblasts are located at the leading edge of invasive colon and gastric cancer models 
(Illemann et al., 2004, Satoyoshi et al., 2015). However, this remains to be explored in detail 
in our model. 
By using 3D spheroids in a matrigel invasion assay, DU145 control cells co-cultured with 
fibroblasts increased their invasivity capacity with larger outgrowths, though it remains 
uncertain whether this penetration occurred on top or through the matrigel. Both DU145 
Rab11bKD or Rab35KD cells severely attenuated tumour invasion, even in the presence of 
fibroblasts. This suggest that Rab11b- or Rab35-dependent vesicles appear key in mediating 
this cross-talk in between tumour and fibroblasts, enhancing the tumour’s invasive capacity.  
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As with stroma activation and motility, CM from fibroblasts treated with vesicles derived 
from DU145 Rab11bKD or Rab35KD cells, showed a decrease in secreted growth factors, such 
as VEGF-A and HGF (shown in Chapter 5), which may be involved in cancer cell invasion. The 
role of secreted VEGF-A and HGF by myofibroblasts, has been documented for supporting 
aggressive tumour cell invasion (Lewis et al., 2004, Cat et al., 2006). Overexpression of HGF 
and c-Met can promote cancer cell invasiveness (Ebert et al., 1994, Gao and Vande Woude, 
2005). Elevation of secreted HGF and VEGF was observed in prostate cancer stromal cells 
and exosome-differentiated fibroblasts (Webber et al., 2015), along with uPA contributing to 
degradation of the basement membrane and ECM (Jeffers et al., 1996, Botta et al., 2012). It 
could be possible that growth factors secreted from exosome-differentiated fibroblasts may 
play a role in triggering a proteolytic cascade for ECM modulation, supporting tumour 
invasion, although we do not have direct evidence for this. 
mRNA analysis from 3D spheroids, revealed highly expressed levels of MMP-1 and MMP-13 
in spheroids with exosome competent tumour cells containing fibroblasts, compared to 
spheroid containing DU145 Rab11bKD or Rab35KD cells. There was only TIMP-3 mRNA present 
in the fibroblast containing spheroids; and knockdown of Rab11b or Rab35 had a similar 
effect on elevating this inhibitor of metalloproteinase function. Quantification of MMP-1 and 
MMP-13 at the protein level was determined by ELISA. The pattern followed that of the 
mRNA data, revealing heightened activity in the presence of fibroblasts; and this influence is 
lost using either DU145 Rab11bKD or Rab35KD cells. This data only reveals MMP quantity, not 
showing MMP activity present within this 3D-microenvironment. Therefore, performing an 
MMP activity assay may answer whether these MMPs are involved in promoting invasion of 
tumour cells. 
Expression of MMP-1 and MMP-13 play a role in degrading collagen type I, II and III, which 
are components of the interstitial stroma (Aznavoorian et al., 1993). Consistent with a 
number of studies, MMP-1 overexpression has been described in a wide variety of advanced 
cancers (Kanamori et al., 1999, Franchi et al., 2002, Liu et al., 2012); and increased MMP 
activity is associated with tumour progression and aggressive invasion (Sakakibara et al., 
1999, Bendardaf et al., 2007). MMP-13 has been shown to enhance pancreatic tumour cell 
migration and invasion in vitro and vivo; and often stained heavily in highly invasive tumour 
cells in pancreatic cancer tissues, compared to weakly invasive cells (Tan et al., 2010, Fan et 
al., 2015). 
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By blocking MMPs, the relative importance they demonstrate in spheroid invasion can be 
proposed. Blockade of MMP-13 with a selector inhibitor (Cmpd-1) has been shown to reduce 
the tumour growth rate of two different primary breast cancer in vivo (Shah et al., 2012). 
Similarly, blockade of MMP-1 activity with specific inhibitors and antibodies, inhibited 
prostate cancer cell migration and invasion in vitro, whilst reducing tumour growth in vivo 
(Pulukuri and Rao, 2008). In many cases, MMP activity can degrade components of the ECM 
(collagens, fibronectin and laminins), generating fragments that have different biological 
activities (Xu et al., 2001, von Nandelstadh et al., 2014). For example, type I collagen 
degradation is mediated by MMP-1 and their by-products aids epithelial cell migration and 
wound healing in culture models (Pilcher et al., 1997). Furthermore, MMP-13 can activate 
the precursors of MMP-9 (Knäuper et al., 1997), which can degrade basement membrane 
type IV collagen, allowing tumour cell invasion and spread. This positive feedback loop lead 
to excessive collagen by-products, elevated during cancer progression and this correlates 
with metastatic cancer (Kehlet et al., 2016). This may activate further MMPs, allowing a 
continuous breakdown of the ECM and supporting the tumour’s invasive nature. 
As for TIMP-3, a variety of studies have shown that TIMP-3 expression is reduced in various 
cancer tissues, compared to non-cancerous tissues (Wu et al., 2012). Decreased TIMP-3 
expression was associated with pathological stage, nodal involvement and poor survival 
(Mino et al., 2007, Ninomiya et al., 2008). Furthermore, elevated TIMP-3 expression is 
proposed to contribute to tumour progression in head and neck squamous cell carcinomas, 
showing to be frequently silenced by promoter hyper-methylation during cancer progression 
(Worsham et al., 2006). Treatment of xenografts of human prostate or breast cancer cells in 
vivo with recombinant TIMP-3 protein, reduced tumour cell proliferation, sensitised cells to 
chemotherapy, reducing tumour growth and invasion (Mahller et al., 2008, Shinojima et al., 
2012). Possibly, TIMP-3 expression may exert its anti-proteolytic function at the invasion 
front of tumour cells, to quench tumour-associated ECM degrading activity, or in the stroma 
itself, where soluble proteases liberate ECM-tethered factors that assist cancer invasion. 
Spheroids containing both exosome competent tumour cells and fibroblasts can up-regulate 
matrix remodelling proteins, which may degrade the ECM and support the aggressive 
invasive nature of the tumour. The data in this Chapter revealed that co-culture of fibroblasts 
and exosome competent tumour cells, maintained an aggressive invasive capacity in vitro. 
However, loss of either DU145 Rab11b- or Rab35-derived exosomes appear detrimental in 
invasion, even in the presence of fibroblasts. Although we may like to believe the disease 
modulation is due to changes in secreted vesicles, it is important that this is not potentially 
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exclusive. The effects could equally be due to cell-contact dependent changes and alterations 
in the secretome. Nonetheless, the targets of Rabs is the best method available to target 
vesicles in complex 3D models or indeed in vivo; and it is likely these observations will be a 
vesicle-driven process. 
Next, we attempted to recapitulate these in vitro findings in an in vivo setting, by establishing 
xenografts consisting of DU145 control, Rab11bKD or Rab35KD cells with fibroblasts. 
Xenografts containing DU145 control cells with fibroblasts accelerated tumour growth, 
compared to DU145 Rab35KD cells with fibroblasts, but this difference was not similar in 
xenografts containing DU145 Rab11bKD cells. From day 35, knockdown of Rab35 significantly 
reduced tumour growth, compared to which controls, suggesting functional differences 
between Rab11b and Rab35 were not apparent from in vitro experiments. Similar 
experiments performed previously by our group, showed differences in attenuated tumour 
growth in xenografts with DU145 Rab27aKD cells with fibroblasts over 32 days, compared to 
controls (Webber et al., 2015). This may be highlighted by differences in phenotype and 
function between these subpopulations of vesicles. 
As demonstrated previously in Chapter 4, the protein profile of remaining vesicle 
subpopulation and secreted cytokines, following knockdown of Rab11b and Rab35 are 
distinct, despite showing similar effects upon fibroblast differentiation and supporting 
angiogenic function. Knockdown of Rab11b was capable of triggering fibroblast 
differentiation, if normalised for vesicle quantity to reach a threshold for activation. In 
contrast, vesicles produced by knockdown of Rab35 remained deficient in differentiation, 
irrespective of normalisation. Perhaps this may be explained by the chronic exposure of 
vesicle-defective tumour cells in vivo, between knockdown of Rab11b or Rab35. Previously, 
we have shown that TRAIL expression on the vesicle pellet was >2 fold increased in DU145 
Rab35KD remaining vesicles and <2 fold decreased in DU145 Rab11bKD remaining vesicles. 
Although the ability of TRAIL to trigger apoptosis in certain cell lines is well-established, its 
physiological role is not fully defined. Though, in mice, lower expression or genetic ablation 
of TRAIL supports the role for this ligand in the suppression of tumour growth and metastasis 
in vivo (Takeda et al., 2001). Similarly, there appears to be an increased susceptibility to 
tumour initiation and metastasis in TRAIL-deficient mice (Cretney et al., 2002). Recently, 
comparison of gene-expression profiles in a panel of >300 human breast cancer samples 
revealed down-regulation of TRAIL correlates with breast cancer metastasis to the brain (Bos 
et al., 2009). Therefore, it could be possible that the distinct protein profiles in remaining 
vesicles, following knockdown of Rab11b or Rab35 in tumour cells, may have different 
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implications on tumour growth, which is broader that simply the effect on stromal 
modulation. 
Furthermore, in similar in vivo studies, knockdown of Rab27a attenuated exosome secretion, 
but also impacted the cell secretome, such as the secretion of MMP-9, PGF and PDGF which 
have implications on modulating the tumour microenvironment (Bobrie et al., 2012, Peinado 
et al., 2012). In our protein profiling data (Chapter 4), as examples, we see that LIF expression 
was >2 fold increased in the DU145 Rab35KD cell secretome, compared to a <2 fold decrease 
in the DU145 Rab11bKD cell secretome. It is reported that elevated LIF expression induces cell 
cycle arrest and apoptosis, along with inhibition of melanoma cell migration (Humbert et al., 
2015). It could be possible that decreased LIF expression may not induce apoptosis and 
migration as extensively in the Rab11bKD xenograft, compared to the Rab35KD; although we 
do not have any direct evidence for this.   
As demonstrated in Chapter 5, normalisation of vesicle quantity to protein following 
knockdown of Rab11b or Rab35, failed to trigger a potent fibroblast differentiation response. 
We did observe that DU145 Rab11bKD cell-derived vesicles still triggered a moderately 
convincing response of fibroblast differentiating into α-SMA positive myofibroblasts, 
compared to DU145 Rab35KD cell-derived vesicles. It could be possible these fibroblasts have 
been ‘educated’ in vivo under the direction of the total secretome following knockdown of 
Rab11b, to become myofibroblasts similar to wild-type cells. Though, we highlight that 
Rab35-dependent vesicles appear to be important for stromal differentiation and this results 
in restricted tumour growth in vivo. Therefore, changes in the vesicle (decreased TRAIL 
expression) or soluble (decreased LIF expression) secretome; and the capacity to drive 
fibroblast differentiation following Rab11b knockdown, may all contribute to tumour growth 
in vivo, compared to the Rab35 knockdown. 
In this Chapter, I have shown that silencing Rab11b or Rab35 has major effects on tumour 
invasion in vitro. This is supported by attenuated levels of matrix degrading enzymes in this 
3D-microenvironment. This is recapitulated in vivo with knockdown of Rab35, however, this 
is not as clear with Rab11b. This may be explained by differences in the remaining vesicle 
subpopulations or cell secretome, following knockdown of Rab11b or Rab35, which may play 
independent roles in tumour growth and progression.
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7.1 General Discussion 
7.1.1 Summarising Discussion 
In this study, we aimed to assess the possible roles of CD9, Rab5a, Rab11b, Rab35, VAMP7 
and VPS25 in exosome secretion. ESCRT proteins are involved in MVE formation in yeast and 
mammalian cells. Silencing VPS25 (part of ESCRT-II) reduced exosome secretion by 20%. 
However, as there are reports of ESCRT-II are not required for viral budding (Langelier et al., 
2006) or degradation of EGFR (Bowers et al., 2006), this suggests that ESCRT-independent 
pathways are potentially present. Yet, we highlight VPS25 appears important for maintaining 
cell viability and proliferation, with signs of toxicity upon VPS25KD. To assess vesicle secretion 
by cells undergoing major toxicity is difficult. Dead cells are unable to produce a complex 
range of particulates, vesicles, molecular proteins of the cells compared to viable cells. 
We chose to examine CD9, because it is very abundant on DU145-derived exosomes, isolated 
by size exclusion chromatography (Welton et al., 2015), sucrose gradients and cushion 
methods (Webber et al., 2014). It was reported that silencing CD9 reduced the secretion of 
EVs in Nalm-6 pre-B cells (Mazurov et al., 2013); and in mouse-derived bone marrow DCs 
(Chairoungdua et al., 2010). Though, we report minimal impact in quantity of secreted 
vesicles following CD9KD, there are differences in enrichment of exosome-associated 
proteins. Little changes in levels of ESCRT-proteins suggests CD9 vesicles are maintained in a 
manner independent of ESCRT, but are perhaps dependent on LAMP or HSP. The importance 
of CD9 in other cell types may play roles in exosome secretion, yet it is not a major influence 
on exosome secretion in DU145 cells. 
Few studies have attempted to address the requirement for SNAREs in vesicle secretion. We 
examined silencing VAMP7 reported a modest decrease in vesicle secretion, yet only a 
modest decrease in LAMP proteins. One study reported that VAMP7 is not required for 
exosome secretion in MDCK cells (Proux-Gillardeaux et al., 2007), but inhibits lysosome 
secretion. In contrast, VAMP7 was found to be involved in exosome secretion by K562 cells 
(Fader et al., 2009). Currently, 36 SNARE proteins have been described in human cells (Jahn 
and Scheller, 2006), but only one SNARE protein has been assessed in this study. Other 
studies may suggest different cell types, may have different SNARE complexes involved in 
fusion of MVEs with the plasma membrane. Possibly, SNARE complexes may mediate fusion 
of specific MVE within a single cell type; and silencing VAMP7 may affect a specific vesicle 
subpopulations. The quantification of several exosome-associated proteins (ESCRT and HSPs) 
appeared to be unaffected, compared to controls, which may provide some insight into the 
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latter possibility. It should be stressed, we cannot convincingly conclude the role of VAMP7 
analysed here in vesicle secretion, as further studies such as molecular profiling data and 
functional data, will be required. 
Rabs constitute the largest family of small Ras-like GTPases, with over 70 types identified 
now in humans (Hutagalung and Novick, 2011). By knocking down Rab5a, an increase in 
vesicle number was observed. Contrasting studies have shown silencing Rab5a inhibited 
exosome secretion (Ostrowski et al., 2010), or increased secretory granules per cell (Azouz 
et al 2014). Different Rab5 isoforms may play different roles, such as trafficking early 
endosomes or trafficking to lysosomes for degradation in different cell types (Chen et al., 
2009). It remains possible that Rab5a may redirect endosomes to undergo exocytosis to 
release vesicles, instead of directing to lysosomes (Tan et al., 2016). As Rab5a is involved in 
endocytosing molecules, autocrine vesicle uptake from the cell may be abrogated; and may 
explain increased vesicle accumulation in the extracellular space. Nonetheless, it’s important 
to consider other Rab5 isoforms and their roles in exosome biogenesis and secretion, but 
also the interplay between either autophagy or endocytosis may explain this increase in 
vesicle secretion. 
By silencing Rab11b or Rab35, little signs of toxicity were shown. Alterations in the late 
endosome was present, as either knockdown revealed an accumulation of CD63, CD81 or 
LAMP1 in peri-nuclear structures. Similarly, these observations were reported in other cell 
types because of attenuated Rab11b (Grimsey et al., 2016), Rab27a (Ostrowski et al., 2010, 
Webber et al., 2015) and Rab35 (Hsu et al., 2010). These observations were consistent with 
the diminished capacity to expel these proteins out of the cell in association with vesicles. A 
20% decrease in vesicle secretion was measured, following Rab11b or Rab35 knockdown by 
NTA. This was also shown with a decrease in exosomal-associated proteins by plate-based 
assays and Western blot. Despite a strong knockdown at the RNA level (95%), the impact on 
exosomes is rather minor. It suggests that other pathways deliver MVEs to the plasma 
membrane, in which Rab11b or Rab35 are redundant; and supports the notion that other co-
existing MVEs are present and differentially trafficked. 
It was suggested that Rab11b or Rab35 regulate the same vesicle pathway, as silencing either 
protein resulted in a vesicle population that was approximately 80% of control cells. It was 
first reported that Rab11 was involved in trafficking MVEs to the plasma membrane (Savina 
et al., 2002), but it remains unknown which type of MVE was trafficked. In one study both 
Rab11 and Rab35 mediated slow endocytic recycling through endosomes to the plasma 
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membrane (Stenmark, 2009). Similarly, Rab35 have been shown to promote the recruitment 
of other related Rab proteins to recycling endosomes in yeast models (Rahajeng et al., 2012); 
and in a neuroendocrine tumour cell line (Kobayashi et al., 2014). Additional roles for Rab35 
has been reported to localise at the newly formed early endosomes to traffic the transferrin 
receptor (Kouranti et al., 2006), or the mannose-6-phosphate receptor (Cauvin et al., 2016). 
However, in oligodendrocytes, Rab35 has been proposed to be involved in acting on the late 
endosome (Hsu et al., 2010). Interestingly, work in C. elegans showed that the combined 
knockdown of both Rab11 and Rab35 leads to a dramatic enhancement of intracellular 
accumulation of endosomal cargo (Sato et al., 2008). We have evidence from the protein 
profiling array to propose both that Rab11b and Rab35 regulating distinct exosome-secretion 
pathways in the remaining (80%) vesicle population; with decreased CXCL6 (Rab11bKD) and 
increased CXCL6 (Rab35KD) as an example. However, the specific endosomal compartments 
that Rab11b and Rab35 regulate are poorly understood; although this thesis provides 
evidence that they possess independent parallel roles in endosomal trafficking rather than 
acting in sequential stages. 
Attenuating Rab proteins has been demonstrated to impact on the soluble secretome 
(Bobrie et al., 2012). Our protein profiling data agrees with this notion, in relation to Rab11b 
and Rab35. As one example, LIF and IL-6 were significantly elevated in the Rab35-knockdown 
secretome, but this was not a feature of the vesicles. This suggests that these factors are 
present as soluble factors, rather than association with vesicles. Profiles of the secretome 
highlight examples of dissimilarities and show that knockdown of Rab11b or Rab35 impart 
distinct effects on the general secretome, which are not vesicle-exclusive effect. 
Previously, it was demonstrated that tumour exosomes can drive fibroblast differentiation 
into myofibroblast (Webber et al., 2010). This distinct myofibroblastic phenotype arising 
from tumour exosome treatment, differs to cancer-associated stromal cells treated with 
rhTGF-β1, as they promote angiogenesis in vitro and tumour growth in vivo (Webber et al., 
2015). Here, we report that the general secretome appeared to lack the capacity to drive 
fibroblast differentiation, despite containing other factors as well as the presence of vesicles. 
Though, this issue may be due to a lack of seeded cell numbers, hence, the number of vesicles 
available from the total secretome is minimal. However, fibroblast differentiation resided in 
the vesicle concentrates, implicating this is a vesicle-driven process. Following vesicle 
concentration from Rab11b or Rab35 knockdown, there was a diminished capacity to drive 
differentiation. This vesicle-mediated differentiation mechanism is dependent on the levels 
of vesicle-tethered TGF-β1 (Webber et al., 2010). This could be explained by the loss of as 
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little as 20% of the vesicle subpopulation to disrupt the threshold required for 
differentiation. Similar studies have also not achieved the required threshold in vesicles, with 
changes in lymphocyte mRNA expression (Muller et al., 2016) or invasion of trophoblasts 
(Salomon et al., 2013).  
Alternatively, a possible explanation for this failure to drive fibroblast differentiation is that 
the vesicle phenotype following knockdown of Rab11b or Rab35 is altered, which renders 
the remaining vesicle population insufficient in this functional activity. We report that by 
treating fibroblasts with equal vesicle quantities in control, Rab11bKD and Rab35KD; the 
Rab11bKD were still capable of driving sufficient differentiation. This was only capable if 
vesicles were added to reach the correct threshold for activation. In contrast, the vesicles 
secreted from Rab35KD cells appeared to be deficient in their ability to differentiation, 
irrespective of normalisation. It could be possible that these Rab35-dependent vesicles may 
contain specific mRNA/miRNA (Valadi et al., 2007), proteins or other molecules, along with 
TGF-β1 delivery, that may drive fibroblast differentiation. Additional investigation would be 
required to understand the molecular features of Rab11b (functional) and Rab35 
(dysfunctional). The profiling performed so far is not of sufficient breadth and complexity to 
provide us with these answers and a more extensive analysis would be required. This data 
highlights the distinct vesicle profiles remaining in cells following knockdown of either 
Rab11b or Rab35, revealing Rab35-dependent vesicles are required for fibroblast 
differentiation into myofibroblasts. 
In the absence of fibroblast differentiation, stromal cells that arise demonstrate poor 
tumour-supporting function, such as angiogenesis. The direct effect of cancer exosomes on 
endothelial cells promoting angiogenesis (Sheldon et al., 2010), or indirectly through 
differentiated myofibroblasts to support angiogenesis has been reported (Webber et al., 
2015). We showed a loss of Rab11b- or Rab35-dependent vesicles can strongly attenuate the 
secretion of pro-angiogenic growth factors, HGF and VEGF; slowing endothelial cell migration 
and inhibiting vessel formation. These regulators also appear to be relevant in context of a 
3D-microenvironment of a tumour:fibroblast co-culture model, that appear to drive an 
aggressive matrix invasive behaviour. We provided some evidence that the presence of 
tumour cells and fibroblasts are present within the leading edge, yet the signal for fibroblasts 
was weak and difficult to detect over time. This invasive behaviour was attenuated when 
Rab11b or Rab35 were knocked down, as this may have interfered with tumour-stroma 
communication. However, we cannot state this effect is exclusively due to vesicle loss, as the 
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knockdowns could influence the soluble secretome, which may impact other aspects of cell 
behaviour, such as adhesion or motility. 
This aggressive invasive behaviour was attenuated in the absence of Rab11b or Rab35, or 
even in the presence of fibroblasts. We reported a reduction in levels of MMPs within the 
3D-microenvironment, containing the knockdown of Rab11b or Rab35. MMPs are reported 
to play roles in promoting tumour growth (Franchi et al., 2002, Shah et al., 2012), by enabling 
penetration through the ECM (Pilcher et al., 1997), supporting invasion (Hsu et al., 2006, 
Bendardaf et al., 2007). However, it remains difficult to determine whether enhanced MMP 
secretion is truly relevant to this aggressive invasion that is observed. Methods would include 
inhibition of MMP activity or detecting levels of MMP activity within the 3D-
microenvironment. It could be possible MMPs may be present on the vesicles, playing this 
invasive function of tumour cells, as demonstrated in melanoma derived exosomes 
(Hakulinen et al., 2008). Nevertheless, this data reports that Rab11b and Rab35 have an 
influence on the invasivity of heterotypic spheroids and MMP levels present in the 3D-
microenvironment; and together with the previous data, this emphasises the importance for 
activation of the tumour-supportive fibroblast functions. 
Many of the in vitro experiments in this study demonstrated that knocking down of either 
Rab11b or Rab35 gives rise to functionally similar effects shown in a multitude of short-term 
based assays. Here, we reported that injecting these manipulated tumour cells with 
fibroblasts showed significant differences. Knockdown of Rab11b had no significant impact 
on tumour growth in vivo, with tumour volume similar to controls. Alternatively, knockdown 
of Rab35 significantly attenuated tumour growth after 46 days. This may be explained by 
differences in the secretome following knockdown of Rab11b or Rab35. The chronic 
exposure to vesicle-defective tumour cells in vivo revealed functional differences that were 
not clear from in vitro experiments. Furthermore, we show differences in secretion of growth 
factors from fibroblasts treated with vesicles, following knockdown of Rab11b (increased 
FGF-2) or Rab35 (decreased uPA). From previous data, we showed differences in the levels 
of CXCL6 following knockdown with decreased CXCL6 (Rab11bKD) and increased CXCL6 
(Rab35KD) as an example. These secreted cytokines may play roles in modulating the immune 
response or enhancing tumour cell proliferation in vivo. In similar models, blockade of 
Rab27a attenuated exosome secretion and impacted the secretion of growth factors (PIGF-
2 or PDGF) or MMP-9, reducing tumour growth and metastasis in vivo (Bobrie et al., 2012, 
Peinado et al., 2012, Webber et al., 2015). Nevertheless, the collective functional data 
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demonstrates the differences in phenotype between vesicle subpopulations and the 
influence they have in driving tumour growth. 
In this Thesis, the data identifies a minor role for Rab11b and Rab35 in regulating the overall 
secretion of vesicles from prostate cancer cells. Interfering with these pathways attenuates 
vesicle secretion by 20%, impacting vesicle-mediated communication between tumour and 
stromal cells; restricting stromal differentiation, angiogenic and invasive behaviours. Here, 
we showed that Rab11b and Rab35 GTPases regulate distinct pathways, resulting in different 
vesicle molecular phenotypes. Attenuating the Rab35-dependent vesicle subpopulation that 
remains functionally important for stromal differentiation, results in reduced tumour growth 
in vivo, as shown in Figure 7.1. Molecular targeting of this specific vesicle subpopulation may 
provide to be a novel avenue likely to attenuate the tumour promoting microenvironment 
to ultimately slow disease progression. 
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Figure 7.1. Schematic summary of Rab11b- or Rab35-dependent vesicle effects on the 
stroma and in vivo. (A) Wild-type tumour cells secrete a heterogeneously subpopulation 
of exosomes, which drives fibroblast differentiation into myofibroblast with a 
subsequent supportive pro-angiogenic and invasive phenotype. This results in 
unrestricted growth in xenografts in vivo. (B) Knockdown of Rab11b resulted in a 20% 
loss in total vesicles, with decreased (Blue) and increased levels (Red) in secreted protein; 
though this is not critical, as the remaining population retains the ability to support 
differentiation and tumour growth. (C) Likewise, knockdown of Rab35 resulted in a 20% 
loss in total vesicles and the remaining vesicles exhibit a distinct protein profile. With 
these vesicles, however, differentiation does not occur and restrict tumour growth was 
shown in vivo.  
 
(A) 
(B) 
(C) 
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7.1.2 Future Directions 
Within this study, specific exosome subpopulations have been demonstrated to be strong 
drivers of fibroblast differentiation, that can aid tumour growth and progression. 
Understanding the molecular phenotype of these Rab35-dependent exosomes and their 
interaction with other cell types within the stroma, may provide additional avenues to slow 
tumour growth and progression. 
Exploring the Importance of CD9, Rab5a and VAMP7 
We have not explored the full importance of CD9, Rab5a and VAMP7 in other roles involved 
in endocytic trafficking. In this study, we have indicated that Rab5a may have a role for 
elevating the EV content of the total secretome, that could occur through accelerated 
exosome secretion or by regulating the capacity of endocytic uptake of exosomes. The role 
of Rab5a has been predominantly involved in mediating the early endocytic pathway (Gorvel 
et al., 1991), or an autophagy-mediated dependent pathway (Tan et al., 2016). As Rab5a is 
involved in endocytosing molecules, autocrine vesicle uptake from the cell may be 
abrogated; and may explain increased vesicle accumulation in the extracellular space. One 
area of investigation would be to explore if different endocytosis pathways are dependent 
on the Rab5a protein; does blockade of Rab5a lead to inhibition of specific endocytosis 
pathways leading to the accumulation of vesicles in the extracellular space? Would the 
presence of additional vesicles within the extracellular space lead to a more aggressive 
tumour-supporting phenotype? 
Few studies have addressed the requirement for SNAREs in exosome secretion. VAMP7 was 
indicated to have a role for attenuating EV secretion (Fader et al., 2009); as shown in this 
Thesis. It could be possible different SNARE complexes could mediate fusion of specific 
subpopulations of MVEs within a single cell type, potentially impacting a specific vesicle 
subpopulations. The data suggests knockdown of VAMP7 or CD9 does not impact ESCRT-
related proteins. Instead, CD9 might be involved in cargo loading on MVEs, as there was no 
significant differences in vesicle number, but changes in the levels of exosomal-associated 
proteins. One area of investigation would be to explore the molecular profile of the vesicles 
following knockdown of CD9, Rab5a and VAMP7, that will give us a greater comprehensive 
understanding of proteins present on the surface. Furthermore, it would be important to 
understand whether these proteins can redirect endosomal trafficking or mediate cargo 
loading onto MVEs.  
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The in-depth Mechanism of Exosome-Induced Myofibroblast Differentiation 
The mechanism behind the generation of myofibroblasts by cancer exosomes remains poorly 
understood. Here, we highlight the role of Rab35-dependent vesicles on triggering 
differentiation and it could be possible these vesicles may incorporate distinct miRNA and 
mRNA (Valadi et al., 2007) into recipient cells, that vary from Rab11b-dependent vesicles. 
Studies have focused on the role of exosomal miRNA in their regulatory role on gene 
expression (Kosaka et al., 2010). As one example, tumour-associated myofibroblasts express 
significantly higher levels of miRNA-21, compared to ovarian tumour cells (Au Yeung et al., 
2016). Co-culture experiments highlight transfer of miRNA-21 to neighbouring tumour cells 
suppressing apoptosis. Though, there are limitations to some of the current functional 
studies associated with exosomal miRNA. As mentioned previously, there are multiple 
methods to isolate vesicles which may vary in the exosomal content, including proteins and 
miRNA (Kosaka et al., 2010, Hu et al., 2012). Though, it leads us to question the role of 
exosomal miRNA, to investigate if Rab35-dependent vesicles contain miRNA differing from 
Rab11b-dependent vesicles that would exert a different functional capacity, such as 
fibroblast differentiation. Though, some studies have implicated exosomes do not exert any 
functions via miRNA, and this is all due to cellular miRNA, it remains to be questioned and 
investigated in greater detail. 
Targeting Rab35-Dependent Vesicles as a Therapeutic Approach 
Since the data emphasises the role of Rab35-dependent vesicles for driving fibroblast to 
myofibroblast differentiation, leading to diminished angiogenesis and attenuated invasive 
behaviours in 3D in vitro models. Silencing Rab35-dependent vesicles significantly reduced 
tumour growth rates in vivo and targeting these vesicles may act as a therapeutic approach 
to slow tumour growth and progression. 
In breast cancer, the expression of human epidermal growth factor receptor 2 (HER2) protein 
can stimulate tumour growth and progression, where this intracellular signalling is proposed 
to be exemplified with exosomes (Marleau et al., 2012). Herceptin® (HER2-blocking 
antibody) is often used as a therapeutic antibody to treat breast cancer and exosomes can 
interfere with its activity. There has been the development of the extracorporeal 
haemofiltration of exosomes from the whole circulatory system, using an affinity 
plasmapheresis platform, known as Aethlon ADAPT™ (adaptive dialysis-like affinity 
technology system), which separates particles based on size and phenotype (Marleau et al., 
2012). This device consists of an outer compartment containing immobilised affinity agents 
(proteins of interest), which the compartment is integrated with a standard renal dialysis 
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machine. As blood passes through this system, particles smaller than 200nm will pass 
through that will be able to specifically bind to exosomes expressing proteins of interest; in 
our case Rab35. Currently, this machine is being used to eliminate Hepatitis C viruses from 
the circulatory system in some infected patients. Though, the safety and efficacy of this 
ADAPT™ machine for exosomal removal remains to be clinically tested, it may introduce a 
new therapeutic avenue to remove vesicle subpopulations. 
There has been approaches to develop inhibitors to block exosome secretion to attenuate 
different disease states. It was demonstrated that a ceramide-dependent mechanism is 
present to secrete exosomes in mouse oligodendroglial cells (Trajkovic et al., 2008). This led 
to the development of the GW4869 drug, a neutral sphingomyelinase (sphingomyelinase 
hydrolyses sphingomyelin into phosphocholine and ceramide) inhibitor, first used to inhibit 
exosome secretion in human embryonic kidney cells (Kosaka et al., 2010); and in mouse 
cardiac endothelial cells (Wang et al., 2014). However, it has been reported that 
administering GW4869 in primary cell line induces cell death, which provides an unreliable 
analysis of exosomes (Colombo et al., 2014); and demonstrated to be cytotoxic even when 
administered at low doses to myeloma cells (Vuckovic et al., 2017). Alternative approaches 
have been investigated in exploring the role of V-ATPase (large multi-subunit proton pump) 
on exosomes. They have roles in acidifying the endosomal lumen by localising the 
concentration of protons, powered by ATP hydrolysis. A study reported that V-ATPase has a 
direct interaction with VAMP protein, appearing to play a role in fusion neurotransmitter 
release (El Far and Seagar, 2011). V-ATPase inhibitors, balfilomycin A1 and concanamycin A, 
were proposed to inhibit the secretion of Rab27b-dependent vesicles in breast cancer cells 
(Rasschaert et al., 2015).  
Here, we would propose developing an inhibitor would be a novel approach to prevent the 
Rab35-dependent vesicle subpopulation, that has the capacity to activate the stroma and 
promote tumour growth in vivo. Future investigation would utilise a high-throughput 
approach to screen for inhibitors, to target their protein-protein interactions in silico and 
translate these findings in vitro and vivo. This would open a novel avenue to target a Rab35-
dependent vesicle subpopulation that is key in driving tumour growth and progression, 
although a limited number of pharmacological approaches have been investigated and this 
would open for further investigation. 
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Concluding Remark 
For the first time, we show that Rab35-dependent tumour vesicles is key for communication 
between cancer and stromal cells; and is essential for generating a tumour 
microenvironment favourable for disease progression. This emphasises along with the 
current literature that the presence of exosome heterogeneity is present and targeting a 
specific subpopulation may provide a novel valuable therapeutic approach for attenuating 
tumour growth and progression.  
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